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Oral squamous cell carcinoma (OSCC) is the sixth most common cancer worldwide. 
It is a result of numerous aetiological factors such as genetic predisposition, smoking, 
excessive alcohol consumption and viruses such as the human papilloma virus. Due 
to late diagnosis it has a high mortality and morbidity rates which has remained 
unchanged over the last 5 decades. 
Currently no screening is available for high risk patients for better monitoring. 
Diagnosing OSCC relies on histopathology of biopsy tissue, reviewed for dysplasia 
and advancing lesions. Although the technique has been used for decades for 
successful diagnosis it fails to identify the molecular signature of OSCC which 
appears much before the visual signs. It also falls short in predicting the malignant 
transformation of pre-malignant oral lesions. Identifying the molecular and genetic 
changes leading to OSCC lesion will aid in more specific (quantitative) and early 
diagnosis of the disease reducing the financial burden of treating late-stage OSCC 
patients on the healthcare system. 
This study focuses on developing new adjuncts which can be used alongside 
histopathology for early diagnosis. There is a need to monitor high risk patients 
through non-invasive methods causing less patient discomfort. We therefore explored 
the potentials of exosomes which are extracellular vesicles secreted by normal and 
tumour cells. They can be isolated from body fluids such as blood and saliva.  
In cancer biology exosomes offer both diagnostic and therapeutic advantage. Their 
involvement in cell-cell communication indicates their influence in tumour 
development, progression, metastasis and therapeutic efficacy. Exosomes released 
by cancerous cells carry numerous biomarkers, which are passed on to healthy cells 
via microenvironment, causing stromal and angiogenic activation along with immune 
escape.  
In this study exosomes were successfully isolated from body fluids (blood, saliva and 
plasma) and cell line supernatant through ultracentrifugation and characterised by 
visual and particle size quantification techniques including Scanning Electron 
Microscopy (SEM) and Transmission Electron Microscopy (TEM), Zetasizer and 
Nanosight Tracking Analysis (NTA). Exosomal specific membrane proteins were 




We report the presence of a potential protein biomarker located exclusively on the 
outer membrane of cancer exosomes. Since body fluids consist of a heterogeneous 
population of exosomes derived from multiple cell types, such surface biomarker can 
potentially be used to isolate OSCC exosomes. 
Characterisation of exosomal mRNA cargo was done using Agilent Bioanalyzer (for 
RNA quantity and quality assurance) and reverse transcription-quantitative PCR (RT-
qPCR; for gene specific quantitation). Functional significance of exosomes was 
studied by transfecting normal oral keratinocyte cells with self and cancer-derived 
exosomes. Through gene-expression microarray and subsequent RT-qPCR 
verification, we report a panel of differentially expressed genes involved in essential 
cellular functions being modulated by exosome transfection. 
A previously developed molecular diagnostic system by our research group called 
quantitative malignancy index diagnostic system (qMIDS) based on FOXM1 
oncogene and its downstream targets was validated on archival formalin fixed paraffin 
embedded OSCC patient biopsy samples. We report that qMIDS index successfully 
correlates with the disease stages including dysplasia, tumour and lymph node 
metastasis.  
Furthermore, through meta-analysis of 8 OSCC microarray studies we identified a 
panel of six genes including PLAU, FN1, CDCA5, CRNN, CLEC3B and DUOX1 (q6) 
which are able to identify two clinically distinct sub-groups of OSCC patient 
population. Through RT-qPCR the expression of q6 biomarkers was established in 
100 OSCC biopsy samples. This information can be of immense importance in 
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1.1 Head and neck squamous cell carcinoma 
Office for National Statistics has reported head and neck squamous cell carcinoma 
(HNSCC) as the eighth most common cancer in the UK (2014). It is the fourth most 
common cancer in males and the 12th most common cancer in females in the UK 
(Office for national statistics, 2017). Historically, the male to female ratio was 3:1 
which has recently changed to 2:1, due to increase in smoking by women and their 
long life expectancy (Joseph A. Regezi et al., 2017).  
Global incidence of HNSCC is 500,000 new cases annually with 350,000 associated 
deaths (Marur and Forastiere, 2016). HNSCC has a high morbidity rate and can result 
in difficulty with eating, swallowing, and speech. It may also interfere with breathing 
when obstructing the airway (Li et al., 2015). In addition, treatments with chemo and 
radiotherapy are associated with high morbidity leading to long-term decrease in 
quality of life (Bar-Ad et al., 2014).  
According to cancer research UK in the year 2014, 11,449 new cases of HNSCC 
were reported. Since 1999 to now there is a 30% increase in the rate of HNSCC 
incidence. The mortality rate was reported as 2,386 deaths in the year 2014, 
accounting to 1% of affected population. Only 19 to 59% of patients showed a 5 to 10 
year survival rate, while 90 to 93% of cases were considered as preventable (Cancer 
research UK, 2014). 
1.2 Oral squamous cell carcinoma (OSCC) 
HNSCC is an aggressive and heterogeneous disease which can occur in oral cavity, 
pharynx, larynx and paranasal sinuses. Among different types of HNSCC, in the oral 
cavity 90% of cases accounts for oral squamous cell carcinoma (Brocic et al., 2009). 
Oral squamous cell carcinoma (OSCC) has been estimated to be the sixth most 
common cancer worldwide (Irani, 2016). It originates from keratinocytes of the oral 
cavity’s stratified squamous epithelial lining. Clinically they present as non-healing 
ulceration due to tissue destruction, induration due to excessive keratin formation 
within tumour stroma, fixation of underlying tissue due to submucosal invasion and 
raised, everted tumour margins (Steel, 2013). It is not surprising that oral epithelial 
cells are vulnerable to cancerous changes, as they act as the first defensive barrier 
against pollutants and carcinogens. 
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Fig 1.1: Clinical presentation of Oral Squamous cell carcinoma lesion at the 
lateral border of the tongue (Brad W. Neville et al., 2003). 
 
Based on the evidence from multiple longitudinal studies it has been established that 
OSCC lesions can progress from potentially malignant lesions such as erythroplakia 
and less commonly leukoplakia (Warnakulasuriya et al., 2007). Developing OSCC 
arises from clonal expansion and aberrant growth of a single stem cell or from a few 
tumour initiating cells that acquire self-renewal capability. These cells escape normal 
growth control and gain growth advantage allowing clonal expansion which replaces 
normal epithelial tissue. As the lesion enlarges, additional genetic damage gives rise 
to sub clones resulting in an invasive cancer (Feller et al., 2013). Metastasis in OSCC 
is fast due to close proximity of several lymph nodes and late diagnosis, resulting in 
lower survival and poor prognosis. 
Our study focuses on OSCC and aims to propose new aids in early diagnosis and 
screening leading to better patient survival. In order to achieve this aim, better 
understanding is required of the disease pathology and risk factors associated with it. 
1.3 Aetiology of OSCC 
Apart from genetic predisposition many environmental factors are associated with the 
development of OSCC including smoked and smokeless tobacco, alcohol, betel quid 
/areca nut chewing and microbes including Human Papilloma Virus (HPV), Epstein 
bar virus and ultraviolet light can all cause OSCC involving mucosa, lip and skin 
(Joseph A. Regezi et al., 2017). 
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Further, a compromised immune system due to diseases such as HIV and organ 
transplants including bone marrow and kidney also contribute to the occurrence of 
OSCC (Joseph A. Regezi et al., 2017). 
1.31 Tobacco  
Many factors are associated with developing OSCC of which the most important is 
tobacco smoking. The trend in the use of tobacco varies in different regions of the 
world. In the western countries tobacco is mostly used in the form of cigarette, cigar 
and pipe smoking. In some European countries tobacco is used in the form of snuff 
which is chewed. 
In the east, especially in South Asian countries including India, Pakistan, Bangladesh 
and Nepal tobacco is consumed in the form of “Birhi” which is smoked without a filter 
and “Paan” which is a form of chewing tobacco (Scully et al., 2005). In addition to 
tobacco, Paan also contains betel quid which is a known carcinogen for OSCC 
(Chattopadhyay and Ray, 2016). It is usually placed in the buccal sulcus for longer 
time durations, resulting in a site specific lesion (Niaz et al., 2017). 
The risk of developing OSCC due to smoking is dose dependent that is the number 
of packs smoked per year and the risk is reduced with smoking cessation (Morse et 
al., 2007). Carcinogenic substances in smoked tobacco modulate the mechanism of 
carcinogenesis; these cause DNA damage and P53 mutation leading to dysplasia 
and OSCC (Pfeifer et al., 2002). 
Tobacco is known to have adverse effects on oral tissues, especially on wound 
healing after surgical and non-surgical procedures (Balaji, 2008). As a peripheral 
vasoconstrictor it causes delays in the rate of healing (Maddock and Coller, 1933). In 
addition combustion of tobacco produces carbon monoxide which reduces the 
capillary blood flow by 40% (Koszowski et al., 2015). Nicotine in tobacco increases 
platelet adhesiveness increasing the risk of microvascular occlusion and tissue 
ischemia (Al-Belasy, 2004). Smoking is also associated with catecholamine’s release, 
resulting in vasoconstriction and decreased tissue perfusion (McDaniel and 
Browning, 2014). 
1.32 Alcohol 
Historically alcohol was not believed to be a carcinogen itself but in combination with 
smoking was considered a risk factor of OSCC. Recent studies have shown that 
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alcohol drinking is an independent risk factor for the development of oral cancer, 
regardless of tobacco use (Maserejian et al., 2006). Similar to tobacco use, it has a 
dose dependent affect (Varoni et al., 2015). Alcohol has the ability to irritate the 
mucosa and to act as a solvent for carcinogens especially those in tobacco 
(McCullough and Farah, 2008). Alcohol also has the capacity to eliminate the lipid 
component of the protective barrier present in the oral cavity that surrounds the 
granules of the epithelial spinous layer (Squier et al., 1986). Further, contaminants 
and additives such as ethyl carbamate found in alcoholic drinks play a role in the 
development of OSCC (Lachenmeier et al., 2010). Alcoholic metabolite, 
acetaldehyde has been found to cause a carcinogenic risk by inducing DNA–protein 
crosslinks and sister chromatid changes (Zygogianni et al., 2011). It also directly 
interacts with DNA, producing DNA adducts, inhibits DNA repair enzymes and 
activates oncogenic transcription factors in oral keratinocytes (Brooks and 
Theruvathu, 2005). 
1.33 Areca nut 
Areca nut chewing is considered an independent risk factor in the development of 
potentially malignant oral sub-mucous fibrosis leading to oral and oesophageal SCC 
(Arakeri et al., 2017). The contact of its extract to oral mucosa caused erosion along 
with genotoxic and cytotoxic effects on oral keratinocytes and fibroblast.  Areca-
related oral carcinogenesis is considered mainly due to its active metabolite arecoline 
N-oxide (Lin et al., 2011). 
The extract of areca nut causes stimulatory effects on cyclooxygenase-2 and 
prostaglandins, which act as inflammatory mediators during tumour initiation, 
development and metastasis (Jeng et al., 2000). While it inhibits the expression of 
tumour suppressor gene P53, impairs DNA repair and activate metalloproteinases 2, 
8 and 9 accelerating tumour migration (Akhtar et al., 2012). 
1.34 Microbes 
The oral cavity hosts many bacterial, viral and fungal species which under 
physiological conditions coexist in harmony with each other and with the human 
immune host defence. Some of these species such as candida can be opportunistic 
causing fungal infections in pre-cancerous lesion (Sankari et al., 2015). It has been 
suggested to play a role in OSCC development by producing the carcinogen N-
nitrosobenzylmethylamine causing cellular dysplasia (O'Grady and Reade, 1992). 
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Epstein barr virus has been linked to other HNSCC including Burkitt’s lymphoma 
(Rowe et al., 2014) and nasopharyngeal carcinoma (Chu et al., 2008). The most 
widely known virus involved in OSCC is the human papilloma virus (HPV). Subtype 
16 and 18 are found to be expressed in 6 to 10% of OSCC lesions while 60 to 70% 
of the tonsillar SCC shows positive expression of these subtypes (Golusinski, 2017). 
In HPV positive tumours the expression of cell cycle regulating protein P16 is found 
to over express and can prove as a valuable prognostic tool (Sritippho et al., 2015). 
1.4 Pathogenesis 
Majority of OSCC lesions are preceded by pre-cancerous lesions which are defined 
by the presence or absence of oral epithelial dysplasia categorised as mild, moderate, 
severe dysplasia and carcinoma in situ according to the presence and severity of cell 
atypia. This classification was designed to assist prediction of malignant 
transformation (Kujan et al., 2006) yet no objective method could be developed, as 
not all dysplastic lesions progress to OSCC. Through a binary classification of oral 
epithelial dysplasia, pre-cancerous lesions can be segregated into high and low risk 
of malignant transformation, improving sensitivity and specificity of detection 
(Nankivell et al., 2013) 
Like most other malignancies, OSCC also arises from accumulation of genetic events 
leading to development of an invasive lesion. Most of these changes occur in genes 
which control basic cellular functions such as cell cycle, cell survival, cell motility and 
angiogenesis (Williams, 2000). 
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1.41 Oncogenes 
Oncogenes are growth regulating and promoting genes that control cellular 
transduction pathways. A mutation in these genes leads to overproduction or an 
increase in the function of stimulatory proteins (Campo-Trapero et al., 2008). 
Numerous oncogenes have been implicated in oral carcinogenesis including 
epidermal growth factor receptor (EGFR) which is found to be upregulated in 40-80% 
of OSCC cases and has been proposed to have prognostic value implying higher 
likelihood of recurrence and worse survival (Grandis and Tweardy, 1993). Other 
oncogenes implicated in OSCC include c-myc which regulates cell proliferation, cyclin 
D1 which controls the cell cycle and fibroblast growth factor 3 regulating the 
proliferation of the stroma (Williams, 2000). 
In our lab extensive amount of research has been done on FOXM1 transcription 
factor, regulating timely mitotic progression. Previous studies have shown that 
upregulation of FOXM1 (isoform B) is an early event in OSCC development where it 
causes genomic instability in oral keratinocytes in the form of loss of heterozygosity 
and copy number variations (Gemenetzidis et al., 2009). Furthermore, FOXM1 
upregulation promoted expansion of progenitor keratinocyte stem cells to induce 
epithelial hyperplasia thereby increasing susceptibility to oncogenic transformation 
(Teh et al., 2010). Overexpression of FOXM1 triggers downstream targets such as 
centrosomal protein CEP55, essential for cytokinesis and Helicase (HELLS) involved 
in cellular proliferation and epigenetic regulations (Waseem et al., 2010). 
1.42 Chromosomal instability 
Cytogenetic analysis has shown a series of consistent chromosomal alterations in 
OSCC, including loss of heterozygosity at 9p21, the site of tumour suppressor genes 
P16 and P14ARF, an early event in 70% of OSCC lesions (Kim and Califano, 2004). 
P16 inhibits CDK2 and CDK6, preventing initiation of cell cycle causing arrest at G1 
(el-Naggar et al., 1995).  Mutations at 17p13, the site of P53 tumour suppressor gene 
has been noted in 79% of OSCC lesions and is considered a late event in progression 
of OSCC (Balz et al., 2003). 
Further, amplification of 11q13 region which encodes proto-oncogene cyclin D1, 
functions to activate retinoblastoma protein (pRb) by phosphorylation and facilitates 
progression of the cell cycle from the G1 to S phase (Kim and Califano, 2004). Hence 
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D1 cyclin activation and P16 inactivation results in the same effect of increased 
cellular proliferation. 
Stem cells are perfect targets for OSCC initiation due to their clonogenic potential and 
plasticity. A study using human organotypic 3D culture system has shown that 
FOXM1 oncogene (isoform B) regulates human adult epithelial stem cell renewal and 
differentiation (Gemenetzidis et al., 2010) and also maintains pluripotency genes 
such as Oct 4, Nanog and Sox2 (Xie et al., 2010). Hence, it was suggested that 
FOXM1 oncogene may be responsible for the replicative properties of stem cells and 
initiates an oncogenic process. 
This indicates that tumour may begin from pre-cancer stem cells which have attained 
high levels of FOXM1 and give rise to progeny cancer stem cells with elevated 
FOXM1 expression (Fig 1.2). Hence aberrant FOXM1 expression causes stem cell 




Fig 1.2 : A model system illustrating the role of FOXM1 in human epithelial cancer 
initiation and progression (Teh, 2012a). 
 
It would be interesting to design therapeutics against cells which have abnormally 
high expression levels of FOXM1 and sparing cells with normal levels to avoid cell 
toxicity (Teh, 2012b). Due to the roles of FOXM1 in tumour initiation (Teh et al., 2010) 
                                                                                  Chapter 1: Introduction                                                                                         
26 
and progression (Gemenetzidis et al., 2009), its expression could be exploited as a 
biomarker for early cancer diagnosis (Teh et al., 2013).   
1.43 Epigenetic alteration 
These alterations affect or inactivate gene function by methylation of the promoter 
region, without changing the structure or sequence of the gene. Methylation is an 
epigenetic modification by which gene activity is controlled by addition of methyl group 
(CH3) to certain DNA cytosine (Shaw, 2006). Both hypermethylation which inactivates 
suppressor gene and hypomethylation by inappropriate oncogene activation aids in 
carcinogenesis (Auerkari, 2006). 
In OSCC methylation of P16INK4a, CDH1(cadherin-1), MGMT (O6-methylguanine-DNA 
methyltransferase) and DAPK1 (Death-Associated Protein Kinase 1) have been 
reported (Ha and Califano, 2006). Hypermethylation of cell cycle regulating gene 
promoter P16 was found frequently in OSCC patients, although no correlation was 
found with clinic pathological characteristics or with prognosis (Viswanathan et al., 
2003). E-cadherin hypermethylation is associated with a more severe histological 
grade and poor patient survival rate (Shaw, 2006). MGMT helps in the removal of 
DNA adducts on the guanine base, thereby helping to maintain normal cell physiology 
and genomic stability (Gerson, 2004). DNA promoter hypermethylation of MGMT is 
associated with recursive mutagenesis and is a promising biomarker for OSCC 
prediction (Jayaprakash et al., 2017a). DAPK1, a mediator of Ɣ – interferon induced 
programmed cell death, is a vital gene in signal transduction and apoptosis (Lin et al., 
2010). Hypermethylation of DAPK1 has not only been associated with OSCC but has 
also been proposed as a potential diagnostic marker (Jayaprakash et al., 2017b).  
We have previously shown that FOXM1 oncogenes regulate HELLS, a SNF/helicase 
involved in DNA methylation, implicating FOXM1 in epigenetic regulation (Waseem 
et al., 2010). Upregulation of FOXM1 supresses the expression of tumour suppressor 
gene P16INK4A through promoter hypermethylation. Through non-bias genome wide 
promoter methylation microarray, it was shown that inducing upregulation of 
FOXM1in normal oral keratinocytes causes global hypomethylation similar to that 
found in HNSCC (SCC15) cell line (Teh et al., 2012).  
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1.44 Tumour-stroma Interactions 
The ability of tumour cells to disintegrate the extracellular matrix (ECM) and infiltrate 
surrounding tissue aids in metastasis. Matrix metalloproteinases (MMPs) play a major 
role in ECM degradation, leading to tumour invasion and metastasis (Sorsa et al., 
2004). In OSCC increased expressions of MMP2, MMP9 and MMP3 have all been 
found to be related to tumour invasion, a more aggressive growth and a worse 
prognosis (Zhang et al., 2013). Expression of these genes could be used as tumour 
progression markers (Andisheh-Tadbir et al., 2016). 
Over expression of VEGF (vascular endothelial growth factor) expression in OSCC 
was increased in insufficiently differentiated invasive carcinomas and was 
overexpressed in invasive oral squamous cell carcinoma but not in intraepithelial 
carcinoma tissues. These findings suggest that VEGF likely plays a role in 
angiogenesis of oral squamous cell carcinoma (Kim et al., 2015). 
1.45 Tumour suppressor genes 
Oncogenes alone are unable to cause cancer; the crucial event of transforming pre-
malignancy into malignancy requires inactivation of negative cell regulators called 
tumour suppressor genes. These genes are frequently inactivated by point mutations, 
deletions and rearrangements in both copies of the gene (Bascones-Ilundain et al., 
2008).  
The most widely studied tumour suppressor genes include retinoblastoma, P53 and 
INK4-ARF encoding retinoblastoma protein (pRB), P53 and P16 proteins respectively 
(Gonzalez-Moles et al., 2007, Ha and Califano, 2006, Pande et al., 1998). These 
proteins regulate the cell cycle and are involved in the inhibition of defective cell 
proliferation. Inhibition of tumour suppressor genes and overexpression of oncogenes 
such as cyclin D1 increases the activity of cyclin-dependent kinases (CDK4 and 
CKD6) resulting in uncontrolled cellular proliferation (Gonzalez-Moles et al., 2007). 




Fig 1.3: Summary of some of the genetic changes involved in developing 
OSCC and its progression to a metastatic lesion. Modified from (Campo-
Trapero et al., 2008) 
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1.5 OSCC Screening 
Oral cancer screening refers to detecting early signs of disease in an asymptomatic 
individual. OSCC screening is of immense importance for individuals predisposed to 
OSCC due to co-factors such as heavy smoking, alcohol consumption and genetic 
pre-disposition. Screening aims to segregate low risk individuals from high risk, this 
in turn will lead to early diagnosis resulting in favourable prognosis. A cohort study on 
colorectal cancer has shown that high risk patients benefitted by early diagnosis and 
better prognosis from screening and surveillance, while the lower risk individuals may 
only require just one follow-up (Atkin et al., 2017). In breast cancer it has been 
recommended that high risk patients expressing biomarkers BRCA1, BRCA2, ATM, 
CHEK2 and PALB2 should be offered breast MRI (magnetic resonance imaging ) 
annually to facilitate early detection (Macklin et al., 2017).  
In addition, reliable screening can reduce the burden of excessive cost from national 
health services used in the treatment of advanced lesions due to late diagnosis. 
These funds can be better utilized to develop personalised treatments for advanced 
lesion patients based on the genetic makeup of the tumour.  
Currently, high risk individuals predisposed to developing OSCC are not screened. If 
the patient is asymptomatic no advice or screening is sought from the dentist. If the 
individual develops a lesion which is painless, again delays are made in making 
dentist appointments. According to the NICE guidelines any suspected lesions that 
persist for more than two weeks is referred for further investigation causing further 
delays. 
An ideal screening adjunct should be non-invasive causing least discomfort to the 
patient. Here we concisely discuss a number of screening techniques and their 
limitation, highlighted in the literature which might be useful in OSCC patients which 
may or may not be symptomatic. 
1.51 Toluidine blue 
Toluidine blue also known as tolunium chloride is an acidophilic metachromatic dye 
that selectively stains acidic tissue components including nucleic acids and abnormal 
tissue (Sridharan and Shankar, 2012). Currently it is used by surgeons as an aid in 
demarcating the extent of the lesions prior to excision (Lingen et al., 2008).  
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Fig 1.4: Toluidine blue staining in oral squamous cell carcinoma. Adapted from 
(Seoane Leston and Diz Dios, 2010) 
 
The lack of use of toluidine blue as an adjunct to clinical examination for the 
identification of premalignant lesions is due to its higher sensitivity to detect 
carcinomas, than dysplasia (Seoane Leston and Diz Dios, 2010). In addition, the 
effectiveness of toluidine blue has only been evaluated in secondary care units on 
high risk population presenting a lesion visible to the naked eye (Gray et al., 2000). 
Hence, its efficiency to identify pre-malignancy in high risk population without 
presenting a lesion has not been tested.  
In a study by Barrellier and colleagues on 235 patients with past history of oral cancer 
showed as many as 58% of patients had a false positive toluidine blue stain (Barrellier 
et al., 1993). Due to these limitations the use of toluidine blue as a screening adjunct 
is inadequate.  
1.52 Light based detection systems 
Tissue reflectiveness has been used for many years in diagnosing cervical and oral 
malignant and premalignant lesion (Lingen et al., 2008). ViziLite Plus (Epstein et al., 
2008) and MicroLux (McIntosh et al., 2009) are two of the products currently available 
in the market, intended to enhance the identification of mucosal abnormalities.  
Prior to screening, patient rinse the mouth with 1% acetic acid which helps to remove 
surface debris and increase the visibility of epithelial cell nuclei due to cellular 
dehydration. This is followed by direct visual examination under blue-white light. 
Normal epithelium appears lightly bluish while abnormal epithelium appears distinctly 
white (acetowhite) (Lingen et al., 2008). 
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Major limitation of this system include low specificity, expensive, the efficiency has 
not been tested on asymptomatic individuals in primary care setup (Seoane Leston 
and Diz Dios, 2010).  
In addition the effectiveness of ViziLite was tested in a clinical survey of 150 patients 
to examine benign, premalignant and malignant lesions. It was found that 32 cases 
of benign leukoedema came positive (actetowhite), representing false positive. 
Similarly 2 of 14 cases of frictional keratosis also came positive. Further, brush biopsy 
of these lesions showed normal cytology (Huber et al., 2004).  
1.53 Exfoliative cytology 
Exfoliative cytology or brush biopsy is the study and interpretation of the 
characteristics of cells that flake off, naturally or artificially from the oral mucosa 
(Perez-Sayansm et al., 2010). It has been well established that DNA aneuploidy could 
predict malignancy prior to histopathology (Remmerbach et al., 2003). Exfoliative 
cytology is a non-invasive, easy, fast and low-cost examination for initial screening 
and early diagnosis of OSCC, with high sensitivity and specificity (Hashemipour et 
al., 2013). 
Brush biopsy is beneficial for patients presenting multiple lesions in the oral cavity 
who are unlikely to consent for multiple scalpel biopsies. It is also useful for non-
compliant patients who are unlike to come back for a follow-up (Babshet et al., 2011). 
Similar to other screening methods brush biopsy has been reported to overestimate 
dysplastic lesions and produce high number of false positive results (Bhoopathi et al., 
2009, Liu et al., 2017). Ongoing research is being done to improve this method of 
early detection. 
1.54 Saliva 
Saliva is another screening tool which has gained much attention because it is non-
invasive and can be collected easily and is cost effective. A recent study has shown 
that good quality mRNA can be extracted from saliva. This advancement will aid in 
identifying molecular biomarkers that appear at the initial stages of the disease. 
Although this study has been done on a small group of samples, further validation will 
be required for saliva to be used as a stable diagnostic tool (Li et al., 2004). 
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1.55 Blood serum 
Blood serum is still being studied to be used as a successful screening tool. A 
metabolic profile can be obtained for early stage disease detection. A distinct 
signature of altered energy metabolism is found in late stage OSCC patients, 
including lipolysis (an accumulation of ketone bodies), a distorted Krebs cycle and 
amino acid catabolism. Some markers such as choline, betaine and carnitine allow 
differentiation between early and late stage disease (Tiziani et al., 2009). 
 
1.6 OSCC Diagnostics 
Most of the oral cancers arise as asymptomatic lesions and only when the patients or 
clinicians notice an abnormal growth the formal diagnostic procedures begin, 
resulting in late diagnosis and poor prognosis. 
One of the biggest challenges in diagnosing oral cancer is the lack of patient 
awareness. Patients are not well informed that any oral lesion that does not heal 
within two weeks need to be examined by a dentist, who are trained to recognize 
early changes of a pre-cancerous lesion. Due to the presence of multiple lymph nodes 
in close vicinity to the oral cavity, delay in diagnosis and treatment often results in 
tumour metastasis and poor patient outcome. 
Hence general public screening is of immense importance in segregating high risk 
population from low risk. Based not only on clinical examination but also on risk 
factors such as tobacco and alcohol consumption, betel nut chewing and exposure to 
microbes (Scully, 2008).  
Currently, histopathology is the gold standard technique used for OSCC diagnosis. 
Histologically, the lesion passes through various phases (pre-neoplastic damage) 
until the ultimate establishment of cancer. This carcinogenesis may be associated 
with precancerous lesions such as leukoplakia and erythroplakia. However, it is 
necessary to consider that not all reactional lesions or potentially malignant lesions 
result in the subsequent development of malignant neoplasms (Ur Rahaman and 
Ahmed Mujib, 2014). 
Most OSCC are moderately or well differentiated lesions. According to their 
histological appearance, lesions are classified according to epithelial changes in 
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which keratin pearls and individual cell keratinization are usually evident (Joseph A. 
Regezi et al., 2017). In addition, pre neoplastic lesions show dysplastic changes 
which can be mild, moderate or severe (Wang et al., 2009) prior to the establishment 
of an invasive carcinoma. These dysplastic changes, subsequently degrades the sub 
epithelial basement membrane (BM). Degradation of the BM results in local 
destruction and distant invasion via metastasis. Local invasion to the underlying 
tissue occurs via the islets and cords of epithelial cells (Fuentes et al., 2012) 
Currently, two systems are used to histologically classify tumour lesions (Rivera and 
Venegas, 2014); the International Histological Classification of Tumours (WHO) 
based on the degree of tumour differentiation (well, moderately and undifferentiated) 
which is essential to evaluate the tumours growth rate and ability to metastasize 
(J.J.Pindborg et al., 1997) and the Tumour Invasion Front (TIF) which constitutes the 
area of the lesion with the greatest depth of invasion and progression into the 
surrounding tissues (Sawair et al., 2003). Since OSCC is a heterogeneous disease, 
cells of the TIF have different molecular characteristics when compared with the 
superficial cells of the tumour (Bankfalvi and Piffko, 2000).  
In practice, diagnosis of OSCC is a combination of clinical and pathological 
information. The TNM staging system (T, tumour size; N, regional lymph node 
compromise; and M, metastasis) (Oliveira et al., 2008) and the degree of tumour 
differentiation (J.J.Pindborg et al., 1997) combined, are the predominant factors that 
determine the treatment strategy.  
The limitation of current diagnostic system is partly responsible for poor prognosis 
and an unchanged 5 year survival rate of OSCC. The histopathological changes in a 
biopsy sample become evident when the disease is at an advanced stage. In addition 
the chances of misdiagnosis are considerable depending on the site from where the 
biopsy is taken. 
Screening aids such as buccal scrapes, saliva and blood are non-invasive, easy to 
collect and cause lower patient discomfort. But none of these methods have been 
proven to give a definitive diagnosis (Scully et al., 2008). For that purpose the 
clinicians still rely on histopathology of the biopsied sample, however there are a 
number of limitations such as exceedingly time consuming, requires pathologists 
interpretation and early stages such as dysplasia can be undetected due to absence 
of histopathological changes.  
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Since cancer is a disease caused by genetic mutations a more sensitive and efficient 
diagnostic system is required. A system based on genetic biomarkers would reflect 
on early molecular changes not visible to the naked eye and will aid in better diagnosis 
and prognosis (Teh et al., 2013). 
1.61  Use of Molecular Markers in Oral Cancer 
Detection 
Although, much progress has been made in understanding the molecular changes 
leading to an aggressive OSCC lesion, none of these changes are given much 
account while diagnosing the disease due to which the molecular make-up of the 
tumour is much ignored. Technological advancements in genomics and proteomics 
have led to identification and revelation of different genomic and epigenomic 
alterations which form cascading pathways in the formation and progression of the 
tumour (De Cecco et al., 2015). 
Over the last decade many molecular changes have been reported in the developing 
OSCC. Some of the major events include aberrant expression of P53, transforming 
growth factor- β (TGF-β), epidermal growth factor (EGFR) and cyclins. In addition 
dysregulation of certain pathways such as anaplastic lymphoma kinase (ALK), 
wingless homeobox genes (WNT) and mammalian target of rapamycin (mTOR) have 
also been reported (Su et al., 2017).  
Diagnosis based on molecular signature offers advantage over conventional 
histopathology as it incorporates an almost complete landscape of gene expression 
within a tumour. Analysis of molecular biomarkers such as oestrogen and 
progesterone receptors and the expression of HER2 in breast tumours has led to 
great advancements in diagnostics leading to better prognosis through targeted 
therapy (De Abreu et al., 2013). 
In the past our research group has translated the molecular make-up of the OSCC 
tumour biopsy samples into a quantitative malignancy index (qMIDs) values based of 
FOXM1 oncogene and its downstream targets (Teh et al., 2013). Through our current 
research we propose that the use to molecular biomarkers as an adjunct to 
histopathology will aid in detecting early molecular changes not visible to the naked 
eye assisting in early diagnosis. Further, this will lead to better outcomes by reducing 
the high mortality and morbidity load carried by OSCC patients. 
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1.62 Liquid biopsy 
In majority of suspected OSCC patients a single site tumour biopsy is taken for 
histological diagnosis. The down side of such a biopsy is that tumour heterogeneity 
can be missed because only a small tissue sample is taken which might not be 
representative of the whole tumour. Evaluating and understanding the importance of 
heterogeneity within these tumours, may allow for better diagnostic methods and 
treatment protocols (Schmidt et al., 2016). Mutli-site and repeated tumour biopsies in 
order to assess tumour heterogeneity is not practical due to increased patient 
discomfort. Further, it has associated risks of complications, cost, spatial 
heterogeneity within the tumour and sampling bias (Visacri et al., 2015). 
Comparison between single and multiple site biopsies of the same tumour tissue 
showed vast diversity in the tumour make-up (Zhang et al., 2016). This could explain 
why some cancers are resistant to treatment, or have much higher metastatic 
potential.  
Targetable mutations may only be found in certain areas of the tumour, not 
assessable to the single biopsy site. Liquid biopsy based on circulating tumour 
extracellular vesicles such as exosomes consisting of DNA, RNA and proteins can 
provide an opportunity to address the issue of tumour heterogeneity. In comparison 
to a conventional biopsy, this would offer the advantage of identifying patients at risk 
of developing metastatic lesions based on molecular biomarkers. Currently, in 
cancers of other origins including pancreatic (Bettegowda et al., 2014), melanoma 
(Tsao et al., 2015), lung (Lebofsky et al., 2015), colorectal (Diehl et al., 2005), breast 
(Dawson et al., 2013) and prostate (Bettegowda et al., 2014) presence of circulating 
tumour DNA in liquid biopsies is being used as a biomarker to study tumour 
heterogeneity. In a cohort study of 93 OSCC patients circulating tumour DNA was 
detected in patient derived blood and saliva where it identified somatic mutations 
including TP53, PIK3CA, CDKN2A, HRAS and HPV (Wang et al., 2015). Further, 
assessing tumour heterogeneity will aid in tailoring personalized treatment options.  
Since liquid biopsy based on blood or saliva would be a non-invasive method causing 
less patient discomfort, it can be used to track patient treatment outcomes and to 
monitor for residual disease.   
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1.7 OSCC prognosis 
Current treatment of OSCC patients in early stages (I and II), aims for a single 
modality–either surgery or radiotherapy. In more advanced stages of the disease (III 
and IV) a combination of treatment modalities such as surgery and radiation or 
radiation and chemotherapy or all three are recommended (Levy et al., 2016). While 
for incurably advanced disease palliative chemotherapy or best support palliative care 
is offered (Economopoulou et al., 2015). Advanced stage cancer requires more 
aggressive treatment, resulting in increased morbidity and reducing the quality of life. 
Upscaling treatment provides no guarantee of cure (Grisanti et al., 2014). In these 
patients earlier diagnosis is desirable in order to reduce morbidity and likelihood of 
cure. 
Based on the molecular changes in OSCC, studies have shown existence of sub-
types among tumours. The diversity in tumours can be driven by ethnicity, exposure 
to different carcinogens and site of tumour development. It has been shown that 
members of the ras oncogene family are overexpressed in OSCC. Although loss of 
control of N-ras is an early step in oral carcinogenesis, with increased expression in 
dysplastic lesions, ras mutations are infrequent in western patients and detected in 
fewer than 5% of oral cancers (Williams, 2000). In  contrast, 55% of lip cancers  have 
H-ras mutation (Milasin et al., 1994), which is also present in 35% of OSCC in  Asian 
populations associated with betel nut chewing (Kuo et al., 1994). 
In OSCC till now four different groups of tumour sub-types have been identified based 
on their molecular signature. Chung and colleagues classified these groups as basal 
like (EGFR pathway signature), mesenchymal enriched type, normal epithelial 
subtype (high expression of cytokeratin 14) and antioxidant type expressing high 
levels of antioxidant enzymes (Chung et al., 2004). Unfortunately, in practice all the 
types are treated the same way with a combination of surgery, radiotherapy and 
chemotherapy. This can be one of the reasons as to why some tumours respond 
better to therapy while others do not. The standard treatment of all OSCC tumours is 
one of the major factors leading to drug and radio resistance leading to poor 
prognosis. 
Platinum-containing chemotherapy drug such as cisplatin is the first generation anti-
cancer compound used in the treatment of OSCC (Larkins et al., 2017). Treatment 
often fails due to rapid development of inherent and acquired chemoresistance (Wang 
and Lippard, 2005). A study by Long and colleagues demonstrated that increased 
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expression of β-catenin, an important adhesion molecule and key regulator of Wnt 
signalling pathway is associated with chemoresistance (Li et al., 2016b) 
Radiotherapy is an inevitable component of OSCC management. The success or 
failure of radiotherapy is dependent on radiosensitivity of tumour cells and the limits 
imposed on treatment by the radiosensitivity of the surrounding normal tissue 
(Ishigami et al., 2007). In OSCC overexpression of COX-2 (Terakado et al.), glycerol 
(Imai et al., 2005b) and P53 DNA contact mutation (Yamazaki et al., 2003) has been 
associated to radioresistance, although the molecular mechanism is still largely 
unknown.  
Studies have already highlighted the possible prognostic role of known biomarkers.  
It has been shown that tumours with nuclear P53 accumulation and loss of P16 is 
indicative of an aggressive disease with possible resistance to drug and radiotherapy 





Aims and objectives 
We aim to explore different methods that can be used as adjunct to histopathology 
for early diagnosis and better prognosis of OSCC.  
1. The aim of this thesis is to test the hypothesis that oral cancer cells secrete 
exosomes which can be isolated from cell culture supernatant and body fluids 
including saliva, blood and plasma. If this hypothesis is true a liquid biopsy 
based on exosomes can possibly overcome the limitation of tumour 
heterogeneity associated with conventional biopsy of OSCC tumours and will 
allow multiple biopsies to check treatment response and prognosis. 
2. The second aim of this thesis is to test the hypothesis that oral cancer 
exosomes are taken up by normal cells and induce aberrant expression of 
genes vital for normal cellular function. If proven this inter cellular 
communication will highlight new pathways involved in the development and 
progression of OSCC. 
3. Correlation between OSCC disease stage and a previously developed 
quantitative malignancy index diagnostic system (qMIDS) based on FOXM1 
oncogene and its downstream targets was investigated. qMIDS formerly 
developed on fresh frozen OSCC biopsy tissue was validated on archival 
FFPE biopsy samples from OSCC patients. 
4. New biomarkers were explored with the aim to differentiate between 
molecularly distinct sub-groups within OSCC patients. This will aid in defining 
molecular heterogeneity among tumour sub-types and developing 
personalized treatment suitable for individual patients. 






Methods and materials 
  
                                                                    Chapter 2 : Methods and materials                                                                                                             
40 
2.1 Cell lines 
Primary normal human oral keratinocyte cell lines OK113, NOK368 and NK4 were 
extracted from normal oral mucosa tissue donated by disease free individuals 
undergoing wisdom tooth extraction (kindly provided by Prof Daniela Costea, 
University of Bergen, Norway). Normal skin keratinocyte cell line N/TERT was derived 
from cells cultured from specimens of normal human epidermis (strain N). They have 
been immortalized by retroviral transduction of h-TERT, a telomerase catalytic 
subunit (Dickson et al., 2000). Normal primary cell lines were cultured in serum free 
medium (SFM) containing 15ng/ml of human recombinant epidermal growth factor 
(cat no. 10450-013), 62.5μg/ml bovine pituitary extract (cat no. 13028-014) and 1% 
penicillin/streptomycin (cat no. 15070-063 from Life technologies UK).  
Normal fibroblast cell line NHOF-1 is derived from normal oral mucosa. They were 
separated from keratinocytes by treatment with 0.02% EDTA for 30s followed by 
addition of equal volume of PBS and vigorous mixing to promote detachment (Lim et 
al., 2011). Primary HNSCC derived cell lines Ca1, CaLH2, SqCC/Y1 are well 
characterized and have been used in multiple studies in our lab to represent disease 
state (Gemenetzidis et al., 2009, Teh et al., 2010). SVpgC2a is a Simian virus 40 T-
antigen-immortalised human buccal keratinocyte cell line. SVpgC2a cells retain a 
non-tumourogenic phenotype and can be used as a model of premalignant oral 
epithelium (Staab et al., 2004). They express low levels of FOXM1 oncogene 
(Gemenetzidis et al., 2009, Teh et al., 2010). SVFN10 cell line has been transformed 
from SVpgC2a by nicotine exposure and FOXM1 retroviral transduction (as a fusion 
EGFP-FOXM1B gene) hence overexpressing high levels of FOXM1 oncogene 
(Gemenetzidis et al., 2009). Normal fibroblast, primary HNSCC and transformed cell 
lines were cultured in Dulbecco's Modified Eagle Medium (DMEM) with 10% foetal 
bovine serum (FBS) (cat no. 02-00-850, from First Link Ltd UK) and 1% 
penicillin/streptomycin. All cells were cultured in a humidified incubator with 5% CO2  
and 95% atmospheric air at 37°C.  
2.2 Isolation of Exosomes by 
Ultracentrifugation 
It is critical to isolate exosomes without any contamination from non-vesicular 
components, including serum abundant proteins, apoptotic bodies, micro vesicles 
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and protein aggregates. Therefore after isolation, validation and characterisation of 
the purified vesicles is essential.  
Exosomes can be isolated by various methods such as immune isolation and 
repetitive density gradient ultracentrifugation (Thery et al., 2006). Immune isolation 
requires the use of monoclonal antibodies bound to magnetic beads against exosome 
surface membrane proteins (Clayton et al., 2001). Isolation by this method has the 
advantage of being independent of ultracentrifugation but since not all surface 
markers are known this method limits the separation of the whole exosome 
population, only isolating a specific group.  
Repetitive density gradient ultracentrifugation requires all the steps of 
ultracentrifugation along with an additional purification step in which a 30% sucrose 
gradient is used to separate the exosomes from other contaminant  based on their 
floating density of 1.15 to 1.19 g/m (Chiou and Ansel, 2016). Apart from the excessive 
time required, repeated ultracentrifugation can result in the loss of a significant 
proportion of the total exosome yield while the effects of 30% sucrose on exosome 
morphology and functionality are unknown. 
Differential ultracentrifugation is based on the principle of centrifugation of enriched 
cell culture supernatant or a body fluid sample containing exosomes at different 
speeds to isolate different fractions of extracellular vesicles. It is the most widely used 
method (Gould and Raposo, 2013) as it offers the advantage of isolating the entire 
exosome population irrespective of membrane surface markers from the enriched 
conditioned medium collected from cells and body fluids. This method was chosen 
based on the benefits mentioned above. 
Cells were seeded in T175 flask of surface area 175 cm2 in DMEM with 10% FCS 
and 1% penicillin/streptomycin. Once the flasks became 90% confluent with 
approximately 18 x 106 numbers of cells the medium was removed and the cells were 
washed with 1×PBS in order to remove any cell debris or remains of serum containing 
medium. Cells were then cultured in SFM for 3 days to allow exosome secretion into 
the supernatant. The conditioned SFM supernatant was collected and centrifuged in 
50 mL tubes at the speed of 500×g for 10 min to remove cellular debris and apoptotic 
bodies. The supernatant was then centrifuged in Sorvall discovery 100SE ultra-
centrifuge with a fixed angle rotor T-865 at the speed of 16500×g for 20 min to collect 
microvesicles. Special polycarbonate high speed centrifuge tubes from Thermo 
Scientific (cat. no. 314348) with screw cap lids (cat no. 314347) were used for high 
speed ultracentrifugation. The supernatant was filtered through a 0.22 µm filter to 
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remove protein and debris prior to centrifugation at 118000×g to obtain the final pellet 
of exosomes (Fig 2.1). For every new cycle of exosome isolation, ultracentrifuge 
tubes and caps were cleaned with 70% ethanol and rinsed in distilled water.  
 
Fig 2.1: Diagrammatic representation of differential ultracentrifugation 
protocol for exosome isolation from cell culture supernatant. Cells were 
incubated in serum free medium for 72 hrs. Different fractions of extracellular vesicles 
including apoptotic bodies, micro vesicles and exosomes were isolation at the speed 
of 500xg, 16,500xg and 118000xg respectively. Contamination by large protein 
aggregates was avoided by filtration through a 0.22 μm filter before isolating the final 
product of exosomes.  
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2.3 Exo-spinᵀᴹ (EXO) systems 
Although ultracentrifugation is the most frequently used method for isolating 
exosomes, it has the disadvantage of being labour intensive and time consuming. 
Secondly, the small invisible pellet of exosomes obtained through ultracentrifugation 
can be missed while collecting the final pellet. In order to overcome these limitations, 
we tested a commercially available exosome isolation kit called EXO-spinᵀᴹ, 
exosome purification kit from Cell Guidance Systems (cat no. EXO1-25). The kit is 
based on incubation of conditioned supernatant containing exosomes with buffer A 
comprising ploy-ethylene glycol (Lane et al., 2015) followed by column purification.  
Conditioned medium was collected from SVpgC2a and SVFN10 cell lines and 
centrifuged at 300×g for 10 min, followed by 20,000×g for 30 min to remove cells and 
debris. Supernatant was transferred to a new centrifuge tube and incubated with half 
a volume of buffer A and mixed well. The samples were incubated overnight at 4°C, 
followed by centrifugation at 20,000×g for one hour. The pellet obtained was 
suspended in 100 µl of 1xPBS. The spin column containing PBS was prepared by 
removing outlet plug and centrifuged at 50×g for 30s. This allowed the PBS to enter 
the column bed. Another 200 µl of PBS was added and spun down at 50×g for 30s to 
equilibrate the column. Exosome pellet suspended in 100 µl of 1xPBS was added to 
the column and centrifuge at 50×g for 30s, elute was discarded. 200 µl of 1xPBS was 
added and the column was centrifuged at 50×g for 1min to elute 200 µl of purified 
exosomes. The use of this kit was further discontinued due to lower particle/ml 
concentration of exosomes. In addition the exosomes were larger in size compared 
to isolation through ultracentrifugation. This might be the result of merging of outer 
lipid bi-layer of exosomes (Appendix Fig: 8.1, 8.2, Page: 189, 190). 
2.4 Isolation of exosomes from blood by 
ultracentrifugation 
Isolation of exosomes from body fluids requires dilution of samples to a workable 
viscosity along with extended duration of centrifuge with additional filtration and 
washing (Thery et al., 2006). 
Before the start of this study whole blood was collected from cancer patients and 
frozen down for future experiments. For exosome isolation the samples were 
defrosted and diluted to a workable viscosity. To facilitate ease of handling, 1.5 ml of 
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whole blood was diluted in 18.5 ml of 1xPBS. The sample was centrifuged at 2000×g 
for 10 min to get rid of cellular debris. It was further transferred into clean 
ultracentrifuge tubes and centrifuged at 20,000×g for 40 min to isolate micro vesicles. 
The diluted whole blood was filtered through 0.22 µm filter and centrifuged again at 
118,000×g for 70 min. The exosome pellet was suspended in 20 ml of 1×PBS and 
was filtered again through 0.22 µm filter and centrifuged again at 118,000×g for 70 
min for a final wash (Fig 2.2). The final pellet of exosomes was verified by NanoSight 
tracking analysis (NTA, section 2.10 below).  
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Fig 2.2: Graphic illustration of exosome isolation from whole blood 
through differential ultracentrifugation. Frozen whole blood was defrosted and 
diluted in 1xPBS to a workable viscosity and centrifuged at 2000xg for 10 min to 
exclude cellular debris. Supernatant was further centrifuged at 20,000xg for 40 min 
to separate micro vesicles. In contrast to the ultracentrifugation protocol for cell 
culture supernatant, whole blood exosome isolation needed addition filtration through 
a 0.22 μm filter and washing for 70 min.  
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2.5 Isolation of exosomes from Saliva by 
ultracentrifugation 
Similar to whole blood, saliva sample was also diluted to a workable viscosity by N-
Acetylcysteine (NaC), a drug derived from amino acid L-cysteine. In the past it has 
been used for effectively diluting patient saliva samples (Ericson et al., 1988) and in 
the  treatment of Sjogren’s syndrome (Walters et al., 1986). 
Healthy volunteers were used to collect 4 ml of saliva in which 8 ml of NaC (5mM) 
was added to decrease viscosity. The suspension was centrifuged at 2000×g at 4˚C 
for 10 min to get a pellet of cellular debris. Carefully without disturbing the pellet, the 
supernatant was taken out and diluted with 8 ml of 1xPBS. The sample was 
transferred to clean ultracentrifuge tubes and centrifuged at 20,000×g for 40min. It 
was further filtered through 0.22 µm filter and centrifuged at 118,000×g for 70 min. 
The pellets were suspended in 1 ml of 1xPBS and pooled together into one tube. To 
attain the final volume of 20ml the tube was topped up with 18 ml of 1xPBS. The 
sample was filtered once gain through 0.22 µm filter and centrifuged at 118,000×g 
(Fig 2.3). The final pellet was suspended in 500 µl of distilled H₂O and used for NTA. 
Attempt was made to isolated exosomes from 500 µl of cancer patient saliva but the 
starting volume was very low for the exosomes to be detected by NTA. 




Fig 2.3: Graphic illustration of exosome isolation from normal saliva sample 
through differential ultracentrifugation. Fresh saliva was diluted to a workable 
viscosity by addition of N-acetylcysteine (NaC) dissolved in double distilled water. The 
sample was centrifuged at 2000xg for 10 min to exclude cellular debris. Microvesicles 
were separated at 20,000xg for 40min. Followed by size exclusion filtration with a 
0.22 μm filter and centrifuged at 118,000xg for 70 min. The final pellet of exosomes 
was washed in 1xPBS at 118,000xg for 70 min.  
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2.6 Isolation of exosomes from plasma 
Healthy volunteer’s plasma was used for optimisation of exosome isolation protocol. 
Unfortunately for this study fresh blood from cancer patients was not available for 
separation of plasma. 
Healthy volunteer’s whole blood was collected in EDTA treated blood collection tubes. 
Whole blood (20 ml) was diluted in 10 ml of RPMI medium to obtain a workable 
viscosity.  Plasma was separated from whole blood by adding 15 ml of FicollTM in a 
50 ml tube, to which 15 ml of diluted blood was added. The tubes were centrifuged at 
650×g at 4°C for 20 min resulting in separation of plasma from red blood cells and 
the buffy coat containing white blood cells. Plasma was carefully collected from the 
top layer. 
Plasma (2ml) was diluted in 18 ml of PBS in a 50 ml tube and centrifuged for 30 min 
at 2000×g at 4°C to exclude cellular debris. The supernatant was carefully transferred 
into ultracentrifuge tubes without disturbing the pellet and centrifuged at 20,000×g for 
40 min to isolate microvesicles. The supernatant was filtered through 0.22 µm filter 
and centrifuged at 118,000×g for 70 min to obtain a pellet of exosomes. The exosome 
pellet was suspended in 20 ml of 1×PBS and was filtered again through 0.22 µm filter 
and centrifuged at 118,000×g for 70 min for a final wash (Fig 2.4). The final pellet 
obtained was used in downstream experiments including NTA and immune TEM. 
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Fig 2.4: Diagrammatic representation of exosome isolation from plasma. 
Whole blood was carefully poured on top of a Ficoll layer in a centrifuge tube and 
centrifuged at a slow speed of 650xg for 20 min; separating plasma from red blood 
cells and peripheral mononuclear cells. It was further diluted and spun at 2000xg and 
20,000xg to segregate cellular debris and micro vesicles respectively. Size exclusion 
of bigger particles was achieved by filtration through 0.22 μm filter. Diluted plasma 
was centrifuged at 118,000xg for exosome isolation. Exosome pellet was further 
washed in 1xPBS, filtered through 0.22 μm filter and centrifuged at 118,000xg for 70 
min to ensure a purified pellet of exosome.  
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2.7 Scanning Electron Microscopy (SEM) 
Given the nano-size of exosomes, they are not visible under a conventional light or 
confocal microscope as these apparatuses are not able to resolve below 20 µm 
(Alberts B et al., 2002). Hence, visualizing exosomes after ultracentrifugation is 
important to confirm successful isolation and characterization of exosomes.  
SEM produces images of a sample by scanning it with a focused beam of electrons. 
The electrons interact with atoms in the sample, producing signals that can be 
detected and contain information about the sample's surface topography and 
composition. Biological specimen normally requires being completely dry, as the 
specimen chamber is maintained at high vacuum. 
To facilitate fixation of exosome pellet, along with 100 µl of spun supernatant used as 
a control was suspended in 90 µl of 1xPBS and 10 µl of 25% glutaraldehyde and 
incubated for one hour prior to a wash step by ultracentrifugation at 118000×g for 90 
min with 20 ml of 1xPBS. The fixed pellets obtained were suspended in 100 µl of 
1xPBS. In order to aid attachment, 13 mm coverslips were incubated for 30-45 min 
at room temperature with 100 µl of fibronectin (0.5 mg/ml) suspended in medium. 
Excess was removed with an aspirator. Without allowing the coverslips to dry, the 
samples were placed in an incubator overnight at 37°C. Further, the coverslips were 
dehydrated by washing in ascending series of ethanol dilutions starting with 30%, 
50%, 70%, 80%, 90% and 95% for 5 min, followed by two 5 min washes in 100% 
ethanol. The sample were chemically dried in 100% HMDS (Hexamethyldisilazane) 
for 3 min. Excess was removed and the samples were placed at 37°C for 30 min. 
Double-sided adhesive carbon conductive tape was used to secure the samples onto 
the SEM stubs. A carbon conducting cement was used to aid a conducting pathway 
between the stub and the coverslips. The cement was allowed to dry for 24 hours. 
The samples were analysed with both gold and carbon coating. Scanning electron 
microscope FEI Inspect F was used at 0.5 to 30 kV to study the samples. Higher kV 
was required for lower magnification. The xT microscope control software was used 
to control the operation of the microscope while the image capturing software was 
used to obtain images. SEM was supervised by Dr Russell Bailey at the Nano Vision 
centre, QMUL. 
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2.8 Transmission Electron Microscopy (TEM) 
Although, SEM is a standard technique used to visualize exosomes, the phenomena 
of agglomeration is commonly observed (Sokolova et al., 2011). This hinders in 
observing the individual morphology of the exosomes. In order to characterize 
exosomes through morphological features previously reported in the literature (Thery 
et al., 2006), TEM was  performed to obtain better resolution of exosomes. 
TEM operates on the same basic principles as the light microscope but uses electrons 
instead of light. Due to smaller wavelength of electrons in comparison to light, optimal 
resolution attainable for TEM images is many orders of magnitude better than that 
from a light microscope. Thus, TEM can reveal the finest details of internal structure. 
A high energy beam of electrons passes through a very thin layer of sample, and the 
interactions between the electrons and the atoms can be used to observe different 
features of the sample such as surface membrane morphology. 
In order to visualize exosomes using TEM, final pellet of SVpgC2a and SVFN10 
exosome along with 100 µl of filtered supernatant (used as a control) was suspended 
in 100 µl of 4% paraformaldehyde for 10 min. Resuspended pellet (5µl) was placed 
on carbon coated EM grids (Catalogue no. S160-4 carbon film, 400 Mesh Cu by Agar 
scientific) for 20 min in dry environment. 
A drop of 100 µl of 1xPBS on parafilm sheet was used to wash the grid (membrane 
side down). The grids were transferred to a 50 µl drop of 2.5% gluteraldehyde for 10 
min, followed by eight washes in 100 µl of distilled water (Thery et al., 2006). The 
samples were stained by 0.4% lead citrate for 1 min. Stained grids were washed 
twenty times with distilled water and air dried on filter paper (Venable and Coggeshall, 
1965). TEM was supervised by Dr Russell Bailey from Nano Vision centre QMUL. 
2.9 Particle size verification by Zetasizer 
Imaging techniques such as SEM and TEM are costly, time consuming and require 
fixation of exosomes making them unusable for further experiments. Particle size 
measurement through Zetasizer does not require fixation and hence the samples can 
be preserved.  
Zetasizer accurately estimates particle size by measuring the Brownian motion of 
particles in a sample using Dynamic Light Scattering. Conditioned medium (80 ml) 
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was collected from SVpgC2a and SVFN10 cell lines and centrifuged at required 
speed to collect fractions of cellular debris (CD), micro vesicles (MV), supernatant 
(from final spin) and exosomes. 
Pellet of CD, MV and exosome were suspended in 1ml of distilled water and 1 ml of 
supernatant was collected as a control after the final centrifuge. The samples were 
transferred to disposable transparent cuvettes and read on the Zetasizer Nano-ZS 
Malvern instrument (Model: ZEN3600, Serial no. MAL500457, Software: Zetasizer) 
to measure the particle size in each fraction. All samples were read at 4°C and particle 
size was measured as intensity percent with respect to diameter in nanometre (nm). 
 
2.10 Particle size verification by NanoSight  
Although Zetasizer is informative of particle size, it does not provide a visual output 
and a particle/ml concentration. Hence, variation in size measurements due to 
formation of aggregates cannot be identified. To overcome this limitation of Zetasizer, 
exosomes were analysed using Nanosight Tracking Analysis (NTA) LM10 instrument 
by Malvern. 
NTA is a unique method of visualizing and analysing particles in liquid suspension 
with or without fluorescent labels, it can measure the size of particles ranging from 
10-2000 nm. The particles are observed under Brownian motion; the rate of 
movement is related only to the viscosity of the liquid, the temperature and size of the 
particle and is not influenced by particle density or refractive index. 
The particles contained in the sample are visualized by virtue of the light they scatter 
when illuminated by laser light. The light scattered by the particles is captured using 
a scientific digital camera with 20x magnification. The motion of each particle is 
tracked from frame to frame by the specially developed software. Also, since video 
clips form the basis of the analysis, accurate characterisation of real time events such 
as aggregation and dissolution of particles was possible. 
Conditioned supernatant from cell lines NK4, OK113, NOK368, Ca1, CaLH2, 
SqCC/Y1, SVpgC2a and SVFN10 were centrifuged to obtain the pellet of exosomes 
and filtered supernatant collected after final centrifugation at 118000×g for 70 min. 
Exosome pellets were suspended in 500 µl of RNA free water. Sterile 1 ml syringe 
was used to load 200 – 300 µl of the sample on NanoSight LM10 sample chamber. 
All measurements were performed at room temperature. For capturing and analysing 
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the data NTA 2.0 software was used. The samples were observed for 60s with manual 
shutter and gain adjustments. Particle size verification of exosomes by NTA LM10 
instrument was carried out in School of Pharmacy, University College London. 
2.11 Western blotting 
For further characterisation of exosomes from cell lines NOK368, NK4, OK113, Ca1, 
SqCC/Y1, CaLH2, SVpgC2a and SVFN10 western blotting for exosome specific 
proteins was done. Exosomal pellet and parental cells were lysed in sample buffer 
(4% SDS, 20% glycerol and 0.125M Tris HCL at pH 6.8). Samples were heated at 
95°C for 5 min to denature the protein. Total protein concentration was measured 
using a BSA standard and the DCᵀᴹ Protein Assay (Bio-Rad, Hamel Hampstead, UK). 
The total protein was analysed using 10% 2-merceptoethanol and 0.004% 
bromophenol blue to the lysate and separated by SDS-PAGE (NuPage Novex 10% 
bis tris protein gels, 1.0mm, 10 wells). For both gel electrophoresis and the transfer, 
Novex mini cell system was used (Invitrogen, Paisley, UK). The membranes were 
blocked with 5% fat-free milk in TBS-T buffer for 1 hour to avoid non-specific binding 
and washed 3 times for 10 min each with TBS-T (20 mM Trizma base, 150mM NaCl, 
1% Tween 20). Membranes were than probed with primary antibody (diluted in 
blocking buffer) overnight at 4°C and washed with TBS-T to prepare for incubation 
with secondary antibody (diluted in blocking buffer) for 1 hour at room temperature 
(Table 2.1 and 2.2) . Membranes were washed again with TBS-T. Proteins were 
detected with Amersham ECL prime western blotting detection reagent (GE 
healthcare life sciences, Little Chalfont, UK). Peroxidase activity was measured in the 
dark room with autoradiography film (Amersham Hyperfilm ELC, GE Healthcare, Little 
Chalfont Bucks, UK) 
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Table 2.1: Primary Antibodies used for western blotting 
 
 
Table 2.2: Secondary Antibodies used for western blotting 
 
 
2.12 Gene Knockdown by siRNA 
Result of gel electrophoresis showed that anti-CEP55 antibody produced two bands 
very close to the target molecular weight of 55 kDa (Fig:3.8, Page no. 95). In order 
to identify the true band and check the specificity of the antibody siCEP55 transfection 
was done to knockdown the protein from SVFN10 cell line. 
SVFN10 cells were seeded in the density of 3×10⁵ in three wells of diameter 34.8 
mm. The cells were incubated overnight in DMEM medium containing foetal calf 
serum (FCS), excluding antibiotics at 37˚C in 5% CO₂.  
For transfection, 5 µM siRNA (CEP55) solution was prepared in RNase-free solution. 
In a 1.5 ml Eppendorf (Tube 1) 10 µL of 5 µM siCEP55 solution was added along with 
190 µL of serum free medium (DMEM without FCS). In another 1.5 ml Eppendorf 
(Tube 2) 194 µL of serum free medium (DMEM without FCS) was added to 6 µL of 
DharmaFECT. The contents of both the tubes were mixed by pipetted up and down 
and incubated for 5 min at room temperature. Further, the contents of tube 1 were 
added to tube 2 and mixed by pipetting and incubated for 20 min at room temperature. 
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Antibiotic free medium (1.6 ml) was added to the mix to make up the final volume of 
2 ml (Table: 2.3).  
The culture medium from SVFN10 cells was removed and the mixture containing the 
content of tubes 1 and 2, and antibiotic free medium, was added to the cells. The cells 
were incubated at 37˚C with 5% CO₂ overnight for 48 hours. The knockdown of 
CEP55 mRNA and protein were analysed by RT-qPCR and western blotting, 
respectively. 
A similar method was used for control sample which was SVFN10 cells transfected 
with siCtrl solution. Untreated SVFN10 cells were used as an additional control. 
 
Table 2.3: Experimental design of siCEP55 transfection in SVFN10 cells. 
 
 
2.13 Immuno-gold labelling of exosomes 
Exosomes were immuno-labelled with antibody against protein CEP55 to investigate 
its presence at the membrane and to compare the level of expression in normal and 
cancer exosomes.  
Exosomes were isolated by ultracentrifugation (Section 2.2, page no. 40) from 
normal oral keratinocyte cell line OK113, tumour derived cell lines SqCC/Y1 and 
normal plasma. The exosome pellet was fixed in 100 µl of 4% Paraformaldehyde 
(PFA) from which 5 µl was placed on carbon coated electron microscopy grids. The 
grids were covered and left for 20 min to facilitate adsorption. Further, the grids were 
washed in 100 µL drops of 1×PBS and transferred in PBS/50mM ammonium chloride 
(NH4Cl) for 3 min. The grids were transferred to blocking buffer (10% foetal calf 
serum) for 10 min followed by a transfer to 5 µl drops of CEP55 antibody in the dilution 
of 1:50 in blocking buffer for 30min. The grids were washed multiple times in washing 
buffer for 3 min. The grids were incubated with secondary (bridging) antibody diluted 
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in blocking buffer for 30 min and transferred to 100 µl drops of PBS/0.5% BSA and 
washed 3 times. 
Further, the exosomes were incubated in 5 µl drops of protein A-gold conjugates 
diluted in blocking buffer for 20 min followed by multiple washes (7 times) in 1×PBS. 
The grids were transferred to 50 µL drops of 1% glutaraldehyde for 5 min to stabilize 
immunoreaction. The grids were washed multiple times (7 times) in 100 µl drops of 
double distilled water, each time for 2 min. The samples were contrasted using 4% 
uranyl oxalate at pH 7 for 5 min. 
Immuno-gold labelling was done by Dr Giulia Mastroianni (TEM Facility Manager) at 
QMUL, following the protocol published in “Isolation and characterization of 
exosomes from cell culture supernatant and biological fluids.” (Thery et al., 2006). 
The CEP55 primary antibody used was the same as used for western blotting (Table 
2.1). 
2.14 Detection of fluorescent labelled 
exosomes by NTA 
The NTA instrument NS500 has the ability to operate in fluorescence mode with a 
range of excitation wavelengths allowing visualization, sizing and concentration 
measurement of fluorescently labelled exosomes. This capability of NTA was used to 
quantify the presence of CEP55 on the membranes of exosomes derived from normal 
oral keratinocyte cell line OK113, tumour derived cell line CaLH2 and transformed 
malignant cell line SVFN10. ALIX an exosomal specific surface protein (Henne et al., 
2011) was used as a positive control for exosomes. 
The exosomes pallets were suspended in 110 μl of 1xPBS and divided in to two equal 
halves of 50 μl. Each half of the sample was incubated with 1 μl of ALIX and CEP55 
antibody (Table 2.1) respectively. After an overnight incubation with primary antibody 
0.5 μl of secondary antibody goat anti-mouse Alexa Fluor 488 (catalogue no. A-11029, 
Life technologies) and goat anti-rabbit (catalogue no. A-11070, Life technologies) 
were added to the samples. 
At the time this study was conducted NTA instrument NS500 was not available in 
Queen Mary University hence our prepared samples were shipped to Malvern 
Company for analysis. 
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2.15 Exosomal RNA Cargo 
To investigate the presence of RNA within exosomes, the final exosome pellet was 
subjected to treatment with RNase A, Proteinase K and triton X. The treatment was 
designed to eliminate contaminating proteins and RNA that spins down with the 
exosomes during ultracentrifugation. 
Exosome pellet was collected from SVpgC2a and SVFN10 cell lines. Each pellet was 
dissolved in 260 µl of RNA free water and divided into five equal parts of 50 µl each. 
Exosomes treated with RNase free water and only RNase A (0.6 μg/ml) was used as 
controls. Rest of the samples were treated with proteinase K (1U/ml), triton X (2%) 
and a combination of two followed by RNase A treatment (Fig 2.5).  
Treatment with proteinase K required the samples to be incubated at 55°C for 10 min 
in order to activate proteinase K, followed by 5 min incubation at 95°C for deactivation. 
Further, RNase A was added to all the samples except the RNase free water treated 
controls and incubated for 30 min at 37°C (Fig 2.5). Total RNA was extracted using 
RNeasy micro kit (74004) from Qiagen, followed by verification through Agilent 
BioAnalyzer and RT-qPCR. 





Fig 2.5: Diagrammatic representation of exosomes treated with proteinase K 
(1U/ml), triton X (2%) and RNase A (0.6 μg/ml) to eliminate extracellular RNA 
contamination that can settle with exosomes during isolation through 
ultracentrifugation. Cellular debris from SVFN10 cells, SVpgC2a and SVFN10 
exosomes treated with RNase free water and only RNase A were used as controls.  
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2.16 Total RNA extraction from exosomes and 
cell lines 
RNeasy Micro Kit (74004, Qiagen) was used to extract total RNA from treated 
exosomes and cell lines. The kit is based on selective binding properties of silica 
based membrane to RNA in combination with high speed micro spin technology. Lysis 
buffer (RLT) containing guanidine thiocyanate and ethanol, added to the samples 
create conditions that promote selective binding of RNA to RNeasy Mini Elute spin 
columns 
Due to the small size of exosomes, they are known to contain short fragments of RNA 
measuring less than 120 nucleotides. For isolation of short fragments 1 volume of 
100% ethanol was added to lysed exosomes in RLT lysis buffer as suggested in 
literature (Valadi et al., 2007). The samples were centrifuged in RNeasy MinElute spin 
columns for 15s at >8000xg and the flow-through were discarded. 
Further according to manufacturer’s protocol 1 volume of 70% ethanol was added to 
the spin columns and spun for 15s at >8000xg and the flow-through were discarded. 
Buffer RW1 (350μl) was added to the spin column and centrifuged for 15s at >8000xg 
again the flow through was discarded. 
Any possible DNA contamination was removed by treatment with DNase1 and the 
samples were washed again in RW1 buffer.  Buffer RPE (500 μl) containing ethanol 
was added to the spin columns and centrifuged for 15s at >8000xg. Further 500μl of 
80% ethanol was added to the spin columns and centrifuged for 2 min at >8000xg 
again the flow-through was discarded. The membranes of the spin columns were 
made dry by opening the lids of the spin columns and centrifugation at full speed for 
5 min. High quality of total RNA was eluted in 15 µl of RNase free water and 
centrifuged at full speed for 1 min to collect 13 µl of total RNA. 
 
Reverse transcription reaction was run to convert total RNA to cDNA. To every 13 
µl of total RNA 7.5 µl of cDNA synthesis mix was added containing: 5×Buffer (4.0 µl), 
dNTP (2.0 µl), dT/rP (0.8 µl), RNasin (0.4 µl), RT enzyme (0.4 µl). Samples were 
placed in a thermocycler at 42°C for 30min followed by 85°C for 5 min, cDNA was 
stored at 4°C.  
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2.17 Agilent BioAnalyzer 
Agilent RNA 6000 pico kit (catalogue no. 5067-1513) containing chips and reagents 
were used to analyse total RNA quality of treated exosomes. Each RNA chip contains 
an interconnected set of micro-channels that are used for separation of nucleic acid 
fragments based on their size as they are driven through electrophoresis. They are 
designed to be used with Agilent 2100 BioAnalyzer instrument. One chip can analyse 
11 samples and require 1 µl of sample volume. A gel-dye mixture was prepared by 
adding 1 µl of dye in 65 µl of filtered gel. It was vortexed and spun at 13000×g for 10 
min at room temperature to ensure a homogenous solution. 
Total RNA (1 μl) extracted from treated SVpgC2a and SVFN10 exosomes (Fig 2.5) 
along with the gel-dye mix was added to the allocated well and the chip was pressure 
primed by using a priming station connected to a 1ml syringe. The plunger was 
pressed for 30 sec and then slowly pulled back to the starting position. RNA 
conditioning solution, marker and ladder was added in respective wells. After adding 
1 µl of the sample, the chip was placed horizontally in an IKA vortex and vortexed for 
1min at 2400 rpm. The chip was run in Agilent 2100 bioAnalyzer instrument within 5 
min. 
2.18 Functional exosome transfer assay 
In order to investigate any functional changes caused by exosomes on recipient cells. 
The cells were transfected with normal, pre-cancerous and cancerous exosomes, for 
different time durations in order to determine a suitable time of exposure that would 
cause an effect. 
Recipient cells in the density of 1x107 were seeded in culture wells of 22 mm in 
diameter (6 well plate), with 500 µl of DMEM medium with 10% FCS and 1% 
Pen/strep. Once the cells were attached to the culture plate 200 µl of the medium was 
carefully removed and exosome pellet dissolved in 200 µl of SFM was added to the 
cells. Cells were also treated with 200 µl of RNase free water and depleted medium 
as controls. The samples were incubated for 24, 48 and 72 hours at 37°C and 10% 
CO₂. 
The concentration of exosomes was determined through NTA and normalized so 
each sample had approximately the same number of exosomes. Total RNA was 
extracted using RNeasy Micro Kit (74004, Qiagen) as per manufacturer’s protocol. 
Quantity and quality of RNA was analysed using nano drop.  
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For functional assay’s carried out on normal oral keratinocytes, the recipient cells 
were grown in SFM without 10% FCS. Through RT-qPCR expression levels of 
multiple senescence and differentiation markers were tested. 
2.19 Quantitative Polymerase Chain Reaction 
(RT-qPCR) 
RT-qPCR is based on amplification of DNA, it can precisely distinguish and quantify 
small amount of specific nucleic acid sequence present in a sample. It is a robust and 
widely used technique with major application in assessment of changes in gene 
expression as a result of deregulation of normal biological processes.  
In the exosome study RT-qPCR was performed using both Taqman probe and SYBR 
green dye. Taqman probe uses a fluorogenic probe specific to target gene to detect 
target as it accumulates during PCR. It offers higher sensitivity and specificity but is 
a costly method. SYBR green dye binds to double stranded DNA and is detected 
during extension phase of RT-qPCR. It is the most widely used method, although it 
does not offer the same level of sensitivity as Taqman probe it is cost effective, 
allowing scanning through numerous genes. 
Since exosomes contain less RNA compared to cells, more specific Taqman gene 
expression assay was used for detection of exosomal RNA. Taqman gene expression 
assays for FOXM1 (Hs1073586_m1), CEP55 (Hs01070181_m1) and β-Actin 
(Hs01060665_g1) were performed using LightCycler® 480 Probes Master 
(#04707494001, Roche Diagnostics) with a pre-incubation of 50ºC, 2 min and 95ºC, 
10 min hot-start followed by 50 cycles of 95ºC, 10s and 60ºC, 60s.  
RT-qPCR was performed using forward and reverse primers (Table 2.4, Page no. 
62) and SYBR green dye on exosome transfected cells in order to evaluate any 
functional changes caused by exosomes. Amplification protocol included 
denaturation at 95°C for 10 min followed by 45 cycles of 95("Stanford Microarray 
Database. [http://smd.stanford.edu/],")° for 10 s, 60° annealing for 6 s and 72°C 
elongation (incubation time depends on the length of the product ; 1s/25 base pairs). 
Fluorescence readings were acquired at 75°C following the elongation step. At the 
end of 45 cycles, samples were subjected to a melting analysis to confirm 
amplification specificity of the PCR product. 
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2.20 β- Galactosidase staining 
Normal cells can permanently lose the ability to proliferate when challenged by 
potential stress, a process termed cellular senescence. Senescence-associated beta-
galactosidase (SA-βgal) activity permits the identification of senescent cells in culture. 
The LacZ gene from E.coli is one of the most commonly used reporter genes for 
testing the efficiency of expression vector mediated gene transfer and for studying 
the regulation of promoters of genes. The LacZ gene encodes the enzyme β-
galactosidase, which is very stable, resistant to proteolytic degradation, can utilize a 
variety of substrates and can be easily assayed in situ. The β_Galactosidase staining 
kit from BioVision (catalogue no. K802-250) utilizes X-gal as the substrate. 
Cells were first treated with chemotherapeutic drugs causing senescence including 
Dimethyl sulfoxide (DMSO), Azacitidine (5AZA), Trichostatin A (TSA) and Etoposide 
(ETO) to check if senescence can be induced (Fig 2.6).  
 
 
Fig 2.6: Drug treatment of SVpgC2a cells to induce senescence. Each well 
contains approximately 0.1x106 of SVpgC2a cells in 1 ml of DMEM medium. Drugs 
were added to provide final concentrations of 1x10-5, 1x10-6 and 1x10-7 M as indicated. 
 
After 24 hrs of drug treatment, cells were prepared for X-gal staining. The medium 
was removed and the cells were washed in 1xPBS followed by addition of 0.5ml of 
fixative solution for 10-15 min at room temperature. Fixed cells were washed twice in 
1xPBS before adding 0.5 ml of staining solution mix in each well containing 470 µl of 
staining solution, 5  µl of staining supplement and 25 µl of 20 mg/ml X-gal in DMF 
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(Dimethylformamide). The plate was covered and incubated overnight at 37°C. The 
cells were observed under a microscope for development of blue colour. 
The treatment with Etoposide in the concentration of 1x10-7  M for 24 hours was able 
to senesce cells. Once senescence was established in SVpgC2a cells, they were 
treated with self and SVFN10 exosomes for 48 hrs. The exosome transfected cells 
were stained for X-gal in the similar way as mentioned above. 
2.21 Microarray 
OK113 cells in the density of 1×105 / well were seeded in 6-well plates. The cells were 
grown in SFM (as mentioned earlier). Once the cells were 70% confluent they were 
transfected with exosomes from cell lines OK113, NK4, NOK368, CA1, CALH2, 
SQCC/Y1, SVpgC2a and SVFN10. The particle/ml concentration of exosomes, 
measured on Nanosight was normalized so that each well contained 2x1010 
exosomes (Table 2.5). Untreated OK113 cells were used as a control. After 48 hrs of 
incubation the cells were washed with 1×PBS and lysed in lysis buffer (RLT buffer) 
for total RNA extraction using RNeasy Micro Kit from Qiagen (catalogue no. 74004). 
Quality and quantity of total RNA was analysed on Nano drop 1000 
spectrophotometer and Agilent Bioanalyzer. 
 
Table 2.5: Normalized concentration of exosomes measured by NTA. 
  
 
An Illumina genome wide gene expression array for human samples HT12v4 
exploring 47,231 genes was performed by Eva Wozniak, Senior Research Technician 
at Barts and The London Genome Centre, Queen Mary University of London. Illumina 
arrays target the 3' end of genes with 50 bp probes bound to microbeads. It is a robust 
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method for surveying global gene expression of protein coding genes. The data from 
microarray was analysed on Genome studio version 3. The results of microarray were 
verified by RT-qPCR. 
2.22 Clinical specimens 
The use of fresh biopsy clinical specimens collected from UK and FFPE samples from 
Norway was approved by relevant Research Ethics committees at each institute UK 
NREC: 06/MRE03/69 (head and neck) and Norway REK Vest: 2010/481-7 (head and 
neck). The samples were collected according to local ethical committee approved 
protocols and informed patient consent was obtained from all participants. The 
histopathology report of each sample was collected from collaborating clinicians.  
The fresh biopsy specimens were stored in RNA later solution (#AM7002, Ambion, 
Applied Biosystems, Warrington,UK) at -20ᵒC. For cDNA synthesis Transcriptor 
cDNA synthesis kit by Roche was used. 
2.23 Total RNA extraction and analysis of FFPE 
samples 
RNA extraction from FFPE samples is challenging because fixation and embedding 
conditions affect nucleic acid, making them fragmented and chemically modified by 
formaldehyde. Resulting in lower molecular weight than those obtained from fresh or 
frozen samples. The RNeasy FFPE kit (Qiagen catalogue no. 73504) was used to 
purify total RNA from FFPE samples, isolating RNA molecules longer than 70 
nucleotides. 
Fifteen samples were tested 3 normal, 4 dysplastic, 4 OSCC and 4 from tumours that 
have metastasized to lymph nodes. Deparaffinization was done by treating samples 
with xylene. Sample incubation in lysis buffer containing proteinase K releases RNA 
from 5 micron FFPE sections. 15 min incubation at 80°C partially reverses formalin 
crosslinking from nucleic acids giving a good quality and a high yield of RNA. 
Treatment with DNAse eliminates all genomic DNA including small segments that 
persist in FFPE samples due to prolonged formalin fixation and storage. 
Buffer RBC containing ethanol was added to provide optimal binding conditions for 
RNA. In RNeasy Mini Elute columns, RNA binds to the membrane while the 
contaminants were washed away. RNA was eluted in 15 µl of RNase-free water giving 
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13 µl of total RNA, where 2 µl accounts for dead volume of RNeasy Mini Elute column. 
Reverse Transcription reaction was run to convert RNA into cDNA. To every 13 µl of 
RNA 7.5 µl of cDNA synthesis master mix was added containing 5×Buffer (4.0µl) , 
dNTP (2.0µl) , dT/rP (0.8µl) , RNasin (0.4µl) , RT enzyme (0.4µl). 
Setting up qMIDS assay in a 384 well plate 
To set up qMIDS assay in a 384 well plate 2 µl of forward and reverse primers (2.5μM) 
of 16 genes were loaded at the bottom of each well using a 16 channel pipette. The 
primers were arranged in the following order (Fig 2.7) 
 
 
Fig 2.7: Order in which primers were loaded into the 384 RT-qPCR plates along with 
their forward and reverse sequence. The diagram was provided by Dr Muy-Teck Teh. 
 
Each qMIDS assay plate measures 10 unknown samples in duplicates with calibrator 
and standard. To each cDNA sample 90 µl of 2 × SYBR Green I Master mix was 
added and 3 µl loaded in to each well, each sample was run in duplicates. RT-qPCR 
384 plate was sealed with Roche’s LC480 RT-qPCR sealing foil. The edges were 
pressed with a plastic spreader and the tray was centrifuged to allow the contents to 
flow to the bottom of the well. 
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RT-qPCR was run on LightCycler LC480 instrument; the touch-down cycles were 
increased from 8 to 13 to allow amplification of samples with high crossing point (Cp) 
values. The samples were labelled and the data was analysed. 
2.24 RNA extraction for fresh frozen biopsies  
Different methods of RNA extraction were tested to affirm a method that would yield 
high quality RNA from heterogeneous fresh frozen biopsy tissue and would aid in 
making the protocol for qMIDS assay concise. Roche mRNA capture kit (Reference 
number 11787 896 001) and Qiagen RNeasy micro kit (catalogue number 74004) 
were compared to the original method used for qMIDs, Dynabeads mRNA direct kit. 
Dynabeads mRNA Direct Kit (Invitrogen catalogue number 610.12) was used for 
mRNA extraction from fresh frozen tissue biopsy samples from OSCC patients. 
Samples were selected in pairs of margin and core tissue from the same patient and 
stored in RNA later at -80ᵒC. 
Tissue digestion 
Frozen samples were defrosted at room temperature and sample ID’s along with the 
date of biopsy were noted down. Tissue was digested in digestion buffer containing 
lysis buffer and proteinase K (1U/ml). A sharp scalpel was used to cut 1-2 mm³ 
sections from biopsy sample. The small piece of tissue was minced into further small 
pieces to aid quick digestion and incubated at 60°C for 20 min. 
 
mRNA extraction 
To the digested tissue 40 µl of Dynabead was added and triturated to reduce the 
viscosity by shearing genomic DNA. Samples were rotated for 10 min on a mixer and 
RT master mix was prepared using the same quantity as mentioned earlier for cDNA 
synthesis. 7.5 µl of the master mix was allocated in each PCR tube.  
The rotated samples were placed on a magnetic rack. The tubes were inverted a 
couple of times to collect all the beads from the cap. Removing the magnetic rack the 
samples were triturated once more to mix the contents. 
The beads were concentrated using the magnetic rack to collect the supernatant. 
Removing the magnetic rack 400 µl of buffer A was added and the samples were 
triturated. Placing the samples back on the magnetic rack buffer A was removed.  
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Same process was repeated with buffer B. Beads were suspended in 13µl of tris HCL 
and placed on the heat block for 2 min at 82°C to elute the mRNA from the beads. 
The samples were immediately placed on the magnetic rack and 13 µl of mRNA was 
collected and added to 7.5 µl of the total master mix. The tubes were capped and 
placed into the thermocycler for cDNA synthesis.  
2.25 Statistical analysis 
For all the data in this thesis statistical significance was calculated by One - way 
ANOVA and t-test on Graph Pad Prism software and Microsoft excel. A Mann Whitney 
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3.1 Introduction 
Oral squamous cell carcinoma (OSCC) is the most common malignant neoplasm of 
the oral cavity. Currently, the gold standard of diagnosing OSCC depends on tissue 
biopsy which is an invasive method performed by a highly skilled oral surgeon and 
the biopsy is subjectively verified by a trained pathologist. There is a need to develop 
an objective and less or non-invasive system of detecting the disease at an early 
stage. This aim led us to investigate the potential of salivary and blood extracellular 
vesicles (EVs) which may contain surrogate cancer biomarkers.  
In the past, EVs were considered as cellular junk but with advancing technology it 
was established that EVs have an important role of maintaining homeostasis and 
regulation of physiological functions (Yanez-Mo et al., 2015). 
Today we know that EV’s are present in nearly all body fluids such as blood, saliva 
(Michael et al., 2010), urine (Gonzales et al., 2010), breast milk (Zhou et al., 2012), 
ascites (Peng et al., 2011), amniotic fluid (Asea et al., 2008), broncoalveolar fluid 
(Rodriguez et al., 2014), cerebrospinal fluid (Teplyuk et al., 2012), seminal fluid 
(Vojtech et al., 2014) and synovial fluid (Skriner et al., 2006). They are multi 
component delivery vehicle for RNA, DNA and proteins. Hence, they have the 
potential to be used as non-invasive biomarkers for early OSCC detection. 
Most cells release varied types of extracellular vesicles into their environment. They 
are important for intercellular communication by providing a mode of transfer for 
cytosolic proteins, lipids, regulatory micro RNA, mRNA and genomic DNA (Balaj et 
al., 2011, Kahlert et al., 2014). This transfer of information can change the fate of 
target cell by regulating gene expression, causing differentiation or dedifferentiation 
(Lakkaraju and Rodriguez-Boulan, 2008). 
3.2 Different types of EV’s 
Extracellular vesicles are differentiated from each other on the basis of size and 
mechanism of formation.  
Apoptotic bodies: 
Apoptotic bodies released during apoptosis (Hristov et al., 2004) are the largest 
measuring 50-5000 nm (Akers et al., 2013). They are formed by nuclear condensation 
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and cytoplasmic shrinkage of the apoptotic cell, followed by blebbing of cytoplasm 
and disintegration of the cell into membrane bound bodies (Catchpoole and Stewart, 
1995). 
Microvesicles: 
Microvesicles or ectosomes are membranous vesicles with a diameter of 100-1000 
nm, they are produced by the budding of plasma membrane (Fig 3.1) (Gyorgy et al., 
2011, Crescitelli et al., 2013).  
Exosomes: 
Exosomes are nano-particles, discovered almost 30 years ago (Trams et al., 1981). 
They are plasma membrane bound; endosomal in origin, measuring 40 to 100 nm in 
size (Kalra et al., 2012, Raposo and Stoorvogel, 2013). They float at the density of 
1.15-1.19 g/ml hence can be separated in the laboratory via centrifugation and ultra-
filtration (Robbins and Morelli, 2014). 
In recent years, exosomes have become the focus of multiple studies due to their 
potential to be used as non-invasive biomarkers, their ability to be bioengineered for 
vaccines and clinical applications such as intracellular drug delivery (Andreu and 
Yanez-Mo, 2014). Their composition depends on the parental cell type and its site of 
origin. Exosomes reflect the physiological or pathological state of parental cells. For 
example epithelial exosomes released from apical and basolateral surfaces are 
different from each other in composition and content (Sreekumar et al., 2010). 
Similarly, exosomes released from T cells and B cells carry cell type specific markers 
indicating their origin (McLellan, 2009, Wahlgren et al., 2012).  
Protein composition of exosomes is informative of any existing pathology as they can 
carry tumour antigens and inflammatory mediators. They also carry customary 
proteins including HSC70,  TSG101 and tetraspanins (Choi et al., 2014), in addition 
they carry specific proteins which are involved in vesicle formation and trafficking such 
as ALIX (Apoptosis linked gene 2-interacting protein X) (Baietti et al., 2012). 
Exosomes are enriched in tetraspanins, a family of proteins that organizes membrane 
microdomains called tertraspanin enriched microdomains, by forming clusters and 
interacting with transmembrane and cytosolic signalling proteins (Hemler, 2005). 
Among tetraspanin CD9, CD63, CD81, CD82 and CD151 have a broad tissue 
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distribution. They are involved in biological processes including cell adhesion, motility, 
membrane fusion, signalling and protein trafficking (Hemler, 2001). 
Similarly, the lipid composition of exosomes is representative of their cellular origin. 
They are enriched in lipids such as sphingomyelin, phosphatidylserine, gangliosides 
and cholesterol as compared to plasma membrane and other intracellular 
membranes (Subra et al., 2007). 
In recent years multiple studies have focused on the RNA content of exosomes, the 
nucleotide sequence, and its ability to be transferred into neighbouring cells and 
function within these cells. Human (HMC-1) and mouse (MC/9) mast cell lines release 
exosomes that contain both mRNA and small RNA including miRNA. The mRNA 
content is found to be transferable to neighbouring cells and is functional in its new 
location (Valadi et al., 2007).  
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3.3 Exosome formation 
Exosomes are formed by the invagination of plasma membrane that pinches off and 
becomes intraluminal vesicle (ILV) , which later transforms into multi-vesicular body 




Fig 3.1: Different mechanism of formation and release of microvesicles 
(ectosomes) and exosomes. The cancer derived microvesicles and exosomes 
are taken up by normal cells causing genetic reprogramming. Adapted from (Choi et 
al., 2014). 
 
Biogenesis of ILV involves endosomal sorting complex required for transport 
(ESCRT). ESCRT consist of approximately 20 proteins that assemble into four 
complexes ESCRT-0, I, II and III with associated proteins VPS4 (Vacuolar protein 
sorting- associated protein 4), VTA1 (vesicle trafficking 1) and ALIX forming ESCRT 
accessory complex (Henne et al., 2011). ESCRT-0 complex recognizes and 
segregates ubiquitylated proteins in endosomal membrane. ESCRT I and II deform 
          Chapter 3: Characterisation and biomarker potential of oral cancer exosomes. 
                                                                                                          
75 
the membrane into buds with sequestered cargo. ESCRT III is responsible for 
cleavage into free vesicles (Colombo et al., 2013). The mechanism by which ESCRT 
III complex detaches ILV into MVB is similar to final cut between two dividing daughter 
cells (Raiborg and Stenmark, 2011). Recent studies have shown formation of a helix 
with a centrosomal protein (CEP55), which trans locates to the mid-body during the 
late phase of cell division and functions as a scaffold for components of the abscission 
machinery (Fig 3.2). CEP55 interacts with ESCRT and Alix binding region (EABR) 
(Lee et al., 2008). Previous study from our lab have shown that CEP55 is a 
downstream target of FOXM1, an oncogene that regulates cell cycle, DNA repair and 





Fig 3.2: A model for the organization of CEP55-ESCRT-ALIX complex 
adapted from (Lee et al., 2008). 
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In oligodendrocytes the mechanism of exosome formation is independent of ESCRT 
complex, requiring inclusion of sphingolipid containing lipid raft in the MVB 
membrane. Sphingolipids releases ceramide through breakdown by 
sphingomyelinases. Ceramide has a role in IVL budding. MVBs formed independent 
of ESCRT complex express high levels of tetraspanins enriched microdomain 
(Trajkovic et al., 2008). 
3.4 Exosome release pathway 
MVB either follows a secretory or a degradative pathway. In the secretory pathway 
MVB is transported to the cell periphery with coordinated action of cytoskeleton, the 
molecular motors and vesicle fusion machinery, where it binds to the plasma 
membrane and releases the vesicles now called extracellular vesicles.  RAB family 
of small GTPases controls MVB trafficking to cell periphery. RAB27A anchors and 
fuses MVB to plasma membrane, whereas RAB27B participates in mobilization of 
MVBs to the actin rich cortex under the plasma membrane (Ostrowski et al., 2010). 
RAB11 promotes the fusion of MVB to plasma membrane in response to increased 
cytosolic calcium (Savina et al., 2005). MVBs fuse to the plasma membrane with the 
help of SNAP receptors (SNAREs). These proteins regulate the fusion and target 
specificity in intracellular trafficking (Fader et al., 2009). The population of MVBs that 
are low in cholesterol and high in lysobisphosphatidic acid are targeted to lysosomal 
pathway (Buschow et al., 2009). 
Accessory proteins including TSG101 (Tumour susceptibility gene 101), HRS 
(Hepatocyte growth factor regulated tyrosine kinase substrate) and ALIX are 
necessary for the secretion of exosomes. Evidence suggests that syndecan heparan 
sulphate proteoglycans and their cytoplasmic adaptors syntenin control the 
biogenesis of exosomes. Syntenin interacts directly with ALIX and support the 
intraluminal budding of endosomal membrane (Baietti et al., 2012). 
3.5 Physiological function of exosomes in 
regulating immune response 
Extracellular vesicles released from immune and non-immune cells have important 
role in regulation of immunity. They can stimulate or suppress immune response and 
hence are important factors in causing inflammatory, auto immune and infectious 
diseases. (Robbins and Morelli, 2014). 
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Exosomes are capable of direct and indirect antigen presentation. Exosomes 
released by B cells carry MHC class II, co- stimulatory and adhesion molecule and 
have been found to directly activate CD4+T cells (Raposo et al., 1996). Exosomes 
released by antigen presenting cells (APC) carry both MHC I and II can activate both 
CD8+ and CD4+ cells. However, in vitro T cell activity caused by exosomes is 10-20 
fold less efficient than that of parent APC (Schneider and Simons, 2013), this might 
be due to their small size and vesicle dispersion caused by Brownian motion. Studies 
have shown that when exosomes were immobilized at high concentration on latex 
beads or when the number of peptide MHC complex was increased per vesicle it 
increased their T cell stimulatory capacity (Hsu et al., 2003). 
Indirect antigen presentation by exosomes involves transfer of antigenic peptides to 
APC (Mallegol et al., 2007). Exosomes bind to dendritic cells via integrins and 
intercellular adhesion molecule (ICAM1/CD54), depending on cellular linage and 
activation stage of parent cell. Ligands and adhesion molecules such as tetraspanins 
and externalized phosphatidylserine are constitutively present on exosomes (Morelli 
et al., 2004). Exosomes internalized by DCs, degrade antigen-MHC complex carried 
by the exosome and is used as a source of peptide to indirectly interact with T cell 
(Montecalvo et al., 2008). 
Another mechanism of antigen presentation by exosomes called cross dressing 
involves transfer of internalized exosomal antigenic peptides to MHC molecule of host 
APC. The host MHC molecules that are loaded with exosomes derived peptide are 
then transported to the APC surface for presentation to T cells. Study by Smyth and 
colleagues suggests that following allograft transplantation, cross dressing of 
recipient APC with donor MHC molecule could be mediated through exosomal 
transfer (Smyth et al., 2007). 
3.6 Role of exosomes in developing oral cancer 
Tumour progression is a result of active partnership between cancer cells and their 
microenvironment. This requires efficient exchange of information by cell to cell 
contact, secretion of signalling molecules and release of cargo vesicles such as 
exosomes into the extracellular environment (Kucharzewska and Belting, 2013). 
Exosomes are unique as they are capable of affecting locally and to distant sites via 
body fluids.  
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3.61 Cancer niche 
Tumour cells tend to secrete more exosomes in comparison to normal proliferating 
cells (Taylor and Gercel-Taylor, 2008). This can be the result of stimulation in 
response to stressful conditions due to excess growth and cell damage (de Jong et 
al., 2012). It has been shown that activation of pro-apoptotic protein p53 results in 
overexpression of tumour suppressive-activated pathway 6 (TSAP6) which increases 
exosome production (Yu et al., 2006). The enzyme heparan sulphate along with 
syndecan-1 is upregulated in many cancer cell lines, also aid in increased exosomal 
release (Thompson et al., 2013). Free exosomes in the extracellular environment 
regulate the release of new exosome hence creating a negative feedback control loop 
(Riches et al., 2014). 
Cells of stroma release exosomes to communicate with each other and with tumour 
cells. It is thought that tumour cells release exosomes making the environment more 
tumour promoting. Most commonly affected stromal cells are fibroblasts, vascular 
endothelial cells and immune cells. Cancer exosomes trigger fibroblastic 
transformation into myofibroblasts through TGFβ/Smad pathway to increase cancer 
aggression (Webber et al., 2010, Webber et al., 2015). 
Tumour derived exosomes aid in evading the immune system by influencing myeloid 
progenitor cells to differentiate into myeloid derived suppressor cells, that promote 
tumour progression (Xiang et al., 2009).  In addition, tumour exosomes decrease T 
cell proliferation and effector functions, cancelling the natural cytotoxic responses 
mediated by natural killer cells (Iero et al., 2008). 
3.62 Angiogenesis 
Exosomes can induce endothelial cell activation and transfer metastatic capacity 
(Tickner et al., 2014). They have the capability to increase angiogenesis. As hypoxia 
promotes in the tumour, cancer exosomes carrying hypoxia inducing proteins, are 
taken up by normal endothelial cells. This uptake stimulates new tubule formation, 
creating a network of blood vessels (Skog et al., 2008). 
3.63 Metastasis 
Tumour metastasis requires cells to undergo epithelial to mesenchymal transition 
(EMT) allowing migration to gain access  to vascular or lymphatics channels (Fidler, 
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2002). As cancer progresses exosomes gain metastatic capability by becoming 
enriched with EMT protein such as vimentin and annexin A2 (Jeppesen et al., 2014b). 
Furthermore, in a study of breast and prostate cancer it was found that hypoxic 
tumour microenvironment induces expression of factors (HIFs) that aid in metastasis 
and are linked to poor prognosis in patients (Kimbro and Simons, 2006). HIFs along 
with tumour exosomes have been found to be involved in formation of a premetastatic 
niche, with ideal tumour growth conditions (Thuma and Zoller, 2014). 
3.64 Chemoresistance 
Exosomes also play a contributing role in chemoresistance. In a breast cancer study 
it was found that tumour cells transmit resistant properties via exosomes to sensitive 
parental cells, making cancer treatment ineffective. This mechanism involves 
intracellular transfer of selective miRNA that alter cell cycle distribution and affect 
apoptosis pathways to decrease drug susceptibility (Chen et al., 2014). Tumour cells 
evade the cytotoxic effects to chemotherapy drugs by packaging it into exosomes as 
soon as it is taken up by cell, thereby preventing the drugs from exerting its cytotoxic 
effects (Federici et al., 2014). 
3.7 Exosomes as Oral Cancer Biomarkers 
Evidence suggests that exosomes can be ideal candidates for early oral cancer 
diagnosis and prognosis, since a tumour tissue biopsy is not required. They can also 
aid in predicting and monitoring therapeutic response. They offer a non-invasive 
testing opportunity causing less patient discomfort. Exosomes can be isolated from 
body fluids such as blood and saliva. Multiple studies have found elevated levels of 
exosomes in cancers of different origins. They offer an enriched source of biomarkers 
as they are packed with biologically active molecules reflecting the pathological state 
of host cells (Brinton et al., 2015). 
Tumour specific markers such as proteins, mRNA and microRNAs (miRNA) have 
been found in circulating exosomes. In colorectal cancer patients, ascites fluid derived 
exosomes show elevated level of claudin-3 a protein diagnostic biomarker (Choi et 
al., 2011). Similarly prostate cancer mRNA biomarker PCA-3 have been isolated from 
urine exosomes (Nilsson et al., 2009).  
In addition circulating miRNA has gained considerable attention as promising 
biomarkers. miRNAs are small noncoding RNAs of 18-24 nucleotide in length that 
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regulate gene expression post transcriptionally (Bartel, 2009). Encapsulation of 
miRNA by exosomes is the primary mechanism by which it stays stable in 
extracellular environment (Takeshita et al., 2013). In a study on ovarian cancer, 
expression levels of eight exosomes derived miRNA were used to successfully 
distinguish between benign and malignant tumours (Taylor and Gercel-Taylor, 2008). 
3.8 Oncogenes packaged in Exosomes 
Tumour cells secrete exosomes in abundance, containing proteins, RNA and DNA 
which reflect the genetic status of the tumour (Raposo and Stoorvogel, 2013, Thakur 
et al., 2014). Recent studies have shown that cancer exosomes carry amplified 
oncogenes such as c-Myc and high levels of retrotransposon RNA transcript that can 
be transferred to normal cells affecting genomic stability (Balaj et al., 2011). 
Exosomes released from breast cancer cells contain miRNA associated with RNA 
induced silencing complex (RISC) and are capable of independently processing 
precursor microRNA (pre-miRNA) into mature miRNA, more efficient in altering gene 
expression post transcriptionally. Cancer exosomes rapidly silence mRNA in recipient 
cells with the help of pre-miRNAs along with catalytic engine of RISC including Dicer 
(multidomain enzyme that generates small RNAs for gene silencing), Argonaute 2 
(Ago2) and the transactivating response RNA-binding protein (TRBP). Hence cancer 
exosomes initiate tumourogenesis in a dicer-dependent manner (Melo et al., 2014). 
This study aimed to isolate and characterised exosomes derived from OK113, NK4 
and NOK368 (normal oral keratinocyte), Ca1, CaLH2 and SqCC/Y1 (OSCC tumour 
derived), SVpgC2a (oral epithelial pre-malignant) and SVFN10 (transformed 
malignant) cell lines (Teh et al., 2013). 
Due to the very small size to exosomes which is comparable to a virus (Gyorgy et al., 
2011), characterisation and visual verification of exosomes are of prime importance. 
Successful isolation of exosomes from cell lines supernatant and body fluids (saliva, 
whole blood and plasma) was verified using different techniques of visualisation 
including Scanning Electron Microscopy (SEM) and Transmission Electron 
Microscopy (TEM). Particle size was verified using Zetasizer and Nanosight Tracking 
Analysis (NTA). Exosomal specific membrane proteins were identified through 
Western blotting. 
          Chapter 3: Characterisation and biomarker potential of oral cancer exosomes. 
                                                                                                          
81 
This study also aimed to explore the biomarker potential of oral cancer exosomes. 
Through Western blotting and immune TEM, we report the presence of a potential 
protein biomarker located exclusively on the outer membrane of cancer exosomes. 
Since body fluids consist of a heterogeneous population of exosomes derived from 
multiple cell types, such surface biomarker can be used to isolate OSCC exosomes 
from body fluids.  
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Results 
3.9 Ultracentrifugation as the superior method of 
exosome isolation 
Exosomes can be isolated by multiple methods including ultracentrifugation, density 
gradient separation and immune affinity capture (Thery et al., 2006). Different 
methods of exosome preparations can contain varying proportions of contamination 
from other membranous vesicles such as microvesicles and apoptotic bodies (Tauro 
et al., 2012), having consequences on downstream experiments. 
All the isolation methods have some limitations such as immuno isolation will only 
segregate a population of exosomes depending on the surface protein chosen for 
capture (Thery et al., 2006), while a 30% sucrose gradient requires repeated 
ultracentrifugation steps resulting in significant loss of the total exosome yield 
(Lamparski et al., 2002).  Ultracentrifugation is the most commonly used method of 
isolation (Gould and Raposo, 2013) as it offers the advantage of isolating the whole 
exosome population. The drawbacks of ultracentrifugation is that it is a time 
consuming process and large protein complexes can sediment with exosomes 
(Jeppesen et al., 2014a), although this can be overcome by additional filtration steps. 
A well- established Thery exosome isolation protocol was followed (Thery et al., 2006), 
which required cells to be seeded in two T-175 flasks. Once the flasks were 90% 
confluent containing approximately 18x106 cells the medium was changed to SFM 
with 40ml in each flask. The cells were further incubated for 72 hours. Enriched 
supernatant was centrifuged at 500xg for 10min to get rid of cell debris. The second 
centrifuge at 20,000xg for 20 min isolated micro vesicles, followed by filtration with 
0.22μm filter. Finally the enriched supernatant was centrifuged at high speed of 
118,000xg for 70 min to isolate the final pallet of exosomes (Fig 2.1 in Methods, 
page no. 42). 
 The process of exosome isolation is very time consuming, each batch takes up to 
almost 10 days. It can become even longer for primary cell lines which require much 
longer to grow. Collecting the final pallet of exosome is very tedious as it is invisible 
and can be very easily missed hence it is very prone to human error.      
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With growing interest in the potential use of exosome as disease diagnostic markers 
and drug delivery vehicles, commercially available new isolation methods are being 
introduced  such as Invitrogen Total Exosome Isolation Kit (Life Technologies, USA) 
and ExoSpinTM Exosome Purification Kit (Cell Guidance Systems, USA). These kits 
claim to give higher yield with comparable size of vesicles using low speed 
centrifugation (10,000-20,000xg), minimizing the dependency on ultracentrifuge for 
exosome isolation. 
In this study isolation method ultracentrifugation was compared with a commercially 
available Exo-spinTM by cell guidance systems. Exo-spinTM precipitates vesicles by 
using ploy-ethylene glycol (Lane et al., 2015). Particle size and concentration of 
isolated exosomes was verified using Nanosight Tracking Analysis system (NTA 
LM10).  
In a pilot experiment, it was found that particle size measurement of SVpgC2a derived 
exosomes isolated through ultracentrifugation and Exo-spinTM system exhibit a mode 
values of 40 nm and 157 nm, respectively. The particle/ml concentration was found 
to be higher 21.65×10⁸/ml through ultracentrifugation and 8.58×10⁸/ml by Exo-spinTM 
(Appendix Fig 8.1, 8.2, Page no. 189,190). 
Similar results were seen for a malignant cell line (SVFN10) derived exosomes 
isolated by ultracentrifugation and Exo-spinTM. A mode value of 62 nm and 145 nm 
was obtained, respectively. Ultracentrifugation yielded a higher particle/ml 
concentration of 25.16×10⁸ as compared to Exo-spinTM which gave 12.54×10⁸ particle 
/ml concentration (Appendix Fig 8.1, 8.2, Page no. 189,190).  
In conclusion, exosome particle size obtained through ultra-centrifugation were more 
similar to the observed size in most of the exosome literature, with majority measuring 
30 to 100 nm (Raposo and Stoorvogel, 2013). While exosomes isolated by Exo-spinTM 
measured 150 to 200 nm. The larger size of exosomes might be because of the glycol 
component in the kit, fusing together the lipid bilayer membrane of exosomes. The 
particle/ml concentration of exosomes was also found to be higher through 
ultracentrifugation (Appendix Fig 8.1, 8.2, Page no. 189,190).  Based on these 
findings it was established that ultracentrifugation was a superior method of isolating 
exosomes.  
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3.10 Visual characterisation of Exosomes 
Exosomes measure between 40-100 nm in size hence they are not visible under 
inverted light microscope (Ishikawa et al., 2014). Techniques allowing higher 
magnification such as electron microscopy were used to visualize exosomes from 
normal and tumour derived cell lines, whole cancer patient blood, normal plasma and 
normal saliva.  
3.10(1) Electron Microscopy (EM) 
Through Scanning Electron Microscopy (SEM) we were able to visualize exosomes 
from SVpgC2A (premalignant) and SVFN10 (transformed malignant) oral 
keratinocyte cell lines. The vesicles were found in clusters, in a size range of 30 nm 
to 157 nm. The technique worked best at lower magnification of 5 µm, which was 
sufficient to visualise clusters of exosomes, however individual morphology was less 
evident. It was difficult to visualise nano-size exosomes at higher magnification of 500 
nm, which is a limiting factor of this technique (Fig 3.3). 
Therefore, subsequently Transmission Electron Microscopy (TEM) was done to better 
visualise exosomes. TEM is an established technique used for characterisation of 
exosomal structures due to its higher resolution. A typically flattened spherical, 
membrane bound particles were identified, confirming the presence of exosomes 
(Thery et al., 2006). Most of the particles measured between 40-100 nm in size (Fig 
3.4).  
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Fig 3.3: Scanning electron microscopy for SVFN10 exosomes. Images 
above showed that exosomes appeared mostly in clusters from magnification of 40 
to 2μm as indicated by respective scale bars within each image. Individual exosomes 
were visualized at the magnification of 1 μm and 500 nm but the flattened spherical 
morphology was not evident due to limited resolution. 
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Transmission electron microscopy 
(TEM) 
 
Fig 3.4: Transmission electron microscopy Showing membrane bound 
exosomes from SVpgC2a (A) and SVFN10 (B) cell lines at the magnification of 50 
nm, measuring between 80-100nm.  
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3.11 Particle size measurement 
EV’s are classified into different subgroups based on their size and mechanism of 
origin. The most widely known are apoptotic bodies, microvesicles and exosomes. 
These subgroups are functionally and morphologically very different from each other 
and contamination of one subgroup with another will have an effect on the outcomes. 
Hence it is essential to verify the size of vesicles for any downstream experiment. 
3.11(1) Zetasizer 
The Zetasizer system determines particle size by measuring the Brownian motion of 
particles suspended in liquid, using dynamic light scattering (Wang et al., 2017). 
Zetasizer instrument ZS used in this study can measure particles in the range of 0.3 
nm to 10 μm. 
Differential ultracentrifugation yields various populations of EV at different speeds. 
This included cellular debris containing apoptotic bodies, microvesicles and 
exosomes. Particle size of these three populations was measured using Zetasizer to 
verify the size of exosomes and to authenticate the ultracentrifugation protocol 
(Methods section 2.2, Fig 2.1, Page no. 42) 
It was found that majority of exosomes from SVpgC2a and SVFN10 cell lines were in 
the size range of 50 to 130 nm. Microvesicles measured from 200 nm to 600 nm and 
the cellular debris showed a particle size of 1000 to 5000 nm (Fig 3.5). The findings 
were similar in three biological replicates.  
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                        Zetasizer
Fig 3.5: Particle size verification using Zetasizer A range of particle size of 
cellular debris (SVpg-CD and SVFN10-CD) measuring 1000-5000 nm, microvesicles 
(SVpg-MV and SVFN10-MV) from 200-600 nm and exosome (SVpg-Exo and 
SVFN10-Exo) 50-130 nm isolated from SVpgC2a and SVFN10 cell lines at different 
stages of ultracentrifugation. This is a representative data of 3 independent 
experiments giving similar results.  
 
3.11(2) Nanosight Tracking Analysis (NTA) 
Nanoparticle Tracking Analysis (NTA) utilizes the properties of both light scattering 
and Brownian motion in order to obtain the particle size distribution and per ml 
concentration of samples in liquid suspension. It is the most widely used technique 
for verification of exosomes (Soo et al., 2012, Fang et al., 2013, Gabriel and 
Giordano, 2010) as it offers the advantage of being inexpensive and less time 
consuming than TEM. It also allows visual verification of individual exosomes while 
formation and dissociation of aggregates can be noted in real time. Since no fixation 
of exosomes is required, they can be reused for further downstream experiments. 
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3.11(2a) Exosomes from Cultured Cells 
Exosomes were isolated from normal oral keratinocyte cell lines (OK113, NK4 and 
NOK368), tumour derived cell lines (SqCC/Y1, Ca1 and CaLH2), transformed 
premalignant cell line (SVpgC2a) and transformed malignant cell line (SVFN10). NTA 
LM10 instrument (UCL, School of pharmacology) was used for size verification and 
particle/ml concentration of exosomes derived from all the above cell lines (Fig 3.6). 
Although it has been reported in the literature that cancer cells secrete higher 
concentration of larger size exosomes, sometimes referred as oncosomes 
(Minciacchi et al., 2015). In our study, exosomes from normal and cancer oral 
keratinocytes were approximately the same size (Table 3.1).  
The concentration (particle/ml) of exosomes was higher in cancer cell lines compared 
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Fig 3.6 Exosome particle size verification using NTA LM10 instrument. 
Exosomes isolated from normal oral keratinocytes (A) OK113 (B) NK4 (C) NOK368, 
tumour derived cell lines (D) Ca1 (E) CaLH2 (F) SqCC/Y1, premalignant cell lines (G) 
SVpgC2a and transformed malignant cell line (H) SVFN10.  
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Table 3.1: Particle size  and concentration (particle/mL) Exosomes isolated 
from normal (OK113, NK4, NOK368) and cancer (Ca1, CaLH2, SqCC/Y1, SVpgC2a, 
SVFN10) cell line supernatant. Particle size (mode value) and concentration 
(particle/mL) were obtained using NTA. Each value represents the mean of mode 
values obtained from three independent experiments.  
 
 
3.11(2b) Exosomes from Body Fluids 
Isolating exosomes from body fluids such as saliva, plasma and whole blood required 
the sample to be diluted to a workable viscosity. The ultracentrifugation protocol was 
modified by allowing longer duration and higher speed of centrifuge as recommended 
in literature (Thery et al., 2006). An extra filtration step was added as body fluids carry 
more cellular debris compared to cell culture supernatant and the purity of exosomes 
was verified through NTA (Methods section 2.4,2.5,2.6 on page no. 45, 47 and 49). 
It was found that exosomes isolated from whole blood had a mean modal diameter of  
151 nm with concentration of 5.61x109 particles/ml (Fig 3.7 A and D). Exosomes from 
normal saliva and plasma had mean modal diameter of 89 nm and 64 nm with 
concentrations of 1.53x109 and 2.73x109 particles/ml, respectively (Fig 3.7 B, C and 
D).  Visual verification on NTA showed no traces of cellular debris in any sample. 
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Fig 3.7: Verification of exosomes from body fluids using NTA (A) 
Exosomes isolated from cancer patient’s whole blood, (B) exosomes isolated from 
healthy volunteer’s plasma (C) exosomes isolated from healthy volunteer’s saliva. (D) 
Table showing size (mode values) and concentration (particle/ml) of respective 
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3.12 Western blot 
Protein component of exosomes was explored for exosome specific markers which 
validate not only successful isolation of exosomes but also reflects the purity of the 
sample. It was analysed by Western blotting (gel electrophoresis and 
immunoblotting). Exosomes were isolated as described above using 
ultracentrifugation from cell lines NOK368, OK113, NK4, SqCC/Y1, CALH2, Ca1, 
SVpgC2a and SVFN10.  Cell lysate from parental cell lines was also collected to 
compare the differences in protein expression. Prior to western blotting protein 
concentration of exosomes and cell lysate were determined by Bradford BSA protein 
assay. 
3. 12(1) Exosome-specific proteins  
ALIX is an exosomal specific membrane protein and a component of ESCRTiii 
complex (Henne et al., 2011) and is involved in the biogenesis of exosomes (Baietti 
et al., 2012). It was expressed in exosomes derived from all the eight cell lines at the 
molecular weight of 102 kDa (Fig 3.8), indicating successful isolation of exosomes. 
Heat shock protein HSC70 (70 kDa) and Glyceraldehyde 3-phosphate 
dehydrogenase GAPDH (37 kDa) were used as loading controls (Fig 3.8). 
In order to rule out extravesicular protein contamination, calnexin, an endoplasmic 
reticulum protein aiding in proper protein folding (Ellgaard and Helenius, 2003), was 
used to investigate the purity of exosomes. Ideally  the expression of calnexin should 
be absent from exosomes since they lack the endoplasmic reticulum machinery. 
Calnexin was expressed in all cell lines at the molecular weight of 90 kDa, while the 
expression was low to absent in the exosome samples (Fig 3.8), verifying that our 
exosomes are relatively clean and free from contaminations. 
Tetraspanin proteins including CD63, CD9 and CD81 have been reported as 
exosomal specific membrane proteins (Andreu and Yanez-Mo, 2014). In this study 
expression of CD63 (63 kDa) and CD9 (25 kDa) was investigated. CD63 was 
expressed in cell lines but the expression was absent from the exosomes (Fig 3.8). 
No expression of CD9 was found in cell lines or exosomes. Further exploration of the 
literature indicates that these markers were reported from studies carried out on 
immune exosomes derived from mast and dendritic cells (Escola et al., 1998, Thery 
et al., 1999).  In conclusion, these surface protein markers are possibly not expressed 
in exosomes derived from oral keratinocyte cell lines. 
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3.12(2) Candidate cancer-exosome specific proteins  
CEP55 (55 kDa) is a centrosomal protein involved in cytokinesis (van der Horst et al., 
2009). It is a partner of Alix in ESCRTiii complex (Lee et al., 2008) . It is also a 
downstream target of FOXM1 oncogene (Waseem et al., 2010). The expression of 
CEP55 protein was exclusive to exosomes derived from malignant cell lines (Fig 3.8). 
Within parental cell lines CEP55 expressed double bands very close to each other at 
the molecular weight of 55 kDa. In order to verify the specificity of our antibody and 
exclude non-specific binding, CEP55 was knocked down in SVFN10 cells by siRNA 
transfection. The successful knockdown of CEP55 mRNA in siCEP55 transfected 
SVFN10 cells was also validated by RT-qPCR (Fig 3.9 A). Silencing of CEP55 protein 
by siCEP55 led to the disappearence of the top band (Fig 3.9 B) indicating that the 
top band was the correct CEP55 protein by Western blotting. Further attempts were 
made to explore the expression of exosomal CEP55 in oral cancer patient whole 
blood and normal plasma through western blotting. Unfortunately, the expression of 
loading controls HSC70 and GAPDH could not be established(result not shown). Due 
to the lack of clinical blood or plasma samples, this was not pursued further.  
GPC1 is a cell-surface heparan sulphate proteoglycan, which acts as a co-receptor 
for heparin binding of mitogenic growth factors. It has a physiological role in cell 
growth and adhesion. GPC1 has been reported to be overexpressed in oesophageal 
squamous cell carcinoma (Hara et al., 2016). According to a recent publication, high 
levels of GPC-1 was found in pancreatic cancer cell lines and exosomes derived from 
them (Melo et al., 2015). In our study GPC-1 was expressed in all cell lines at the 
molecular weight of 62 kDa. In exosomes GPC-1 was only slightly detected in 
SVFN10 exosomes (Fig 3.8). This can be due to high levels of FOXM1 causing 
increase in the cell cycle and aiding in cell growth. 
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Fig 3.8: Western blotting for exosomal proteins and candidate cancer 
markers. Protein expression of ALIX, CD63, Calnexin, CEP55, GPC-1, , HSC70 and 
GAPDH in exosomes (top) isolated from parental cell lines (bottom) including normal 
(NOK368, OK113, NK4) and cancer (SqCC/Y1, CaLH2, Ca1, SVpgC2a, SVFN10) 
oral keratinocytes. 
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Fig 3.9: Specificity of CEP55 antibody verified by CEP55 knockdown       
siRNA transfection of SVFN10 cells with siCEP55 and siCtrl. Untransfected SVFN10 
cells were used as an additional control. (A) mRNA expression of CEP55 via RT-
qPCR after successful siCEP55 transfection. (B) Western blotting showing loss of top 
band in siCEP55 transfected cells. HSC70 was used as a loading control. 
 
  
          Chapter 3: Characterisation and biomarker potential of oral cancer exosomes. 
                                                                                                          
97 
3.13 CEP55 as a potential biomarker of oral 
squamous Cell Carcinoma (OSCC) 
Given that CEP55 protein was found to be enriched in exosomes from cancer cell 
lines, we further investigated if this protein was specific to OSCC exosomes or non-
specifically co-purified with exosomes. Immune-gold TEM was performed on 
exosomes to directly visualise CEP55 protein in exosomes isolated from normal oral 
keratinocyte cell line OK113, tumour derived oral keratinocyte cell line SqCC/Y1 and 
normal plasma. Exosomes were incubated with CEP55 antibody and the gold labels 
were primed against CEP55 antibody. Immuno-TEM images showed that CEP55 gold 
labels appeared to be clustered around debris in normal plasma and OK113 
exosomes while SqCC/Y1 exosomes showed CEP55 gold labels appeared on the 
outer membrane of exosomes (Fig 3.10). Although these are not quantitative, it 
provided some qualitative confirmation that CEP55 could be a specific cancer 
exosomal membrane marker. 
We concluded that although CEP55 membrane protein was found on SqCC/Y1 
cancer exosomes this finding needs to be quantified using another technique such as 
single exosome sorting by nano FACS analysis. Since we did not have such a facility 
at our institute, attempt was made to quantify CEP55 expressing exosomes by 
immuno-NTA. The samples were prepared using rabbit anti-CEP55 and Alexa fluor 
488 antibody and were sent to Malvern company for analysis. Report from Malvern 
was inconclusive and further optimisation of sample preparation was suggested (data 
not shown). Ideally the presence of CEP55 specific exosomes should be verified on 
OSCC patient plasma compared to healthy controls. Request for clinical samples has 
been forwarded to our clinical collaborator. 
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Fig 3.10: Immuno-gold labelling of exosomes on transmission electron 
microscopy. Exosomes were isolated from OK113, SqCC/Y1 and normal plasma. 
The gold labels (black dots) indicated the localisation of CEP55 protein on the 
membrane of cancer exosomes from SqCC/Y1 cell line. No gold label or non-specific 
labelling was noted in normal exosomes (OK113 and normal plasma). 
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3.14 Discussion 
Oral squamous cell carcinoma (OSCC) is the most common oral malignancy, 
representing approximately 3% of all malignancies in the body and accounting for 
more than 300,000 newly diagnosed cancer cases each year worldwide (Siegel et al., 
2013). The disease is related to high morbidity and mortality rate due to close 
proximity of cervical lymph nodes resulting in fast spread. 
Patients with OSCC are diagnosed only when the disease has reached an advanced 
stage, leading to a five year survival rate of only 20% (van der Waal, 2013). OSCC 
diagnosis is currently based on histopathology, which is an invasive method requiring 
biopsy samples. The limitation of this system is that it is unable to recognise early 
genetic changes aiding in the development and progression of the disease. Thus, the 
identification of biological biomarkers that assist in early diagnoses of OSCC is 
essential.  
Advancement in technology has led to increased interest in EVs research.  Today we 
know that EVs are released by all cell type. Out of all the different types of EVs 
(Apoptotic bodies, microvesicles, exosomes) exosomes have gained the most 
popularity because they initially form from intracellular compartments, having 
immense resemblance to their parental cells. They play an essential role in cell-to-
cell communication by carrying their contents including proteins, metabolites, RNA 
(mRNA, miRNA, long non coding RNA), DNAs (mtDNA, ssDNA, dsDNA) and lipids 
(S et al., 2013, De Toro et al., 2015) which can be transferred to neighbouring and 
distant cells upon fusion with extracellular membrane.  
Due to the presence of exosomes in body fluids they have great potential to serve as 
a liquid biopsy tool for various diseases. In pancreatic cancer Melo and colleagues 
have reported the presence of Glypican-1 as a cancer exosome biomarker (Melo et 
al., 2015). Similarly in ovarian cancer multiple potential exosome biomarkers have 
been reported (Tang and Wong, 2015). 
Exosome based liquid biopsy offers many advantages in comparison to conventional 
diagnostic methods. A small sample size of tissue biopsy cannot provide the detailed 
information of genetic heterogeneity within a tumour. However, exosomes shed from 
heterogeneous tumour can be collected at once and provide the dynamic information 
from the tumour. Since exosome based biopsy is non-invasive it causes less patient 
discomfort. 
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In the field of OSCC, search for a non-invasive diagnostic aid is ongoing. This would 
offer an advantage of early disease screening segregating high risk individuals from 
low risk. The high risk individuals can be further kept under observation for detecting 
early changes to disease state.  
Saliva is a very relevant body fluid associated with OSCC. Salivary diagnostics offer 
many clinical advantages including undemanding collection, as trained personnel are 
not need. It is non-invasive hence causing no discomfort to the patient. Saliva 
samples are easier to handle and store, unlike blood saliva does not clot. 
To date only a few studies have shown the presence of OSCC bio-markers in saliva 
(Radhika et al., 2016, Gleber-Netto et al., 2016, Sahibzada et al., 2017). All these 
studies have proposed increased levels of cytokines (IL-8, IL-6 and TNF alpha) as 
markers of OSCC initiation. The limitation of cytokines as OSCC markers is that the 
levels are found to be significantly increased in inflammatory diseases.  
With the aim to develop a non-invasive diagnostic test, which is able to report the 
genetic changes leading to disease development and progression, we looked into the 
subject of acquiring potential OSCC biomarkers from cancer exosomes in body fluids.  
In this study exosomes were successfully isolated from normal and cancer oral 
keratinocyte cell lines (culture medium), saliva, plasma and blood through 
ultracentrifugation by optimizing Thery protocol (Thery et al., 2006).  
Due to the very small size of exosomes, they are not visible under an inverted light 
microscope. Multiple visualisation and particle size measuring techniques were used 
for verification and validation of successful exosome isolation. These include SEM, 
TEM, zetasizer and NTA (Fig 3.3, 3.4, 3.5, 3.6 and 3.7. Page no. 85,86,88, 90,92). 
Through NTA it was found that cancer cells released more exosomes compared to 
normal cells, presumably involved in facilitating cancer progression and spread 
(Table 3.1, Page no.91). Similar finding has also been reported by Tickner and 
colleagues (Tickner et al., 2014).  
Further, the presence of exosomal specific protein ALIX was verified in our collected 
samples through Western blotting indicating successful isolation (Fig 3.8, Page no. 
95). Expression of other exosomal specific proteins including CD63 and CD9 was not 
found in exosomes from oral keratinocytes.  
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We found our samples to be free of cellular contamination which was verified by 
absence of Calnexin (endoplasmic) protein (Fig 3.8, Page no 95).  
3.14(1) CEP55 as a potential biomarker of OSCC 
exosomes 
In adult tissue, CEP55 is most highly expressed in germ cells (testes and ovaries) 
(Martinez-Garay et al., 2006). It is well known for its role in cytokinesis (Carlton and 
Martin-Serrano, 2007, Lee et al., 2008). More recently it has been found to regulate 
a major pro-survival pathway PI3K/AKT pathway (Jeffery et al., 2015) and hence is 
indispensable for embryonic development. CEP55 also regulates stemness and is 
found to promote tumorigenesis (Kuo et al., 2011).  
Recently increased expression levels of CEP55 were found in human urinary bladder 
transitional cell carcinoma and prostate cancer (Singh et al., 2015, Kulkarni and 
Uversky, 2017). In gastric carcinoma along with increased expression levels, CEP55 
was also found to regulate cell proliferation (Tao et al., 2014).It has also been found 
to play a role in development of laryngeal squamous cell carcinoma (Hui et al., 2015). 
CEP55 is a direct transcriptional target of FOXM1 (Waseem et al., 2010, 
Gemenetzidis et al., 2009). FOXM1 transcriptional program is activated during G2/M 
to allow normal progression through mitosis in a timely fashion. FOXM1 is 
overexpressed in many cancers, where it is associated with chromosomal instability 
(Laoukili et al., 2005, Laoukili et al., 2007). 
In OSCC, FOXM1 is found to be overexpressed, where it correlates with CEP55 
overexpression in lymph node metastasis. In contrast, both genes are expressed at 
low levels in the basal layer of normal oral mucosa (Waseem et al., 2010). 
Furthermore, CEP55 has been reported as a driver of FOXM1 expression in OSCC 
cell lines where it up regulates FOXM1 levels in a dose dependent manner, resulting 
in increased transcription and activity of MMP-2 (Chen et al., 2009). These findings 
suggest that CEP55 exist in a positive feedback loop with FOXM1, where CEP55 
promotes FOXM1 expression, which in turn increases transcription of CEP55 (Jeffery 
et al., 2016). 
In our study expression of FOXM1 protein was not found in oral keratinocytes 
exosomes from normal and cancer cell lines, while the expression of CEP55 protein 
was exclusively found in cancer exosomes (Fig 3.8, Page no. 95). Specificity of  
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CEP55 antibody was established through CEP55 knockdown in SVFN10 cell line (Fig 
3.9, Page no. 96). We further investigated this finding by immuno TEM and found 
CEP55 was expressed on the outer surface of cancer exosomes isolated from 
SqCC/Y1 tumour derived cell line and not on normal exosomes from OK113 cell line 
and healthy volunteer plasma (Fig 3.10, Page no. 98). This finding suggests that 
CEP55 can be used as a potential OSCC biomarker to segregate cancer exosomes 
from normal in a diverse body fluid such as saliva and blood. 
Immuno TEM is a subjective technique and a more quantitative method such as nano 
FACS needs to be done for a definitive conclusion. Furthermore, these findings need 
to be verified on OSCC patient plasma and saliva. 
 
3.15 Limitations 
Isolating exosome from cell lines and body fluids such as saliva and blood is a time 
consuming and laboursome process. It can take up to ten days to isolate exosomes 
from cell lines and almost double the time when collecting from primary cell lines, 
which grow at a much slower rate. 
Isolating exosomes from body fluids requires diluting it to a workable viscosity. The 
duration and speed of centrifuge has to be increased and extra filtration is needed to 
get rid of debris. The final pellet of exosomes is invisible to the naked eye; hence it 
can be easily missed resulting in no to low yield. Novel nanoparticle 
isolation/detection technology may have to be developed to help resolve this problem. 
OSCC is a heterogeneous disease involving majorly epithelial cells and surrounding 
supporting tissue. Developing a diagnostic or screening test for OSCC based on 
exosomes isolated from saliva has the limitation that saliva is a product of salivary 
glands, majorly made of secretory acini cells and not epithelial cells. Although some 
literature has suggested that circulating biomolecules that originate from the disease, 
entering bloodstream may eventually be transported in to the salivary glands resulting 
in changes in the composition of saliva (Schafer et al., 2014, Yoshizawa et al., 2013), 
this mechanism needs to be further investigated. 
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In addition, due to gaps in our knowledge currently we are unaware as to how long it 
would take for cancer exosomes to appear in the peripheral blood or saliva to be 
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4.1 Introduction 
The emerging role of exosomes as a liquid biopsy tool and a therapeutic delivery 
vesicle to cells has overshadowed its functional significance in health and disease 
state. Today we have limited knowledge regarding the effects on exosomes on it 
neighbouring cells. Since exosomes are known to participate in intercellular 
communication and are capable of transferring their content including mRNA (Janas 
et al., 2015), miRNA (Taylor and Gercel-Taylor, 2008), siRNA, piRNA (Baixauli et al., 
2014), dsDNA (Thakur et al., 2014), proteins (Buschow et al., 2005) and lipids 
(Record et al., 2014) to neighbouring cells and to distant cells via the bloodstream 
(Taylor and Gercel-Taylor, 2013). It has been hypothesized that this transfer of 
information can possibly lead to cell fate determination. A detailed insight into the 
content of exosomes reported to date can be reviewed on ExoCarta database 
(http://www.exocarta.org/) (Keerthikumar et al., 2016) and vesiclepedia (Kalra et al., 
2012). 
Their involvement in cell-cell communication is indicative of their influence on tumour 
development, progression, metastasis and therapeutic efficacy (Kucharzewska and 
Belting, 2013). Exosomes released by cancerous cells carry numerous biomarkers, 
which are passed on to healthy cells via microenvironment, causing stromal and 
angiogenic activation along with immune escape (Tickner et al., 2014). They 
contribute to metastasis by aiding in epithelial to mesenchymal transition and 
formation of pre-metastatic niche (Jeppesen et al., 2014b). Exosomes also shield 
tumour cells from cytotoxic properties of chemotherapeutic drugs and transfer chemo-
resistant effects to nearby cells (Federici et al., 2014). 
Multiple studies have focused on the miRNA content of exosomes, as it is abundant 
and regulates the mRNA expression within recipient cells (Valadi et al., 2007). Study 
by Grange and colleagues have reported that exosomes from cancer stem cells 
contained miR29a, miR650 and miR15, all associated with tumour invasion and 
metastasis. In addition exosome bound miR19b, miR29c and miR151 are found to be 
up regulated in patients with renal carcinoma (Grange et al., 2011) 
In a study on oesophageal squamous cell carcinoma (ESCC) serum exosomal 
miRNA-1246, associated with metastasis through tumour microenvironment has 
been found to be upregulated in ESCC cell lines. miRNA-1246 has been proposed 
as a diagnostic and prognostic biomarker in ESCC (Takeshita et al., 2013). 
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Studies have shown that the expression of miRNA is higher in exosomes compared 
to parental cells (Goldie et al., 2014) and many of the RNAs enriched in exosomes 
may not be abundant or even detectable in the parental cell or highly expressed within 
the cell and low or absent within exosomes (Taylor and Gercel-Taylor, 2013, Taylor 
and Gercel-Taylor, 2008), indicating sorting of specific RNAs into exosomes 
(Guduric-Fuchs et al., 2012). Although the mechanism of this selective sorting is 
unclear, some have proposed this selectivity relates to miRNA/RNA induced silencing 
complex (RISC) component (Taylor and Gercel-Taylor, 2013). 
With so much work focused on miRNA, very little is known regarding the mRNA 
content of exosomes (Valadi et al., 2007, Tomasoni et al., 2013). Studies on transfer 
of reporter mRNA and their translation into proteins, suggests that mRNA delivered 
from exosomes to recipient cells are functional (El-Andaloussi et al., 2012, Tetta et 
al., 2013).  
Exosomes derived from colorectal tumours (Silva et al., 2012) , lung (Rabinowits et 
al., 2009), and prostate (Bryant et al., 2012) cancer cells alter the phenotype of normal 
cells by transferring specific RNA subsets. In contrast, exosomes released from 
normal surrounding cells may modify cancer cell gene expression (Bryant et al., 
2012). 
To date only a hand full of studies have been conducted on OSCC exosomes. Winck 
and colleagues reported that salivary exosomes from OSCC patients were enriched 
with proteins responsible for molecular transport, cell growth and proliferation (Winck 
et al., 2015). While another study have suggested that Epstein Barr Virus infected 
cells package the virus in exosomes which manipulates the tumour microenvironment 
and contribute to tumour escape mechanisms by inducing apoptosis of immune cells 
(Principe et al., 2013).  
Exosomes derived from HNSCC cell lines have been found to promote cell survival 
after ionizing radiation (Mutschelknaus et al., 2016) by triggering DNA repair as it has 
been shown that phosphorylation of critical DNA repair proteins is influenced by 
exosomes (Dutta et al., 2014). 
In the field of oral cancer the miRNA content of exosomes have already been studied 
(Sakha et al., 2016). Through mi-RNA sequencing it was found that exosomes 
derived from Hypoxic oral squamous cell carcinoma deliver miRNA-21 to surrounding 
normal cells. Exosomal miRNA-21 markedly increased the expression of snail and 
vimentin gene giving way for Epithelial Mesenchymal Transition (EMT) to elicit a pro-
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metastatic phenotype (Li et al., 2016a). Currently, not much is known about mRNA 
cargo of oral cancer exosomes and their implication on neighbouring healthy cells. 
To our knowledge no study has been published on the functional significance of 
mRNA content of OSCC exosomes on recipient cells. Hence we took the opportunity 
to explore the effect of packaged mRNA within exosomes secreted by normal, pre-
cancerous and cancerous oral keratinocytes cells on recipient cells. 
In this study characterisation of exosomal mRNA cargo was done using RT-qPCR 
and Agilent Bioanalyzer. Functional significance of exosomes was studied by 
transfecting normal oral keratinocyte cells with self-derived and cancer-derived 
exosomes. Through gene-expression microarray and RT-qPCR, genes affected by 
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Results 
4.2 RNA cargo protected within exosomes 
Exosomes were isolated by ultracentrifugation (Methods Fig 2.1, Page no. 42), there 
is a possibility that some free RNA or protein complexes containing RNA may be 
precipitated alongside exosomes. In order to validate that exosomal mRNA were 
protected within exosomes, we subjected exosomal pellet to various biochemical 
treatments, involving TritonX, proteinase K and RNase A (Fig 4.1). Treatment with 
proteinase K and RNase A, revealed that RNA is protected within exosomes and is 
not associated with protein aggregates. Addition of TritonX which is a detergent 
resulted in rupturing of exosomal lipid bilayer, allowing complete degradation of RNA 
by RNaseA (Fig 4.1). This indicates that RNA is truly protected within exosomes. We 
verified this finding through Agilant BioAnalyzer (Fig 4.2) and RT-qPCR. Total RNA 
from treated exosomes was used to verify the size and quality of RNA by Agilent 




Fig 4.1: Experimental approaches for the validation of exosomal RNA 
Diagrammatic representation of various biochemical treatment approaches using 
proteinase K (for protein digestion) and RNase A (for RNA digestion). Addition of 
TritonX breaks the protective lipid bi-layer exposing RNA to RNase A for degradation.  
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Fig 4.2: Exosomal RNA size and quality validation. Total RNA isolated from 
exosomes, pre-treated with various combinations of RNase, TritonX and Proteinase 
K (PK) as indicated, analysed on BioAnalyzer 6000 Pico chip. Cell RNA, indicates 
untreated parental cell total RNA, was used as a control showing two ribosomal RNA 
bands at around 2000 and 4000 nucleotides.  
 
4.3 FOXM1 mRNA is found within exosomes 
derived from SVFN10 
Having verified that our exosomes contain RNA cargos, we next investigated if cancer 
exosomes contain mRNA sequence of oncogenes. Total RNA was purified from 
exosomes prior to reverse transcription and cDNA was used to perform RT-qPCR for 
detection of FOXM1 mRNA in two cell lines. SVpgC2a expresses very low levels of 
FOXM1 mRNA whilst SVFN10 consitutively expresses high levels of FOXM1 
(Gemenetzidis et al., 2009). We were able to detect high levels of FOXM1 mRNA in 
exosomes derived from SVFN10 compared to SVpgc2a cells (Fig 4.3).  
As SVFN10 cells expresses high levels of FOXM1 mRNA, to rule out the posibility 
that the FOXM1 mRNA were extravesicular, we subjected exosomes to various 
                                      Chapter 4: Functional significance of oral cancer exosomes. 
                                                                                                          
110 
treatments as described in  Fig 4.1. Treatment with RNase alone did partially reduce 
FOXM1 mRNA levels (not significant), but pretreatment with RNase plus TritonX 
significantly abolished FOXM1 mRNA levels (Fig 4.4). This indicates that large 
proportion of FOXM1 mRNA were protected within the exosomes. Similarly, 
pretreatment of exosomes with proteinase K and RNase A did not degrade FOXM1 
mRNA indicating that it is not being protected as a protein-mRNA aggregages. 
Addition of TritonX, Proteinase K and RNase once again led to degration of all mRNA 
(Fig 4.4), confirming that FOXM1 mRNA were protected within exosomes. 
 
 
Fig 4.3: Presence of FOXM1 mRNA detected in SVFN10 exosomes 
through RT-qPCR. mRNA expression levels of FOXM1 in exosomes derived from 
SVpgC2a (SVpgC2a EXO) and SVFN10 (SVFN10 EXO) cell lines. The error bars 
represent the standard error of the mean of three independent experiments (n=3). 
Significant P values are denoted by (***P<0.001). 
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Fig 4.4: Validation of exosomal FOXM1 mRNA Exosome pellets were pre-
treated as shown in Figure 4.1 prior to RT-qPCR to investigate if FOXM1 mRNA were 
protected within exosomes. The error bars represent the standard error of the mean 
of three independent experiments (n=3). Significant P values are denoted by 
(*P<0.05).  
 
The same experiments were then repeated to measure reference gene, we have 
chosen β-Actin (ACTB) as it is expressed equally in exosomes from both cell lines 
(Fig 4.5). Similarly, pre-treatment of exosomes with RNase A and proteinase K alone 
reduced slightly the levels of mRNA of ACTB while adding triton X significantly 
lowered the mRNA levels (Fig 4.6). This indicates that the yield of exosomes in the 
two cell lines are equivalent and that the low levels of FOXM1 mRNA found in 
SVpgC2a exosomes (Fig 4.3) were not due to low exosome yield, but rather due to 
low level of FOXM1 gene expression in this cell line. 
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Fig 4.5: mRNA expression levels of β-Actin. Nearly equal levels of ACTB 
mRNA was detected in SVpgC2a (green) and SVFN10 (blue) exosomes. The error 




Fig 4.6: Validation of exosomal β-Actin mRNA levels. Significantly low levels 
of RNA were found on treating the pellet with triton. The error bars represent the 
standard error of the mean of three independent experiments (n=3). Significant P 
values are denoted by (*P<0.05). 
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Apart from ACTB, mRNA expression levels of reference gene GAPDH were also 
examined in treated exosomes and the expression was found similar to ACTB 
(Appendix Fig 8.3, Page no. 191). 
4.4 Genes are not equally sorted into exosomes 
Treated SVpgC2a and SVFN10 exosomes were also screened for other oncogenes 
including HOXA7, CCNB1, CENPA, DNMT3B, DNMT1, CEP55, NEK2, HELLS, and 
BMI1. We found low levels of mRNA packed within exosomes which were detectable 
after RNase treatment by RT-qPCR. Only HOXA7 mRNA expression levels were 
found to be upregulated (not significantly) in SVFN10 exosomes compared to 
SVpgC2a. Whereas MAPK8, AURKA and ITGB1 degraded with RNase treatment 
suggesting they are not packed with in exosomes but co purify with protein 
aggregates during isolation (results in Appendix Fig 8.4, Page no. 193). 
We conclude that exosomal mRNA is protected from extracellular environment 
including RNase and proteinase. We also report that cancer cells package oncogenes 
in exosomes although a mechanism which is not fully understood but a sorting system 
seems to exist through which some genes appeared to be preferentially packed within 
exosomes. 
4.5 Functional effects of exosomes on recipient 
cells 
Many studies have reported the functional transfer and effects of miRNA from 
exosomes to cell (Pegtel et al., 2010, Stoorvogel, 2012) but again very few studies 
have focused on the effects of mRNA transfer from exosomes to cells (Valadi et al., 
2007). In this study, having established the presence of mRNA within exosomes, we 
investigated if cancer cells utilise exosomes as a vehicle to export oncogenic mRNA 
to normal cells. Given that we found high levels of FOXM1 mRNA within exosomes 
secreted from a malignant cell line (SVFN10), we performed an exosome transfer 
experiment (which we subsequently termed as “transfection”). We have chosen 
SVpgC2a cells for transfection as they not only express low levels of FOXM1 
oncogene but are also easier to grow in comparison to primary keratinocytes. 
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SVpgC2a cells were transfected with SVFN10 exosomes, while SVpgC2a cells 
transfected with self-exosomes (exosomes isolated from SVpgC2a) and exosome-
depleted supernatant from ultracentrifugation were used as controls. After 24 hours 
of transfection, SVpgC2a cells showed observable morphological change in the 
SVFN10 exosome-transfected cells which became larger and more granular in 
appearance, similar to the morphology of SVFN10 cells. SVpgC2a cells transfected 
with SVpgC2a exosomes or depleted supernatant did not show much morphological 
change (Fig 4.7). The morphological changes became pronounced at 24 hours 
following transfection with exosomes (Fig 4.7)  
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Fig 4.7: Morphological changes in SVpgC2a cells transfected with 
SVFN10 exosomes. (A) Untreated SVpgC2a and SVFN10 cells in growth medium. 
(B) SVpgC2a cells at 24 hrs following transfection with SVpgC2a (+SVpgExo) and 
SVFN10 (+SVFNExo) exosomes and corresponding exosome-depleted supernatant 
(SN).  
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Following transfection, to investigate if the recipient cells have taken up SVFN10 
exosomes (containing high levels of FOXM1 mRNA), the relative mRNA expression 
of FOXM1 over the reference gene ACTB was analysed through RT-qPCR. It showed 
slightly increased levels of FOXM1 mRNA at 48 hours of incubation, this effect was 
lost at 72 hours of incubation (Fig 4.8). Although the relative increase in FOXM1 
mRNA levels was not statistically significant, this result suggests that the SVFN10 




Fig 4.8: mRNA transfer from SVFN10 exosomes to SVpgC2a cells.          
Relative expression of FOXM1 mRNA (normalised with ATCB reference gene) in 
SVpgC2a cells, transfected with SVpgC2a and SVFN10 exosomes for 24, 48 and 72 
hours. Un-transfected SVpgC2a (Ctrl-No EXO) were used as controls. The error bars 
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4.6 Effects of Exosomes on Senescence in oral 
keratinocytes 
Given that we noted morphological changes in recipient cells within 24h of exosomes 
transfection and the levels of exogenous FOXM1 mRNA did not peak until 48h, 
FOXM1 mRNA transfer may not be related to morphological change. We therefore 
further investigated the possible reason for such morphological changes in cells 
transfected with exosomes. Literature reported that exosomes can potentially induce 
senescence in cells (Urbanelli et al., 2016). Given that the morphological change did 
resemble senescence phenotype, we hypothesised that SVFN10 exosomes 
transfection may have triggered senescence in the recipient SVpgC2a cells. In order 
to investigate this mechanism we first checked the ability of SVpgC2a cells to senesce 
with drug treatment. Through a dose response experiment we found that treating 
SVpgC2a with a chemotherapeutic drug etoposide but not 5-Azacytindine or vehicle 
DMSO at the concentration of 1x10-7 M, was the minimally effective dose for activating 
senescence without causing toxicity to cells. These finding were verified by beta 





Fig 4.9: Beta galactosidase assay on SVpgC2a cells. SVpgC2a cells were 
treated with vehicle Dimethyl sulfoxide (DMSO; 0.05%) 5-Azacytidine (5AZA) or 
Etoposide (ETO) at the concentration of 1x10-7 M. Note the blue staining of SVpgC2a 
cells treated with etoposide (+ETO) indicating senescence. Untreated SVpgC2a cells 
were used as a control. 
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Once senescence was established in SVpgC2a cells, they were transfected with 
SVpgC2a and SVFN10 exosomes for 24 and 48h hrs. No senescence was detected 
through Beta gal assay; hence we decided to check if senescence markers could be 
detected through another technique. 
Through RT-qPCR, we assessed the presence of senescence markers including 
tumour suppressor gene (P53), cyclin dependent kinase inhibitor 2A (P16), cyclin 
dependent kinase inhibitor 1A (P21) and chromobox7 (CBX7). We found slight 
increase in mRNA expression levels of P21 and CBX7 but they were not statistically 
significant (Fig 4.10). In control cells treated with etoposide, all 4 genes were 
significantly upregulated compared to untreated cells. 
                                      Chapter 4: Functional significance of oral cancer exosomes. 
                                                                                                          
119 
 
Fig 4.10: mRNA expression of senescence markers (A) P53 (B) P21 (C) P16 
and (D) CBX7 in SVpgC2a cells transfected with SVpgC2a (+SVPG EXO) and 
SVFN10 (+SVFN EXO) exosomes. Untreated and etoposide treated SVpgC2a cells 
were used as controls. The error bars represent the standard error of the mean of 
three independent experiments (n = 3). 
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4.7 Effects of exosomes on senescence on oral 
fibroblasts 
Since no evidence of senescence was found in oral keratinocyte (SVpgC2a) cells 
transfected with cancer exosomes, further research into the literature suggested that 
exosomes have an effect on surrounding supporting tissue (Urbanelli et al., 2016). 
This led us to investigate if cancer exosomes may cause senescence in normal oral 
fibroblast (NHOF-1) cells. NHOF-1 cells were treated with either Etoposide or 
transfected with SVpgC2a or SVFN10 exosomes. We were unable to establish 
senescence in NHOF-1 cells through Beta galactosidase assay (Appendix Fig 8.5, 
Page no. 194) and RT-qPCR. Due to the unavailability of another normal oral 
fibroblast cell line this experiment was not pursued.  
4.8 Effects of exosomes on differentiation in 
SVpgC2a oral keratinocytes 
In addition to senescence, such morphological changes can also be noted in 
differentiating cells (Quesenberry et al., 2015). The ability of SVpgC2a cells to 
differentiate was verified with calcium chloride (CaCl2) treatment at the concentration 
of 1mM and confirmed through qPCR. SVpgC2a cells were transfected with either 
self or SVFN10 exosomes for 48 hours. Un-treated and CaCl2-treated SVpgC2a cells 
were used as negative and positive controls, respectively. Through RT-qPCR mRNA 
expression of various differentiation markers including involucrin (IVL), 
trandglutaminase 1 (TGM1), vimentin (VIM), cornifin (CORN), loricrin (LORI), filaggrin 
(FLG), keratin 1 (K1) and keratin 10 (K10) were investigated (Fig 4.11). In transfected 
cells we found slight increase in the levels of IVL, TGM1, K1 and K10. Statistically 
Significant increase was noted in mRNA levels of CORN, LORI and FLG (Fig 4.11). 
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Fig 4.11: Effects of exosomes on mRNA expression of differentiation 
markers in recipient SVpgC2a oral keratinocytes. (A) involucrin (IVL) (B) 
trandglutaminase 1 (TGM1) (C) vimentin (VIM) (D) cornifin (CORN) (E) loricrin (LORI) 
(F) filaggrin (FLG) (G) keratin 1 (K1) and  (H) keratin 10 (K10) in SVpgC2a cells 
transfected with SVpgC2a (+SVPG EXO) and SVFN10 (+SVFN EXO) exosomes. Un-
treated and CaCl2 treated SVpgC2a cells were used as controls. The error bars 
represent the standard error of the mean of three independent experiments (n = 3). 
Significant P values are denoted by *P<0.05 and **P<0.01.  
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4.9 Effect of exosomes on differentiation in 
primary normal oral Keratinocytes 
We further expanded our study to investigate if differentiation could be induced by 
exosomes in normal primary oral keratinocytes (NK4). The cells were treated with 
CaCl2, increased expression levels of differentiation markers were verified through 
RT-qPCR. NK4 cells were transfected with self-exosomes; tumour derived exosomes 
from cell lines SqCC/Y1 and CaLH2, premalignant SVpgC2a and transformed 
malignant SVFN10 exosomes. Un-transfected and CaCl2-treated cells were used as 
controls. 
After 48 hours of incubation, NK4 cells transfected with exosomes did not show any 
morphological changes (Fig 8.6 in Appendix, Page no. 195). mRNA expression 
levels of IVL, CORN, FLG, VIM, K13, K1 and K10 were investigated through RT-
qPCR (Fig 4.12). Through expression levels of IVL, CORN and FLG we found that 
SVFN10 exosomes suppressed differentiation indicated by low expression while 
SVpgC2a exosomes induced differentiation indicated by increased expression. This 
finding is in line with mechanism of tumour development where most of the cells inside 
the tumour are highly proliferative and poorly differentiated. 
Although it was evident that transfection with exosomes caused a reaction that was 
reflected by altered mRNA levels in transfected cells compared to un-transfected 
cells. However, no clear pattern was evident.   
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Fig 4.12: mRNA expression levels of differentiation markers in exosome 
transfected normal primary oral keratinocytes (NK4). (A) involucrin (IVL), (B) 
cornifin (CORN), (C) filaggrin (FLG), (D) vimentin (VIM), (E) keratin 13 (K13) (F) 
keratin 1 (K1) and (G) keratin 10 (K10). NK4 cells were transfected with exosomes 
from NK4, CALH2, SqCC/Y1, SVpgC2a and SVFN10 cell lines as indicated. 
Untreated and CaCl2-treated NK4 cells were used as controls. The error bars 
represent the standard error of the mean of three independent experiments (n = 3). 
Significant P values are denoted by *P<0.05, **P<0.01 and ***P<0.001. mRNA 
relative expression is calculated against reference genes YAP1 and POLR2A. 
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4.10 Time and dose response of exosome 
transfection on differentiation in epidermal 
keratinocytes 
Upon finding weak evidence of exosome-induced differentiation in oral keratinocytes, 
we re-evaluated the time and dose-response of exosomes transfection using an 
immortalised epidermal keratinocyte cell line (N/TERT) known to retain the potential 
for differentiation (Dickson et al., 2000). To date no studies have been done on the 
minimum required dose and time of exosome exposure. We investigated this by 
transfecting N/TERT with exosomes derived from a HNSCC cell line SqCC/Y1 for 24, 
48 and 72 hours at the dose of 50 μl (9.35E+09 particles/ml) ,100 μl (1.87E+10 
particles/ml) and 200 μl (3.74E+10 particles/ml). 
mRNA expression levels of  IVL, VIM, S100A16 (involved in differentiation and EMT), 
FOXM1 (cell cycle/oncogene), CBX7 (senescence related), MMP13 (matrix 
metallopeptidase 13) were explored by RT-qPCR in exosome-transfected N/TERT 
cells (Fig 4.13). Of all these genes, VIM was the only gene significantly increased in 
a dose- and time-dependent fashion following exosome transfection. The rest of the 
genes appeared to be downregulated by exosomes although none of these effects 
were statistically significant. We realized that we needed to know about more relevant 
genes that would be affected at mRNA level by exosomal transfection. 
These results were part of an MSc project performed by Christina Puspita Sari. 
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Fig 4.13: Time and dose-response effect of cancer exosomes on mRNA 
expression levels in recipient N/TERT cells. (A) Involucrin (IVL) (B) FOXM1 
(C) CBX7 (D) MMP13 (E) Vimentin (VIM) (F) S100A16 at the dose of 0 μl (No 
exosomes) 50 μl (9.35E+09 particles/ml), 100 μl (1.87E+10 particles/ml) and 200 μl 
(3.74E+10 particles/ml). Un-treated and CaCl2 treated N/TERT cells were used as 
controls. The error bars represent the standard error of the mean of duplicate 
determinations (n = 2).. Significant P values are denoted by *P<0.05, **P<0.01 and 
***P<0.001. 
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4.11 Microarray 
To date no study has reported a total RNA microarray gene analysis of oral 
keratinocyte cells transfected with normal and cancer exosomes. The limitation of 
exploring genes through RT-qPCR is that only a limited number to genes can be 
explored to study the effects and mechanisms triggered by exosomes on recipient 
cells. By using microarray, we were able to investigate the global gene expression 
profile (approximately 50,000 genes) in an unbiased way to understand the functional 
effects in recipient cells triggered by normal vs cancer-cell derived exosomes. The 
microarray data has been published on Gene expression Omnibus GSE89217. 
Total RNA microarray gene analysis was done for normal primary oral keratinocyte 
cell line (OK113) transfected with equal concentrations of normal and cancer-cells 
derived exosomes (Methods Table 2.5, Page no. 65). OK113 cells were transfected 
with exosomes from normal oral keratinocyte cell lines (OK113, NK4, NOK368), 
tumour derived cell lines (Ca1, CaLH2, SqCC/Y1), premalignant (SVpgC2a) and 
transformed malignant cell line (SVFN10) for 48 hours prior to harvest. No 
morphological changes were evident after 48 hours of incubation (Fig 4.14). Un-
transfected OK113 cells were used as controls.  
Total RNA was extracted from transfected and un-transfected OK113 cells. 
Concentration and purity of RNA was verified through NanoDrop and Agilent 
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Fig 4.14: Morphology of OK113 with and without transfection at 48hrs 
Images (x200) showing morphology of un-transfected OK113 cells in comparison to 
transfected  OK113 with self-exosomes and exosomes isolated from NK4, NOK368 
(normal oral keratinocyte) Ca1, CaLH2, SqCC/y1 (tumour derived oral keratinocyte) 
SVpgC2a (premalignant oral keratinocyte) and SVFN10 (transformed malignant oral 
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4.11(1) Gene expression profile in exosome-
transfected normal oral keratinocytes 
Microarray data was analysed in two categories. Firstly, comparison was made 
between un-transfected and exosomes-transfected OK113 to analyse genes that are 
up- and down-regulated by exosomes transfection irrespective of their origin (Fig 
4.15).  
Comparing between transfected and un-transfected OK113 cells revealed 
approximately 38.4% of the genes were upregulated while majority of the genes i.e. 
61.6% were down regulated (Fig 4.15 A). This pattern of expressing matched with 
our qPCR data as we noted a global decrease in the mRNA levels in most of the 
genes studied.  
The top 50 of the most upregulated and downregulated genes were shortlisted (Fig 
4.15 B), from which 20 were chosen for validation on a biological replicates through 
RT-qPCR (Fig 4.17 A). Selection of the genes was based on whether they were 
coding or non-coding (this study focused on coding genes) and the availability of 
specific primers sequence. Upon validation using RT-qPCR, we found that MMP9, 
TUBB6, FEZ1, OAS1, PGAM1 (upregulated) and TSC22D3, OTUD1, BBOX1 (down 
regulated) were the most reproducible. These genes are found to be involved in 
important cellular functions such as regulation of extracellular matrix, cytoskeleton, 
intracellular transport, immune response, regulation of P53 and glycolysis. The genes 
along with their cellular functions are listed in Table 4.1. 
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Fig 4.15: Total RNA Microarray gene analysis between un-transfected vs 
exosome transfected oral keratinocytes. Gene analysis of untransfected 
OK113 cells compared to transfected OK113 cells by normal (OK113, NK4, NOK368) 
and cancer (SqCC/Y1, CaLH2, Ca1, SVpgC2a, SVFN10) exosomes. Data was 
pooled from eight transfected samples. (A) Relative gene expression showing 38.4% 
of upregulated and 61.6% of down regulation of genes (B) List of top 50 upregulated 
(red) and down-regulated (green) genes obtained by Log2 ratio of gene expression 
between transfected and un-transfected. The diagram was created by Dr Muy-Teck 
Teh. 
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Table 4.1: Genes affected by exosomes and their cellular functions.  
These genes were found to be up (red) and down (green) regulated by normal and 




4.11(2) Differential gene expression profile 
between normal and cancer exosomes 
transfection 
The second category of microarray gene data analysis was done by comparing 
normal and cancer exosome transfected OK113 cells to identify which genes are 
differentially up and down-regulated by cancer exosomes (Fig 4.16).  
Comparison between OK113 cells transfected with normal oral keratinocytes 
exosomes (NK4, NOK368 and OK113) and with cancer exosomes (Ca1, CaLH2, 
SqCC/Y1, SVpgC2a and SVFN10), revealed almost equal percentage of the genes 
were up (50.3%) and down (49.7%) regulated. Similarly, we shortlisted 50 top most 
up and down-regulated genes in an attempt to understand if recipient cells respond 
differently to cancer exosomes. Out of these 50 genes 20 were shortlisted based on 
the same criteria as mentioned earlier, for validation using RT-qPCR.  
We found EFEMP1, EEF2K, DKK3, LAMP2, SRPX, SPARC, and ADAM9 among the 
up regulated genes and SPRR2E, IGFBP3, RRP12, KLF6 among the downregulated 
genes were the most reproducible genes through RT-qPCR (Fig 4.17 B). In 
agreement with our experiments on N/TERT (Fig 4.13 E, Page no. 128), vimentin 
(VIM) was also found to be upregulated by cancer exosomes (Fig 4.16 B #32). 
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These genes are found to be involved in vital cellular functions including cell growth 
and adhesion, regulation of cellular morphology, protein synthesis, Wnt signalling 
pathway, autophagy, deposition of extracellular matrix, regulation of cornified cell 
envelop , maturation of ribosomal subunits and regulation of signal transduction 
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Fig 4.16: Total RNA Microarray gene analysis between normal and cancer 
exosome transfected oral keratinocytes. Gene analysis of pooled data from 
OK113 cells transfected by normal exosomes (OK113, NK4, NOK368) compared with 
OK113 cells transfected by cancer exosomes (SqCC/Y1, CaLH2, Ca1, SVpgC2a, 
SVFN10). (A) Relative gene expression showing 50.3% of upregulated and 49.7% of 
down regulated genes (B) List of top 50 upregulated (red) and down-regulated (green) 
genes obtained by Log2 ratio of gene expression between cancer and normal 
transfected cells. The diagram was created by Dr Muy-Teck Teh. 
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Table 4.2: Genes affected by cancer exosomes and their cellular 
functions.  These genes were found to be up (red) and down (green) regulated by 
cancer exosomes in normal oral keratinocyte cell line OK113. 
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Fig 4.17: Validation of microarray results through RT-qPCR. (A) mRNA 
expression of OK113 cells transfected with exosomes compared to un-transfected. 
(B) mRNA expression of OK113 cells transfected with cancer exosomes compared 
to normal exosomes. Red and green represents up and down regulated genes 
respectively. Grey indicates the genes which were not reproducible via RT-qPCR. 
The error bars represent the standard error of the mean of three independent 
experiments (n = 3).  
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Through microarray gene analysis we were able to have an insight into the genes 
expression profile triggered by exosome transfection and by cancer exosomes 
exclusively. We had planned to study the expression of these genes identified through 
microarray on another normal oral keratinocyte cell line transfected with exosomes, 
but due to time and financial restrictions we were unable to carry out such an 
experiment. To take full advantage to these gene markers their function and pathway 
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4.12 Effective dose and exposure time of 
exosome 
Isolation of exosomes through ultracentrifugation is very labour some and time 
consuming. From seeding cells to getting one exosome pellet (enough for 1 
experiment) can take up to 2 to 3 weeks. Till now no guidelines are available in the 
literature on the most effective exosome dose and exposure time to cause a response 
in recipient cells. Because of this gap in our knowledge we aimed to further investigate 
using RT-qPCR on the time and dose responses of exosomes in recipient cells by 
measuring the validated genes from the above microarray study. 
Through microarray gene analysis we were able to recognize the pattern of 
expression of a number of genes affected by exosome transfection. We used this 
information to determine the lowest dose and shortest time period required by 
exosomes to trigger a response in recipient cells. 
Normal oral keratinocyte cell line OK113 seeded in a 6 well plate at the confluency of 
0.2x106 cells/well. Once attached they were transfected with tumour derived 
SqCC/Y1 exosome at the dose of 50μl, 100μl and 200μl with the particle/ml 
concentration of 1.87E+11 for 24 and 48 hrs prior to harvest for RT-qPCR. According 
to RT-qPCR gene validation results above, we chose genes MMP9 and BBOX1 as 
they were the most up- and down-regulated genes in recipient cells, respectively. Un-
treated OK113 cells were used as controls.  
MMP9 mRNA expression was found to be highly dependent on exosome dose. The 
trend of increase was similar at 24 and 48h hrs but the gene activation was greater 
at 24 hrs compared to 48 hrs (Fig 4.18 A). Conversely, BBOX1 was dose-
dependently down–regulated. The trend of downregulation was more pronounced at 
48 hrs compared to 24hrs (Fig 4.18 B). 
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Fig 4.18: Time and dose-response of exosome transfection on gene 
expression in recipient cells. mRNA levels of MMP9 (up-regulated) and BBOX1 
(down-regulated) at 24 and 48 hours in OK113 cells transfected with SqCC/Y1 
exosomes  at the dose of 50,100 and 200μl (1.87E+10 particle/ml concentration).  The 
error bars represent the standard error of the mean of two independent experiments 
(n = 3). Significant P values are denoted by *P<0.05, **P<0.01 and ***P<0.001 
 
A similar experiment was done to measure MMP9 and BBOX1 in OK113 cells 
transfected with self-exosomes and the findings were highly comparable to that of 
SqCC/Y1 exosome transfection (result not shown). This indicates that regardless of 
the origin of exosomes (whether it was normal or cancer-derived), exposure to 
exosomes triggers specific genes in recipient cells. 
To further investigate specific genes triggered by cancer exosome, an identical 
transfection experiment was set up to understand that effect of exosome dose and 
exposure time on genes EEF2K (up-regulated) and SPRR2E (down-regulated) by 
cancer exosomes. OK113 cells were transfected with self-exosomes at the dose of 
50μl, 100μl, 200μl and SqCC/Y1 exosome with the same range of doses and 
particle/ml concentration as mentioned previously. Untreated OK113 cells were used 
as controls.  A LOG2 ratio was used to calculate the difference between the normal 
and cancer exosome transfection. 
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We found that in the first 24 hrs of transfection, EEF2K was up regulated with 
increasing number of exosomes while the expression was down regulated at 48 hrs 
(Fig 4.19 A). The levels of SPRR2E were down-regulated with increasing exosome 
particles which was more pronounced at 48 hrs (Fig 4.19 B). 
 
 
Fig 4.19: Time and dose-response of normal vs cancer exosome 
transfection on gene expression in recipient cells. Log2 ratio of mRNA 
relative expression of OK113 cells transfected with self and SqCC/Y1 exosomes. (A) 
mRNA expression of EEF2K (up-regulated) and (B) SPRR2E (down-regulated) at 24 
and 48 hours. Different doses of OK113 and SqCC/Y1 exosomes were used 50μl 
,100μl and 200μl while the particle/ml concentration was 1.87+E10. The error bars 
represent the standard error of the mean of two independent experiments (n = 2). 
Significant P values are denoted by *P<0.05, **P<0.01 and ***P<0.001 
 
We conclude that a concentration of exosomes as low as 3E+09 particle/ml was 
enough to elicit statistically significant gene expression responses. The most 
noticeable change in mRNA expression were noted at around 3E+10 particles/ml 
which in our experiment coincided with 200μl of exosome stock volume. Up-regulated 
mRNA levels of MMP9 and EEF2K, and down-regulated mRNA expression levels of 
BBOX1 and SPRR2E were consistent with the microarray data. We found that 24 
hours of exosome exposure was enough to elicit altered gene expression patterns. 
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4.13 Discussion 
Initial research in the field of exosomes had proposed their role in maintaining cellular 
homeostasis by removing undesired molecules from cells (Raposo and Stoorvogel, 
2013, Harding et al., 2013) including harmful cytoplasmic DNA (Takahashi et al., 
2017). However, emerging evidence has revealed that exosomes play an important 
role in cell to cell communication by activating various signalling pathways in recipient 
cells (Schorey et al., 2015, Cheung et al., 2016).  
In the field of OSCC the functional significance of oral cancer exosomes on normal 
recipient oral keratinocyte cells is unknown. Hence, we took the opportunity to explore 
the effects of exosomal mRNA on recipient cells to better understand the mechanism 
of cell to cell communication within OSCC development and progression.  
In this study, successful isolation and characterisation of exosomal RNA was verified 
by Agilent bio-analyzer and RT-qPCR. Through treatment with RNAse, proteinase K 
and Triton-X it was shown that exosomal RNA is well protected within the surrounding 
lipid bi-layer and only degrades with Triton-X breaking down the lipid bi-layer (Fig 4.2, 
4.4, 4.6, Page no. 109,111,112). Our data also shows that not all genes are equally 
expressed within exosomes (Fig 4.3,4.5, Page no. 110,112), indicating a mechanism 
of selective packaging. 
Further, the functional importance of cancer exosomes was studies by transfecting 
non-cancerous cells with cancerous exosomes expressing high levels of FOXM1 
oncogene, morphological changes within recipient cells were noted within 24 hours 
of incubation (Fig 4.7, Page no. 115). In addition mRNA expression of FOXM1 
oncogene also increased within recipient cells at 48 hours but only transiently (Fig 
4.8, Page no. 116). This indicates that mRNA content of tumour derived exosomes 
was transferred to normal recipient cells. Further research needs to be done in order 
to find if long term exposure to cancerous exosomes would result in normal cells 
changing phenotype to cancerous cells permanently. 
As suggested by literature such morphological changes might be a result of 
exosomes inducing senescence (Urbanelli et al., 2016). We screened for senescence 
phenotype through beta-gal assay. Through RT-qPCR expression of senescence 
markers including P16, P53, P21 and CBX7 were explored (Fig 4.10, Page no. 119). 
Upon finding no evidence of recipient cells senescing, further literature review was 
done, where studies have reported that exosomes are capable of inducing 
differentiation into recipient cells (Cheung et al., 2016). Expression of differentiation 
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markers including IVL, TGM1, VIM, CORN, LORI, FLG, K1, K10 and K13 in exosome 
transfected cells was explored through RT-qPCR but no specific trend could be 
established (Fig 4.11, 4.12, Page no. 122, 125). 
In order to determine dose and time required by exosomes to elicit a response in 
recipient cells, N/TERT (normal immortalised epidermal keratinocytes) cells were 
transfected with cancer exosomes with different doses at three time points (24h, 48h, 
72h). Through RT-qPCR, differential gene expression of IVL, FOXM1, CBX7, 
MMP13, VIM and S100A16 were observed. Interestingly, except for VIM all the other 
genes were found to be downregulated by exosome transfection (Fig 4.13, Page no. 
128). We hypothesize that this downregulation might be a self-protecting mechanism 
within cells such as autophagy (Shintani and Klionsky, 2004) or RNA interference 
(Tijsterman and Plasterk, 2004) that shuts down the expression of important genes 
upon exposure to foreign exosomes. Evidence of such mechanism can be found in 
RNA interference involving dicer effect (Tijsterman and Plasterk, 2004). 
In order to explore specific genes altered by exosomes, gene expression microarray 
profiling was done on normal oral keratinocyte cells (OK113) transfected with self, 
normal (NK4, NOK368) and cancer exosomes (SqCC/Y1, CaLH2, Ca1, SVpgC2A, 
SVFN10) for 48h. 
Through microarray profiling we found that exosomes irrespective of their origin 
(normal or cancer) altered gene expression in recipient cells. Amongst the top 
differentially altered gene list, we have validated using RT-qPCR that MMP9, TUBB6, 
FEZ1, OAS1 and PGAM1 genes were upregulated in recipient cells compared to 
untreated cells, while TSC22D3, OTUD1 and BBOX1 were found to be 
downregulated (Fig 4.17, Page no. 137). 
Cancer exosomes were found to exclusively increase the expression of EFEMP1, 
EEF2K, DKK3, LAMP2, SRPX, SPARC and ADAM9 while the expression of 
SPRR2E, IGFBP3, RRP12 and KLF6 was down regulated (Fig 4.17, Page no. 137). 
We look into literature to understand the physiological and pathological involvement 
of these markers in cellular functions. 
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4.13(1) Genes up regulated by exosome transfection 
MMP9 Matrix metallopeptidase 9 is a class of zinc dependent proteinases (Nagase 
and Woessner, 1999) involved in the breakdown of extracellular matrix in normal 
physiological processes such as embryonic development (Gu et al., 2015) and wound 
healing (Amar et al., 2017) and pathological processes such as cancer metastasis 
(Deryugina and Quigley, 2006). 
In OSCC salivary MMP9 has been found to be upregulated in patient sample 
compared to normal healthy saliva suggesting its potential use as an early diagnostic 
tool (Peisker et al., 2017). In another study upregulated expression of MMP9 was 
observed in patients with metastatic oral cancer compared to patients with non-
metastatic oral cancer (Qin et al., 2017). To our knowledge, we are the first to report 
increased expression of MMP9 as a result of oral keratinocyte exosome transfection. 
MMP9 may play an important role in angiogenesis and neovascularization (Bergers 
et al., 2000). For example, MMP9 appears to be involved in the remodelling 
associated with malignant glioma neovascularization (Wang et al., 2003).  
MMP9 is greatly upregulated during human respiratory epithelial healing (Buisson et 
al., 1996). Using a MMP9 deficient mouse model, it was seen that MMP9 coordinated 
epithelial wound repair while deficient mice were unable to remove the fibrinogen 
matrix during wound healing (Mohan et al., 2002). 
Limited studies have looked into the effects of exosomes on MMP9.  It has been 
reported that hepatocellular carcinoma-derived exosomes enhance migratory and 
invasive ability of non-cancerous recipient cells by triggering PI3K/AKT and MAPK 
signalling pathway with increased secretion of active MMP9 (He et al., 2015). 
 
TUBB6 Tubulin beta 6 class V has been found to be preferentially expressed in cells 
with secretory function such as pancreatic, salivary ductal cells (Chao et al., 2012). 
Abnormal distribution and expression of β- tubulin isotypes have been reported in 
numerous malignancies (Orr et al., 2003), indicating a more aggressive and drug 
resistant tumour phenotype (Kavallaris, 2010). Hence it has been proposed that 
altered expression of TUBB6 may be associated with tumorigenesis and may be a 
useful diagnostic tool and a potential prognostic marker (Chao et al., 2012). Any 
influence of TUBB6 on OSCC development is yet to be established. 
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FEZ1 Fasciculation and elongation protein zeta 1 has been known for its role in onset 
and progression of neurodegenerative disorders (ND) such as Alzheimer’s and 
schizophrenia (Chua et al., 2013). Defects in intracellular transport and autophagy 
are the causative factors of ND. 
In normal physiology the FEZ1 binds to neuronal SNARE protein Syntaxin 1A and 
control the synaptic vesicle exocytosis (Chua et al., 2012). FEZ1 disruption results in 
intracellular transport defects (Maturana et al., 2010). 
Through microarray, presence of FEZ1 in exosomes has been reported in a rat model 
of pancreatic adenocarcinoma where it is proposed to induce vascular endothelial 
growth factor (VEGF) (Nazarenko et al., 2010) GSE18812. The biological mechanism 
behind the activation of VEGF by FEZ1 is largely unknown. This is the first study to 
report aberrant expression of FEZ1 due to exosome transfection. 
OAS1 2′-5′ oligoadenylate synthase (OAS) is well known for its function as an immune 
regulator (Choi et al., 2015). Research has also shown that OAS1 is involved in other 
cellular functions such as apoptosis (Domingo-Gil and Esteban, 2006) required for 
elimination of viral-infected cells and inhibiting tumorigenesis (Castelli et al., 1998). 
OAS1 is also known for its tumour suppression in breast and ovarian cancer by 
activating apoptosis of cancer cells and countering tumour progression (Latham et 
al., 1996). In addition, OAS1 is also found to regulate nuclear events, including pre-
mRNA splicing (Sperling et al., 1991). To date no study has reported increased 
expression of OAS1 due to exosome transfection. 
 
PGAM1 Phosphoglycerate mutase 1 is an important enzyme in the glycolytic pathway 
of glucose metabolism where it catalyses the conversion of 3-phosphoglycerate into 
2-phosphoglycerate (Jiang et al., 2014). PGAM1 has been found to be up regulated 
in human colorectal, liver, lung (Durany et al., 1997) and breast (Durany et al., 2000) 
cancer tissue and hence has been extensively studied as the potential candidate for 
developing cancer therapeutics (Sheng and Tang, 2016). A recent study has shown 
that PGAM1 inactivation leads to nucleotide depletion, which causes defective DNA 
repair, suggesting that targeting PGAM1 increases cancer cell susceptibility to DNA 
damaging agents (van Vugt, 2017). 
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4.13(2) Genes downregulated by exosome transfection 
 
TSC22D3 TSC22 Domain family member 3 also known as Glucocorticoid-induced 
leucine zipper (GILZ) is a potent anti-inflammatory protein. GILZ regulates signal 
transduction pathways of inflammation and plays a role in cell survival (Espinasse et 
al., 2016) by exerting pro- or anti-apoptotic effects, depending on the cell type and 
the stimuli used (Asselin-Labat et al., 2004). In a study on apoptosis of myocardial 
cells during myocardial infarction, has shown that miR-140-3p regulates the 
expression of TSC22D3 in mouse model (Liu et al., 2015). 
 
OTUD1 OTU deubiquitinase 1 is a cysteine protease that hydrolyzes the cleavage of 
ubiquitin in vitro (Mevissen et al., 2013). Cozier and colleagues were the first to report 
that OTUD1 is located in chromosome 10p12 (Cozier et al., 2012). OTUD1 regulates 
the stability of tumour suppressor gene P53. Not much is known about its substrates 
and its role in cellular functions is largely unknown. OTUD1 overexpression increased 
p53 stability, whereas OTUD1 knockdown decreased p53 stability. OTUD1 has also 
been known to inhibit cell growth and increases apoptosis by controlling S and G2/M 
phase checkpoints (Piao et al., 2017). 
 
BBOX1 gamma-butyrobetaine hydroxylase 1 catalyses the formation of L-carnitine, 
essential for transport of fatty acids across the mitochondrial membrane (Rigault et 
al., 2006). Not much is known about other cellular functions of BBOX1. Through meta-
analysis of microarray data from 13 different types of cancers, BBOX1 has been 
proposed to have an important role in cancer development (Dawany et al., 2011). 
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4.13(3) Genes up-regulated exclusively by 
cancer exosomes 
 
EFEMP1 Epidermal growth factor containing fibulin like extracellular matrix protein 1 
(EFEMP1) also known as Fibulin 3 is a member of the fibulin family of secreted 
glycoprotein (Shen et al., 2017). Fibulin family is known to regulate cell morphology, 
adhesion, growth and motility (Timpl et al., 2003). Initially, EFEMP1 was identified as 
a senescence protein (Lecka-Czernik et al., 1995) which takes part in regulation of 
body weight and behavioural control (Weedon et al., 2008). EFEMP1 is linked to the 
primary precursor of elastin and hence is widely distributed throughout the body (de 
Vega et al., 2009). It is also detected in ensheathing olfactory cells, promoting their 
proliferation (Vukovic et al., 2009). Studies have reported that EFEMP1 regulates 
matrix metalloproteinase (MMPs) and tissue inhibitors of matrix metalloproteinase 
(Rahn et al., 2009, Wen and Kesari, 2008) 
The role of EFEMP1 is controversial in tumorigenesis. It has been found to play 
tumour suppressive functions in tumours origination from lungs, endothelial cells and 
Kaposi sarcoma and elicit oncogenic activities in tumours of brain and pancreas 
(Obaya et al., 2012). 
In recent studies EFEMP1 has been found to play a more pro tumour development 
role. In a study on bladder cancer high expression of EFEMP1 has been found in T2 
vs T1 tumour stage, correlating with increased tumour invasiveness, while 
knockdown restored the invasive and migratory potential (Han et al., 2017). High 
expression of MiR-338-5p has been shown to supress to the expression of EFEMP1 
reducing migration, invasion and promote apoptosis in brain cells (glioma) (Lei et al., 
2017). In gastric cancer through meta-analysis of multiple micro array studies, 
EFEMP1 has been identified as a potential prognostic biomarker (Min et al., 2017). 
 
EEF2K Eukaryotic elongation factor-2 kinase is a structurally and functionally unique 
protein kinase in the calmodulin mediated signalling pathway. It is involved in the 
regulation of translation and protein synthesis (Zhu et al., 2015, Kaul et al., 2011). 
Previous studies have reported increased expression of EEF2K in breast cancer 
(Meric-Bernstam et al., 2012) and glioma (Zhang et al., 2011a), where it plays a 
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critical role in cell cycle, autophagy and apoptosis (Tekedereli et al., 2012, Leprivier 
et al., 2013) making it a potential target for cancer therapy. 
 
DKK3 is a member of dickkopf WNT signalling pathway inhibitor family. Wnt signalling 
plays an important role in embryogenesis (Komiya and Habas, 2008) and cancer 
development (Zhan et al., 2017). The expression of DKK3 has been found to be down 
regulated in cancer of many origins including glioma (Gotze et al., 2010), 
oesophageal SCC (Liu et al., 2011), gastric adenocarcinoma (Yu et al., 2009), 
colorectal adenocarcinoma (Wang et al., 2012), breast cancer (Veeck et al., 2009) 
and cervical squamous cell carcinoma (Lee et al., 2009). This loss of expression was 
mainly due to CpG island methylation (Gotze et al., 2010, Yu et al., 2009, Ding et al., 
2009). Hence, DKK3 was considered a tumour suppressor gene. 
However studies on head and neck squamous cell carcinoma have reported 
overexpression of DKK3 in HNSCC cell lines associated with higher rate of 
metastasis and shorter disease-free survival rate (Katase et al., 2012). In oral 
squamous cell carcinoma increased expression of DKK3 has been correlated with 
cancer progression where its expression changes from cell membrane in normal 
mucosa to cytoplasm in dysplasia suggesting its involvement in carcinogenesis (Fujii 
et al., 2011). 
In a recent study overexpression of DKK3 was found to increase cellular proliferation, 
invasion, and migration in HNSCC and resulted in increased expression of cyclin D1 
and c-myc mRNA expression (Katase et al., 2017). 
 
LAMP2 lysosomal associated membrane protein 2 is one of the major protein 
components of lysosome. It is an important protein in the chaperone mediated 
autophagy pathway, responsible for the lysosomal degradation of approximately 30% 
of modified and oxidatively damaged cytosolic proteins (Saha, 2012).  
In a study on Oesophageal squamous cell carcinoma (ESCC) LAMP2 expression 
levels correlated with tumour histological differentiation and TNM stages. High 
expression of LAMP2 predicted poor prognosis in patients with ESCC (Li et al., 2017). 
In salivary adenoid cystic carcinoma (SACC) over expression of LAMP2 was 
observed in patient samples compared with normal tissue. It was found to be 
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associated with carcinogenesis and progression of SACC, suggesting its usefulness 
as a molecular target (Huang et al., 2016) 
Similar to exosomes, LAMP2 is endocytic in origin hence some studies on plasma 
and serum derived exosomes have reported its presence within exosomes 
suggesting its use as an exosomal specific marker (Caby et al., 2005, Caradec et al., 
2014). 
 
SRPX sushi repeat containing protein, X-linked is involved in cell growth, cytoskeletal 
organisation and cellular spreading (Burnicka-Turek et al., 2010). In invasive 
hepatocellular carcinoma cells high expression levels of SRPX was found to promote 
cellular proliferation (Lin and Chuang, 2012).  Through meta-analysis of cancer 
microarray studies SRPX was identified to be up-regulated in cancers of five different 
origins, although its specific role and mechanism has not been investigated (Ma et 
al., 2009). To date no association has been published between exosomes and SRPX. 
 
SPARC Secreted protein acidic and rich in cysteine also known as osteonectin is a 
matricellular glycoprotein that mediates interaction between cells and their 
surrounding microenvironment (Framson and Sage, 2004). SPARC is highly 
expressed during embryogenesis but the expression is reduced in adult tissue. 
However, increased expression is noted in response to inflammation, tissue injury, 
tumour invasion and metastasis (Arnold and Brekken, 2009, Chlenski and Cohn, 
2010). 
In breast cancer increased expression of SPARC was found, associated with 
increased levels of MMP2 and MMP9 which resulted in degradation of extracellular 
matrix leading to increased tumour invasion and metastasis (Kim et al., 2017). 
In oral squamous cell carcinoma SPARC aberrant expression was detected both in 
stromal and tumour cells collected from saliva, biopsy material, and fresh cell 
scrapings of patients with OSCC, where it correlated with presence of metastasis, 
patient survival and tumour grade (Aquino et al., 2013) suggesting its potential as a 
prognostic marker. To date no association has been made between exosomes and 
cellular up regulation of SPACR. 
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ADAM9 ADAM metallopeptidase domain 9 is a transmembrane protein involved in 
cell adhesion, proliferation, migration and proteolysis (Ambatipudi et al., 2011, Duffy 
et al., 2011).  Through gene profiling, ADAM9 has been implicated as a potential 
oncogene and therapeutic target in breast cancer (Fry and Toker, 2010) and NCI-60 
human tumour cell lines (Kohn et al., 2012). 
Increased expression of ADAM9 has been identified in high risk oral premalignant 
lesions, where it possibly plays a role in transformation into OSCC (Tsui et al., 2009). 
In another study on OSCC, genome wide analysis of copy number alteration showed 
high amplification frequency of ADAM9 suggesting it has a potential oncogenic role 
(Vincent-Chong et al., 2013). Currently, no study has reported increased expression 
of ADAM9 due to exposure to cancer exosomes. 
 
4.13(4) Genes down regulated exclusively by cancer 
exosomes 
 
SPRR2E Small Proline Rich Protein 2E is part of the human epidermal differentiation 
complex on chromosome 1q21 and code for precursor proteins of the cornified cell 
envelop, a structure which is characteristic for terminally differentiated keratinocytes 
(Gibbs et al., 1993). This envelope serves as a protective barrier against extracellular 
and environmental factors. 
In a study on epidermal squamous cell carcinoma low expression of SPRR2 was 
noted in malignant keratinocyte cell lines compared to normal suggesting defective 
terminal differentiation, a characteristic of carcinogenic transformation (Lohman et al., 
1997). Similar expression of SPRR2 has been observed in neoplastic keratinocytes 
of the anal track (Zucchini et al., 2001). 
To the best of our knowledge, expression of SPRR2E has not been studied in the 
development of oral squamous cell carcinoma and its down-regulation due to 
exosome transfection has not been reported. 
 
IGFBP3 insulin like growth factor binding protein 3, a major carrier protein for insulin-
like growth factors (IGF)-I and IGF-II in circulating blood, is known to regulate the 
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bioavailability of insulin and insulin-like growth factors by modulating their interactions 
with signalling receptors in insulin like growth factor (IGF) signalling pathway (Jogie-
Brahim et al., 2005). 
Historically IGFBP3 was considered as a tumour suppresser gene as it’s over 
expression was found to induce apoptosis in breast cancer (Butt and Williams, 2001, 
Gill et al., 1997).  
In recent studies the prognostic potential of IGFBP3 has been reported. In 
hepatocellular carcinoma and oesophageal squamous cell carcinoma, low levels of 
IGFBP-3 expression correlated with clinicopathological features of the tumour stage 
and poor overall patient survival rate (Yan et al., 2017, Zhao et al., 2012). 
In OSCC studies, up-regulation of IGFBP3 has been reported in cell lines derived 
from cervical lymph nodes where mRNA expression was significantly associated with 
lymph node metastasis through an IGF-independent mechanism (Yen et al., 2015). 
Due to high levels of IGFBP3 and its positive correlation to disease progression and 
metastasis, it has been proposed as a potential biomarker in OSCC (Zhong et al., 
2008). More research needs to be done to determine the expression of IGFBP3 in 
oral keratinocytes and its association with exosome exposure. 
 
RRP12  Ribosomal RNA processing 12 homolog encodes a nuclear protein involved 
in ribosomal subunit maturation and export (Oeffinger et al., 2004, Vanrobays et al., 
2008). RRP12 was found to play an important role in cell cycle progression and 
response to DNA damage, where loss of RRP12 caused defects in S-phase entry 
and progression, in efficient DNA damage response, and a delay in M/G1 transition 
(Dosil, 2011). 
The effect of RRP12 in mammalian cells was studied in nuclear stress conditions in 
osteosarcoma cells. It was found that the overexpression of RRP12 stabilized P53 
expression promoting resistance to cytotoxic stress while down regulation enhanced 
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KLF6 Kruppel Like Factor 6 is involved in differentiation and development. Its role in 
growth-related signal transduction pathways, cell proliferation, apoptosis and 
angiogenesis drew attention to its possible role in tumorigenesis (Bieker, 2001). KLF6 
has been extensively studied for it tumour suppressor function in prostate (Narla et 
al., 2001), colorectal (Reeves et al., 2004), hepatocellular carcinoma (Kremer-Tal et 
al., 2004)and glioblastoma (Camacho-Vanegas et al., 2007). It performs its tumour 
suppression function by promoting G1 cell cycle arrest mainly through cyclin-
dependent kinase inhibitor 1A promoter transactivation (Kimmelman et al., 2004). In 
a recent study down regulation of KLF6 was found to promote NF-kB oncogene 
signalling which suppresses programmed cell death and promotes tumour growth and 
invasion in glioblastoma (Masilamani et al., 2017). 
In HNSCC KLF6 loss of heterozygosity correlated with disease progression, 
recurrence and poor patient survival in oral and oropharyngeal squamous cell 
carcinoma patient samples, while silencing KLF6 in HNSCC cell lines increased 
cellular proliferation and decreased P21 expression (Teixeira et al., 2007). To date 
down-regulation of KLF6 in cancer has not been associated as a result of exosome 
transfection in recipient cells. 
4.14 Limitations 
Isolating enough exosomes for RNA isolation can be challenging as it is easy to miss 
the collection of the final exosome pallet. Hence the yield of one isolation cycle can 
vary from another. 
The expression of the effected genes by exosome transfection on recipient cell can 
vary depending on the source of exosomes and the recipient cells.  
Due to gaps in our knowledge we are not sure if exosomes contain full length RNA or 
short segments. Although, in our study we have used EGFP primers and other full-
length FOXM1 primers with similar results, indicating that the full-length mRNA is 
inside the exosomes. However, this does not prove if it is an intact full-length mRNA 
unless we sequence it through and through using RNAseq. 
There is a problem with traceability of cancer exosomes whereby the tumour location 
may not be found. This limits the clinical benefit of detecting cancer without a 
treatment option. Exosomes should be exploited for developing cancer vaccines or 
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5.1 Introduction 
Currently oral squamous cell carcinoma (OSCC) is diagnosed by histopathological 
examination of biopsy tissue, which is very subjective to pathologist opinion.  
Secondly, histopathology is unable to identify lesions which would potentially develop 
into OSCC (Warnakulasuriya et al., 2007). By the time these changes become evident 
to the pathologists, the disease is well established with enduring consequences.  
Hence an early detection system is much needed that would aid in diagnosing 
alongside pathological findings. Given that molecular alterations precede phenotypic 
change in many cancers, identifying molecular markers associated with early phase 
of oncogenesis may be the key to early cancer diagnosis. 
We have previously identified an oncogene FOXM1 involved in initiation and 
progression of head and neck squamous cell carcinomas (Gemenetzidis et al., 2009). 
FOXM1 belongs to FOX family which consist of 55 distinct mammalian members 
grouped in 17 subfamilies according to sequence homology within the DNA binding 
domain (Kalin et al., 2011). In Humans there are 3 FOXM1 isoforms.  FOXM1A is 
found to be transcriptionally inactive due to the presence of inhibitory exon while 
FOXM1B and FOXM1C are transcriptionally active and play an important role in cell 
cycle and proliferation (Korver et al., 1997). It is expressed in embryonic tissue but in 
healthy adult tissue the expression is limited to highly proliferative tissues such as 
intestines, testis, thymus and colon (Ye et al., 1997).  
The active role of FOXM1 in cell cycle is indicative of its subsequent role in 
tumourigenesis. Elevated expression of FOXM1 are found in cancers of different 
tissues and organs such as  basal cell carcinoma, liver, breast, prostrate, lung, brain, 
colon, pancreas, testis, kidney, ovary and oral cancers and has been shown to be 
related to poor prognosis (Teh, 2012b). Both FOXM1B and FOXM1C isoforms were 
found to be upregulated in cancers. However, it has been found that FOXM1B was 
more potent in inducing malignant transformation than FOXM1C (Lam et al., 2013). 
We have developed a diagnostic system based on FOXM1 called quantitative 
malignancy index diagnostic system (qMIDS) consisting of 14 molecular biomarkers 
associated with FOXM1 (isoform B). Functionally they are involved in regulation of 
the cell cycle, differentiation, ageing, genomic stability, epigenetic and stem cell 
renewal along with two reference genes. Their mRNA expression was translated into 
a metric scoring system using an algorithm (Fig 5.1). 
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In a study involving 299 patients, qMIDS was validated on fresh biopsy samples from 
normal, dysplastic and head and neck squamous cell carcinoma respectively. We 
tested the diagnostic precision of this system compared to conventional 
histopathological examination of the biopsy samples, as it quantifies the biomarkers 
and indicates the aggressiveness of the disease. This method of diagnosing cancer 
is being exploited for early disease detection with an aim to improve disease 
prognosis and reduce the cost of health care (Teh et al., 2013). 
 
 
Fig 5.1: Fourteen biomarkers associated to FOXM1. With the exception of 
IVL and ITGB1 which are downregulated the rest are upregulated with an increased 
expression of FOXM1. The algorithm translated the gene expression signature into a 
malignancy index values, calculated to fit a linear scale. In the formula T is the target 
gene normalized against two reference genes. Tn is the sum of n number of target 
gene mRNA transcripts measured in each cDNA samples. Tm represents a median 
value. Tnm is the sum of the n number of Tm values. Q₁, Q₃ and Q₄ represents the first 
(25%), third (75%) and fourth (100%) rank quartile of the x number of target gene 
absolute fraction Log₂ ratio (│Log₂[T(Tnm)/Tm(Tn)]│) distribution values within each 
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Small cohorts of FFPE samples were tested in the original study but they were taken 
from different patients at different stages of the disease. In contrast, the FFPE 
samples in this study were collected from the same patient at different time points 
during the progression of the disease. This gave an advantage of observing the trend 
and accuracy of qMIDS index in progressive OSCC as it transforms from dysplasia 
to lymph node metastasis. This study aims to test qMIDS on retrospectively collected 
archival formalin fixed paraffin embedded (FFPE) tissue samples from normal healthy 
oral mucosa, oral dysplasia, OSCC and lymph node metastasized tumour and its 
correlation to disease stage.  
The samples were collected at The Gade Institute, Bergen, Norway. The use of 
human tissue was approved by research ethics committee from Norway REK Vest: 
2010/481-7. The samples were collected from four cancer patients over a period of 
time, at different stages of oral squamous cell carcinoma including dysplasia, tumour 
and lymph node metastasis. 
Gene expression levels in biopsy specimens were quantified using RT-qPCR. The 
mRNA levels of 14 biomarkers and two reference genes were translated into qMIDS 
indexes to indicate disease aggressiveness of each sample.  
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Results 
5.2 Validation of qMIDS on FFPE samples 
Formalin fixation followed by dehydration and paraffin embedding (FFPE) is the most 
commonly used method to preserve clinical tissue samples for histological studies 
and to establish archival tissue banks. Extracting high quality RNA from FFPE tissues 
remains a challenge for molecular studies (Evers et al., 2011). RNA can degrade due 
to dehydration caused by sample treatment before and during fixation (Hewitt et al., 
2008) or long term storage in paraffin (von Ahlfen et al., 2007). In addition, 
crosslinking of formaldehyde to other macromolecules reduces the yield of RNA 
(Feldman, 1973). 
To overcome these problems we used a commercially available kit from Qiagen which 
overcomes formalin crosslinking and maintains the integrity of RNA (von Ahlfen et al., 
2007).  
Preliminary results showed that moderate to good yield of RNA could be extracted 
from FFPE tissue, which was verified by nanodrop. In addition, the gene signature 
within FFPE tissue was sufficiently preserved that enabled quantification of qMIDS 
assay. The qMIDS assay was successfully validated on 15 FFPE samples consisting 
of 3 normal healthy oral mucosa and triplets of dysplasia, OSCC tumour and lymph 
node metastatic tumour of disease tissues from four cancer patients.  
Normal samples gave qMIDS index values between 1 and 4 (Fig 5.2 A). In patient 1 
there was a gradual and statistically significant increase in the qMIDS index value 
from dysplasia to lymph node metastatic tumour (Fig 5.2 B). In patient 2 statistically 
significant increase in qMIDS index value was observed from OSCC to lymph node 
metastatic tumour (Fig 5.2 C).  In patient 3 and 4 increase in qMIDS index was noted 
between dysplasia and OSCC tumour although not statistically significant (Fig 5.2 D 
and E). A combined analysis of qMIDS score from all four patients did not show any 
statistically significant trend between normal, dysplastic, tumour and lymph node 
metastatic tumour. 
Through our findings, we report that there is a possible correlation between patient’s 
histopathological diagnosis and the acquired qMIDS score from FFPE samples. This 
finding needs to be further verified on a larger sample size. 
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Fig 5.2: qMIDS index values of (A) normal healthy oral mucosa (B) Patient 1 (C) 
Patient 2 (D) Patient 3 (E) Patient 4. Each sample was processed in duplicates; mean 
of malignancy index values was calculated. The error bars represent the standard 
error of the mean where n=3. T test was performed using Graph  Pad software, 
significant p values are denoted by (*). 
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5.3 Discussion 
In diagnosing OSCC the importance of identifying pre-cancerous lesions and early 
detection of the disease cannot be under emphasized. These factors are of immense 
importance for early intervention leading to decreased mortality and morbidity.  
Currently the most reliable method for OSCC diagnosis is histopathology. Key 
limitations of histopathology are that it is extensively time consuming and subjective 
to pathologist interpretation. In addition presence of dysplasia can be missed as the 
molecular changes responsible for malignant transformation do not produce 
histopathologically detectable changes (Braakhuis et al., 2003). Hence there is a 
clinical need for a quick, quantitative and conclusive molecular test that would 
complement histopathology. 
With this aim in mind qMIDS was developed. It is based on FOXM1 (isoform B) 
oncogene and its downstream targets. It is a rapid method in comparison to 
histopathology as biopsy tissue does not require fixation and embedding.  It is also 
quantitative based on RT-qPCR which is widely available in diagnostic laboratories 
(Teh et al., 2013). 
In comparison to the developed world the prevalence of OSCC is much higher in the 
underprivileged parts of the world. High incidence of the disease is found in South 
East Asian population including India, Pakistan and Bangladesh (Joshi et al., 2014). 
This is mostly due to lack of awareness regarding risk factors such as smoking and 
chewing tobacco in rural population. In addition lack of finances leads to poor 
healthcare facilities resulting in late diagnosis which further increases the burden on 
healthcare systems. Setting up qMIDS in high incidence regions can be challenging 
due to lack of infrastructure and equipment required for storage and processing of 
fresh biopsy tissues. Hence, validating qMIDS on FFPE samples is of prime 
importance for such populations as fixing samples in formalin is a cost effective 
method of preserving samples, it has no special storage requirements and can be 
easily shipped for analysis. 
Although our study is limited to a small patient sample size, we were fortunate to get 
retrospectively collected FFPE samples from OSCC patients with known diagnostic 
outcomes. The samples were collected at different stages of the disease including 
dysplasia, OSCC tumour and metastasis to lymph nodes. Such archival tissues are 
very rare to find as they require long term patient follow up. Our data shows significant 
correlation between progressions of the disease at different stages with an increasing 
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qMIDS index. Due to lack of more FFPE samples we were unable to validate our 
findings on a larger sample size. 
 
5.4 Limitations 
Although qMIDS is efficient in segregating high risk individuals from low risk, it has 
certain limitations. It is an invasive test, requiring biopsy samples leading to patient 
discomfort. 
In addition, cancer development involves change of expression of multiple genes 
leading to disruption of multiple cellular pathways. qMIDS only focuses on the 
expression levels of oncogene FOXM1B and its associated genes. Other biomarkers, 
although some may be feeding into FOXM1 pathway,  such as Ras (Murugan et al., 
2012), c-myc (Perez-Sayans et al., 2011), EGFR (Bernardes et al., 2013) and cyclin 
D1 (Das et al., 2011) that play key roles in OSCC development and progression could 
be  overlooked using qMIDS  diagnostic system. 
Despite subjective opinion, histopathology (on frozen section) has an advantage that 
it is less time consuming in reporting than qMIDS as the latter requires purification of 
mRNA from tissues and RT-qPCR requiring at least two hours using the current 
protocol. The pathologist can visualize abnormal changes in the tissue while the 
patient is being operated for tumour removal. This guides the surgeon in obtaining 
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6.1 Introduction 
Head and neck squamous cell carcinoma (HNSCC) is the commonest form of head 
and neck cancer. It is a multifactorial disease predisposed by many risk factors such 
as smoked or chewed tobacco, excessive alcohol consumption, betel quid, areca nut 
and human papilloma virus. It is also a result of abnormal genetic alterations such as 
point mutations, amplifications, rearrangements and deletions of genes, making way 
for  tumour progression (Williams, 2000).  In order to detect genetic changes a 
molecular diagnostic test is much needed, that would aid in early diagnosis, resulting 
in better prognosis.  
Much progress has been made in cancers of other origins such as breast and lung 
where reliable diagnostic markers HER2 and EGFR mutant have been identified 
respectively (Pao and Chmielecki, 2010, Pinto et al., 2013). Apart from assisting in 
diagnosis these markers also aid in directing a more customised therapy resulting in 
a more favourable outcome.  
Efforts are being made in the field of HNSCC to find reliable biomarkers that would 
reflect the molecular make-up of the tumour. Through systemic reviews and meta-
analysis studies, EGFR and cyclic D1 have been reported as potential serum 
diagnostic marker (Guerra et al., 2016), furthermore ANO1 and FADD have been 
reported as possible prognostic markers (Reddy et al., 2016). Via meta-analysis 
genomic changes such as hyper methylation of RAS association domain family 
protein 1a (RASSF1A), a tumour suppressor gene has been associated to high risk 
of developing HNSCC (Meng et al., 2016). 
Previously developed diagnostic system (qMIDS) heavily relies on the expression 
levels of FOXM1B oncogene and its associated genes within a biopsy sample. It 
overlooks numerous other genetic biomarkers that are independent from FOXM1B 
and play key roles in carcinogenesis. In order to overcome this limitation of qMIDS, 
in this study we aimed to explore unbiased HNSCC biomarkers, which would be 
independent of FOXM1B expression.  
Meta-analysis of eight independent HNSCC microarray studies was done to obtain 
most significantly up and down regulated genes in studies comparing HNSCC 
samples with normal samples. The expression of selected genes was established in 
approximately hundred OSCC biopsy samples in pairs of margin and core. Molecular 
findings from each sample were correlated with patient’s clinical report.  
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6.2 Gene selections from 8 microarray datasets 
A cancer microarray database called Oncomine (Rhodes et al., 2004) 
(www.oncomine.org) was used to select eight head and neck cancer studies. All these 
studies analysed HNSCC cancer samples versus normal samples (Table 6.1). The 
bioinformatics gene selection was initially part of previous intercalated BSc project 
(performed by Sungjae Hwang).  
Table 6.1: Selected microarray studies along with PubMed ID, GEO accession 
number, number of tumour, normal and lymph node metastasis samples. *microarray 
data submitted only to Oncomine database. 
 
 
From the above mentioned eight studies 20 differentially expressed genes were 
selected based on their P-value. Out of which 10 were significantly up regulated 
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Table 6.2: Over expressed and under expressed genes selected from 8 
microarray studies on head and neck squamous cell carcinoma. 
 
 
6.3 Functional validation of candidate markers 
on cancer cell lines 
 
Primers for each gene were designed using the Roche Applied Science Universal 
Probe Library Assay Design Centre for RT-qPCR. Initial testing of primer specificity 
and expression of selected biomarkers was established on cDNA from normal and 
HNSCC cell lines (Fig 6.1B).  
Based on primer specificity and good reproducibility three differentially expressed 
biomarkers were identified, of which, PLAU, FN1 and CDCA5 were found to be 
upregulated; whereas CRNN, CLEC3B and DUOX1 were found to be downregulated 
when comparing cancer to normal cell lines. For ease we called them q6 
(quantification of selected six biomarkers). The q6 biomarkers were found to be 
involved in important cellular function, listed in Table 6.3 
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Table 6.3: Shortlisted over expressed (Red) and under expressed (Green) genes 
and there function. 
 
 
6.4 Validation of candidate markers on clinical 
samples 
RT-qPCR assays was carried out to produce quantitative data on expression of these 
selected genes (relative to two reference genes) on paired margin and core fresh 
biopsy samples from OSCC patients.  
Individual relative expression between core and margin tissue was calculated for each 
gene. In order to obtain a clinically meaningful index value from 6 genes, we derived 
an equation to summarise the degree of differential gene expression.   
q6 Value / Differential ratio = (Sum of Log2 Ratios of the 3 upregulated genes) 
– (Sum of Log2 Ratios of the 3 downregulated genes). 
Differential ration (q6) value of each sample is listed in Table 8.1 in appendix section, 
Page no. 196. 
We found that within the 100 patient samples, two distinct groups of patient population 
could be identified (Fig 6.1 A). The group of patients with positive q6 values 
expressed the predictable expression of q6 markers which was noted in oral cancer 
cell lines with PLAU, FN1 and CDCA5 being upregulated and CRNN, CLEC3B and 
DUOX1 being downregulated. Majority of the patients fell into this group (Fig 6.1 C). 
While the other group of patients had lesser number of patients, exhibiting negative 
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q6 values with inverse expression of q6 markers with PLAU, FN1 and CDCA5 being 
down regulated and CRNN, CLEC3B and DUOX1 were up regulated (Fig 6.1 E).  
The patient group in the middle had a mixed expression of q6 markers with most of 
the q6 markers following the expected trend. Approximately ten patients were found 

















Fig 6.1: Log 2 ratio of q6 biomarkers between margin and core biopsy tissue 
samples. (A) Differential ratio of biopsy samples from 100 OSCC patients (B) Pattern 
of expression of the six biomarkers in HNSCC cell lines SCC4 and SqCC/Y1 (C) 
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6.5 Clinicaopathological analysis of two patient 
groups with opposing q6 gene expression 
In order to understand the different pattern of q6 biomarkers, our collaborating 
clinician Dr. Anand Lalli (Dept. of Oral Surgery, Barts and the London School of 
medicine and dentistry) helped in correlating patient’s clinical reports with our 
molecular findings.  
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Patient and tumour details were collated retrospectively for the 20 most positive and 
20 most negative q6 values. In each group, data collection was incomplete for a 
number of patients (for example due to an inability to trace the clinical records or the 
clinical records being incomplete for all the data required in this study) and therefore 
these individuals were removed from the analysis.  
Clinical data from 13 patients with +q6 values was compared to 8 patients with –q6 
values. We found statistically significant difference in age, sex, ethnicity, alcohol 
consumption and paan usage among the two groups. In the +q6 group the mean age 
was 63 with more males than females, while in -q6 group the mean age was 56 with 
more females than males (P=0.04). Additionally, more patients of Bangladeshi 
descend were found to be in -q6 group (P=0.04) (Table 6.4).  
Statistically significant difference was found in the two groups with regards to 
associated risk factors. High levels of alcohol consumption was found in +q6 group 
(P=0.04), while patients in the -q6 group were mostly paan chewers (P=0.02) (Table 
6.4). No difference was found in the smoking habits, tumour site and size among the 
two groups. Recurrent lesions were only found in -q6 group although not statistically 
significant, which might be due to small sample size (Table 6.4). 
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6.6 Discussion 
Even with increasing advancement in the field of oral cancer diagnosis and treatment. 
The five year survival rate has remained unchanged. Currently the mainstays of 
treatment for advanced tumours are surgery combined with post-operative 
radiotherapy. All HNSCC patients are subjected to the same treatment irrespective of 
the genetic makeup of the presenting tumour. This is due to the gap in our knowledge 
regarding relevant prognostic biomarkers that can be used to distinguish between sub 
populations of HNSCC patients and to inform the most suitable intervention based on 
individual tumour molecular profile. 
Molecularly targeted therapy is expected to be more selective towards cancer cells 
minimizing damage to normal cells; however targeted therapy involves genome 
based individualized treatment of oral cancer patients. Importantly, the determination 
of genetic signatures and potential biomarkers for aggressiveness of HNSCC would 
allow predicting the chances of survival and recurrence of the disease. Developing 
potential important biomarkers would allow more precise therapeutic approach for 
each individual case during the treatment. 
Previously we have developed a quantitative malignancy index diagnosis system 
called qMIDS. It was based on FOXM1 oncogene and its related genes. In this study 
we aim to explore new potential biomarkers which are not restricted to FOXM1B 
expression but also differentially expressed in cancer vs normal tissue. Using the 
online database Oncomine, a list of differentially expressed genes were shortlisted 
from 8 independent microarray studies. These genes include PLAU, FN1, and 
CDCA5 which were found to be significantly upregulated in HNSCC and CRNN, 
CLEC3B and DUOX1 which were significantly downregulated. 
Tissue samples for this study were collected at the time of tumour resection. The 
decision to treat surgically was made on standard clinic-pathological factors by a 
multi-disciplinary team of surgeons, oncologists and allied health professionals in 
conjunction with the patient’s wishes as per NHS best-practice policy. This would 
suggest the study sample represents a proportion of all head and neck tumours 
diagnosed in the study period with other tumours being either inoperable (e.g. due to 
size, position, metastatic spread, patient’s general health or patient wishes) or 
managed without a tissue sample being generated (e.g. chemo-radiotherapy or laser 
ablation).   
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Gene expression level was measured using absolute RT-qPCR in paired margin and 
core OSCC specimens. Data was collected from 100 patients with the purpose to 
validate if these genes could be used as OSCC biomarkers. 
We found that within this group of patients, existed two distinct subgroups one which 
expressed the predictable expression of q6 biomarkers with PLAU, FN1, CDCA5 
being upregulated and CRNN, CLEC3B and DUOX1 being downregulated. Patients 
in this group gave a positive q6 value.  Majority of the patients were found to be in 
this group. From the clinical reports of 13 patients from this group we found that this 
group consisted of mostly older men who consumed more than the recommended 
units of alcohol per week along with smoking. Both of these are known high risk 
factors for developing OSCC. This finding is consistent with the majority of oral 
cancers found in the UK population as a whole. 
The other group consisting of twenty three patients who showed an inverse 
expression of q6 biomarkers with PLAU, FN1, CDCA5 being downregulated while 
CRNN, CLEC3B and DUOX1 being upregulated. This study utilised tissue samples 
collected from the Royal London Hospital locality in Tower Hamlets, East London 
which comprises the highest concentration of Bangladeshi individuals in the Western 
World with specific cultural risk factors for OSCC that are usually only prevalent on 
that subcontinent, such as ‘paan’ (areca nut) usage. This population is known to be 
at higher risk of developing OSCC than the UK population as a whole and in particular 
at a younger age and in women due to these cultural influences. Therefore, the finding 
that patients with negative q6 values (8 patients) in this study are markedly different 
from the positive group in age (significantly younger) and gender (more females) as 
well as paan users is extremely interesting as it suggests that the biomarker response 
confirms the epidemiological data indicating these are two distinct groups of OSCC.  
This is further supported by the statistically lower reported alcohol consumption in the 
negative group as alcohol usage is low in Islamic cultures but a significant issue in 
the UK population as a whole. 
All 3 patients with a recurrence of their primary tumour were in the –q6 group, 
although no statistically significant difference between the two groups was noted. This 
may be an important finding as it suggests that the negative q6 group are more prone 
to recurrence. In addition to the small sample size it must be noted that to be included 
in this study the recurrence must have been treated by surgical excision and therefore 
operable so this finding must be interpreted with extreme caution but warrants further 
investigation. 
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Patients in both the groups suffered from the same disease and were offered the 
same treatment. The genetic analysis of the biopsy tissue indicates that molecularly 
the tumours in each group were different and showed different expressions of q6 
biomarkers.  
A further study conducted in our lab by an MSc student Huma Habib Dar on 
chemotherapeutic drug and gamma irradiated resistant oral keratinocyte cell lines 
demonstrated that the downregulation of PLAU biomarker might be an indicator of 
tumour being resistant to radiation therapy with high chances of recurrence (Fig 6.2). 
This finding needs to be verified and validated through further studies.  
 
Fig 6.2: Relative expression of cells treated with Etoposide (SVpgC2aETO, 
SVFN10ETO) and gamma irradiated (SVFN10Ɣ) compared to untreated controls 
showing data of q6 genes and corresponding statistical t-test (p-value). The diagram 
was created by Dr Muy-Teck Teh. 
 
In view of the biomarkers used in this study representing tumours that are resistant 
or responsive to chemo and radiotherapy (RT) this is potentially an extremely 
important clinical finding as it identifies patients who, for example, may not respond 
to post-operative RT and therefore could benefit from a more aggressive surgical 
approach. 
Smoking and tobacco usage is difficult to interpret as the clinical records often 
recorded cigarette smoking and pack per year etc. but did not record whether paan 
users incorporated tobacco in their mixture. Additionally, cigarette smoking is 
                      Chapter 6: Meta-analysis of head and neck cancer genetic biomarkers                                                                                                       
173 
reported as a predominantly male practise in the Bangaldeshi population and 
therefore it is unsurprising that there was no difference between the two groups. 
However, it may have been expected that the negative group would present with more 
buccal sulcus tumours as this is the predominant site of paan placement and larger 
tumours as the Bangladeshi population are known to be poor users of healthcare 
facilities but this was not evident in the study perhaps due to the small sample size. 
All patients were followed up for at least 2 years following surgical resection of their 
primary tumours and all tumours were histologically confirmed oral squamous cell 
carcinomas (OSCC) .The 18 primary OSCC were excised and subsequently treated 
with post-operative RT with the tissue samples for this study being taken prior to RT 
whilst the recurrences had originally been resected and all had post-op radiotherapy 
at that time. 
Interpretation of results from a retrospective study of this type must be done with 
caution particularly when assessing patient treatment modalities, which cannot 
ethically be influenced by the study design. The various forms of selection bias was 
a significant concern in this study as was the small sample size augmented by the 
inability to collect patient details on a proportion of each group. However, this data 
indicates the need for a prospective observational study of the correlation between 
patient factors and OSCC treatment response.  
We further look into literature to understand the role of q6 bio markers in OSCC 
development and progression. 
PLAU (plasminogen activator, urokinase) encodes a serine protease involved in 
degradation of the extracellular matrix and possibly tumour cell migration and 
proliferation. PLAU has been shown to be a novel biomarker with high tumour 
expression levels in head and neck squamous cell carcinoma and is linked to inferior 
disease free survival rate with increased disease progression and relapse (Sepiashvili 
et al., 2012). In breast cancer cells, PLAU was indicated to have a marked role in 
transformation by increasing invasiveness (Iliopoulos et al., 2011).  
In prostate cancer and laryngeal SQCC PLAU gene amplification was preferentially 
found in advanced stage, but not detected in benign lesions, suggesting PLAU may 
have a tumour stage-dependent expression pattern (Bloch et al., 2007, Hui et al., 
2015). To date no study has related altered PLAU expression to drug or radiotherapy 
resistance.  
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FN1 (Fibronectin 1) encodes fibronectin, a glycoprotein present in a soluble dimeric 
form in plasma, and in a dimeric or multimeric form at the cell surface and in 
extracellular matrix. Fibronectin is involved in cell adhesion and migration processes 
including embryogenesis, wound healing, blood coagulation, host defence and 
metastasis. A study on salivary gland carcinoma has verified using cDNA array and 
immunohistochemistry that FN1 is overexpressed in mucodermoid, acinic cell and 
salivary ductal carcinoma (Zhang et al., 2011b). 
FN1 is also a downstream target of SATB1 oncogene. It is found to be up regulated 
in oesophageal squamous cell carcinoma resulting in enhanced cell proliferation and 
migration ability (Song et al., 2017) 
In other cancers FN1 induced specific metalloproteinases, such as MMP9/MMP2 to 
promote invasion and metastasis (Qian et al., 2011, Shibata et al., 1997, Moroz et al., 
2013). 
CDCA5 (Cell division cycle associated 5 or Human Sororin gene) is involved in sister 
chromatid cohesion, separation and tumour genesis. The cellular localization and the 
levels of Sororin proteins differ in stages of cell cycle. A higher level of protein is seen 
from S to G₂ phase and a decline following mitotic exit (Zhang and Pati, 2012). The 
role of CDCA5 has not been extensively studied in tumour initiation but a study on 
lung cancers has shown high levels of CDCA5 and its association with poor prognosis 
(Nguyen et al., 2010). 
In a study on OSCC, CDCA5 was found to be upregulated in 4 human OSCC cell 
lines by RT-qPCR. Knockdown of CDCA5 inhibited the growth of OSCC cells while 
the expression levels of CDCA5 proteins were found to be associated with overall 
survival (Tokuzen et al., 2016). 
Evidence from the literature suggests that CDCA5 is likely to play a significant role in 
OSCC progression, so that targeting CDCA5 may be a potentially useful diagnostic 
and therapeutic approach for OSCC patients. 
CRNN (Cornulin) also known as squamous epithelial heat shock protein 53 belong to 
the “fused gene” family and is involved in mucosal/epithelial immune response and 
epidermal differentiation (Contzler et al., 2005). CRNN is an important molecule in 
normal oesophageal tissue; it is localized to cytoplasm and perinuclear region of the 
prickle and functional cell layers.  In oesophageal squamous cell carcinoma it is 5 fold 
down regulated in 89% of cases indicating the loss of CRNN during the transformation 
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from normal to neoplastic (Pawar et al., 2013). Significant loss of CRNN expression 
is associated with advanced stage, invasive behaviour of the tumour, lymph node 
metastasis and poor survival (Chen et al., 2013, Hsu et al., 2014, Pawar et al., 2013). 
Similar to oesophageal squamous cell carcinoma CRNN expression is found to be 
down regulated in OSCC (Imai et al., 2005a). Direct sequencing of CRNN gene 
elucidated loss of heterozygosity and microsatellite instability at chromosome 1q21.3 
region, as possible mechanisms of CRNN down regulation in OSCC (Salahshourifar 
et al., 2015). 
These findings provide evidence on the role of CRNN in tumour progression of OSCC 
as a prognostic marker to predict disease outcome. 
CLEC3B (C-type lectin domain family 3, member B) encodes tetranectin protein 
which is found to be a potential biomarker for metastatic oral cancer.  In serum and 
saliva of metastatic OSCC compared to primary OSCC, tetranectin was found to be 
significantly under expressed. Decreased levels of tetranectin have been assoiciated 
with cancer progression. Though the exact mechanism is not known  but it is believed 
this down regulation aids in the activation of plasminogen cascade causing increased 
proteolytic processes (Arellano-Garcia et al., 2010).  
In ovarian and breast cancer, decreased serum levels of CLEC3B has been 
associated with adverse prognosis due to poor treatment response (Hogdall et al., 
1993b, Hogdall et al., 1993a) 
These findings support that CLEC3B may be used as a markers for metastasis. 
DUOX1 (dual oxidase 1) encodes a glycoprotein and is a member of the NADPH 
oxidase family. Named as dual oxidase because it has both a peroxidase homology 
domain and a gp91phox domain. This protein generates hydrogen peroxide and 
thereby plays a role in the activity of thyroid peroxidase, lactoperoxidase, and in 
lactoperoxidase-mediated antimicrobial defense at mucosal surfaces.  
It has been found that in 50% of lung cancers NADPH oxidase DUOX1 and DUOX2 
go under epigenetic silencing via hyper methylation of CpG-rich promoter regions and 
can be restored after treatment with 5-aza 2'-deoxycytidine. Introducing normal levels 
of DUOX1 into lung cancer cell lines increased cell migration and wound repair 
without affecting cell growth (Luxen et al., 2008). 
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In liver cancer low levels of DUOX1 expression were found, while normal levels were 
indicative of disease free survival. Hence DUOX1 is a potential prognostic tool (Chen 
et al., 2016). To date the potential of DUOX1 as a diagnostic or prognostic tool has 
not been explored in HNSCC. 
Through literature review it is much evident that q6 biomarkers are responsible for 
much of the molecular changes required for the transformation of normal tissue into 
disease tissue. Through multiple microarray studies the expression of these six 
biomarkers have been established in HNSCC with PLAU, FN1, CDCA5 being 
upregulated and CRNN, CLEC3B, DUOX1 being downregulated. Although through 
our study it seems that there is a possibility that the inverse expression of these six 
markers might not necessary mean that the individual is disease free but suggests 
that the individual might be presenting a tumour that is genetically different which may 
possibly linked to therapeutic treatment resistance. The expression of q6 biomarkers 
can be different depending on the carcinogen or the risk factors that the patient is 
exposed to. More research is needed to understand the mechanisms altering the 
expressions of q6 biomarkers. 
6.7 Limitations 
Similar to previously developed qMIDS, acquiring q6 values also required biopsy 
samples, which makes it an invasive methods leading to patient discomfort. 
Obtaining q6 values required RNA extraction followed by conversion into cDNA and 
establishing relative expression of each gene through RT-qPCR. This process can be 
time consuming requiring at least two hours.  
In ability of finding clinical records retrospectively led to analysing a very small sample 
size which might not be a true representation of a group. Further request has been 
sent to collaborating clinician to provide additional clinical data. 
Within the clinical findings tobacco usage in Paan users was not established as they 
were not asked if they added tobacco to Paan. Subsequently Paan also contain areca 
nut a known OSCC carcinogen. It is important to distinguish if the molecular finding 
in –q6 patients (paan users) are an effect of chewed tobacco within Paan or areca 
nut. It can possibly be a combined effect of both carcinogens. 
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Since Paan usage is habitual in South Asian population determining the patient’s 
ethnicity is essential.  We were informed by the collaborating clinician that patients of 
South Asian origin, born in the UK identified themselves as British and were not 
further questioned regarding Paan practice, although it is possible for these patients 
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OSCC is the commonest tumour in the oro-facial region with increasing incidence in 
the recent years. Curing the disease is challenging, as it depicts a heterogeneous 
tumour with high morbidity and mortality rate. Clinico-pathological data, tumour site, 
lymphnode metastasis (TNM) staging, histological grade and invasion have been 
evaluated in great depth in relation to OSCC. Co-morbidity factors like the use of 
tobacco, alcohol consumption and various other factors including genetic pre-
disposition have been looked at for finding a suitable treatment protocol. The problem 
in understanding the complexity of oral cancer lies in the biological heterogeneity of 
the tumour. Similar heterogeneity has been noted in clinical presentation, 
histopathology, and molecular changes at cellular levels. 
In spite of the disease being diagnosed, a prediction of behaviour and response to 
treatment remains elusive. Early screening of asymptomatic high risk patients using 
non-invasive techniques will provide an opportunity to closely monitor early signs of 
disease aiding in lower mortality and morbidity. In this study we look beyond the 
histopathological features of OSCC, increasingly into the molecular and genetic 
changes driving the disease which will help in segregating a high risk population from 
low risk. Such a method will also aid in designing and implementing of a targeted drug 
therapy (Bavle et al., 2016). 
Currently histopathology is the gold standard technique used for diagnosing OSCC 
lesions. Histopathology has certain limitations such as by the time these histological 
changes become evident the disease is at a much advanced stage. Since the oral 
cavity is surrounded by multiple sets of lymph nodes the disease spreads at a very 
fast rate causing much destruction of the surrounding tissue and bone leading to a 
low overall survival rate. In addition, histopathology is not a quantitative technique 
and is very subjective to pathologist interpretation which might vary from one clinician 
to another. The clinical appearance and histopathological features of OSCC lesions 
might vary among patients. Some lesions are followed by pre-cancerous lesions and 
dysplasia while others might not (Carnelio et al., 2011). Secondly, not all dysplastic 
lesions transform to OSCC at least 50% of the lesions arise from clinically normal 
mucosa (Speight, 2007). Hence it is difficult to predict as to what causes the 
transformation of a benign lesion into malignant lesion. 
Since OSCC is a heterogeneous disease, a single site tissue biopsy taken at one time 
point does not reflect the ongoing changes occurring in the tumour and the 
surrounding tissues.  
                                       Discussion 
180 
7.1 Non-invasive exosome based liquid biopsy 
Liquid biopsy from body fluids such as blood and saliva offers an alternative to the 
limitation of heterogeneity in OSCC tissue biopsy as the liquid biopsy would not be 
site specific and can be taken multiple times causing less patient discomfort due to 
its less invasive nature. These biopsies will not only reflect the heterogeneous make-
up of the disease but can also be used to follow treatment response, reveal the 
presence of residual disease and alert the oncologist in case of re-emerging disease. 
Ultimately, if clinicians can match results from liquid biopsies with a cocktail of 
targeted anticancer therapies, the promise is that advanced cancers could become 
manageable chronic diseases, much like HIV is today (Webb, 2016). 
Researchers have known for decades that tumours shed cells in body fluids 
(circulating tumour cells – CTCs) and that apoptotic cancer cells shed DNA fragments 
into the blood stream (circulating tumour DNA – ctDNA). Living cancer cells also shed 
extracellular vesicles containing cellular material including DNA, RNA and proteins, 
known as exosomes and microvesicles (Ko et al., 2016). 
In this study we propose the use to exosomes based liquid biopsy for OSCC early 
diagnosis. Compared to CTCs and ctDNA exosomes are much more stable and 
resistant to destruction due to the protective lipid bi-layer outer membrane. In addition 
exosomes are more abundant and hence easier to detect than CTCs and ctDNA 
(Lang et al., 2012). 
Exosomes are considered superior as diagnostic and prognostic tools than 
microvesicles as they are endosomal in origin and enriched for proteins related to 
transport and fusion (e.g. flotillin, caveolin-1) (Logozzi et al., 2009), heat shock 
proteins (e.g. Hsp90), and lipid-related proteins (Zeringer et al., 2015). In addition 
they contain nucleic acids such as miRNA and mRNA (Valadi et al., 2007) as well as 
double stranded DNA (Thakur et al., 2014). Microvesicles are produced by the 
budding of plasma membrane and are more reflective to cellular cytoplasm. 
Historically, due to different methods of EVs isolation studies have used microvesicles 
and exosomes interchangeably and hence it is difficult to differentiate them on the 
basis of their contents. In order to overcome this issue Professor Suresh Mathivanan 
from the La Trobe Institute for Molecular Science in Australia has created a valuable 
online resource that catalogues the cargo of exosomes and microvesicles from 
various origins, with the database including lipids, proteins, and RNAs 
(http://www.exocarta.org). 
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In this study we successfully isolated exosomes from oral keratinocyte cell culture 
supernatant and body fluids including whole blood, plasma and saliva. Validation of 
effective isolation was done using particle size (zetasizer, NTA) and imaging 
techniques (SEM, TEM and NTA) (Fig 3.3, 3.4, 3.5, 3.6, 3.7 Page no. 88-92). 
Through western blotting samples were tested for the presence of exosome specific 
proteins such as ALIX, CD63 and CD9. We found that oral keratinocyte exosomes 
express more of ALIX protein (part of the ESCRT III complex), than tetraspanin 
proteins (e.g CD63 CD9 and CD81) which are much talked about in exosome 
literature (Rana and Zöller, 2013) (Fig 3.8, Page no. 95). Tetraspanin proteins are 
cell surface proteins regulating cell morphology, motility, invasion, fusion and 
signalling in the brain, immune system and on tumours (Hemler, 2005). 
In addition, CEP55 a centrosomal protein and a partner of ALIX in ESCRT machinery, 
was found to be exclusively expressed in cancer exosomes (Fig 3.8, Page no. 95). 
We suggest a potential use of CEP55 as a biomarker to selectively isolate OSCC 
cancer exosome from body fluids. We have attempted to validate the specificity of 
CEP55 as a cancer exosome marker through gold label immuno TEM (Fig 3.10, Page 
no. 98), whereby we found that CEP55 protein was indeed localised on exosomal 
membranes. Further validation through a quantitative technique such as nano flow 
cytometry would be required to confirm if CEP55 protein is enriched in OSCC derived 
exosomes.  
Our further characterisation study on exosomes confirmed that RNA contents of 
exosomes are well protected within the lipid bi-layer membrane and is resistant to 
degradation by RNase. We further questioned whether RNA cargo could be passed 
from one cell to another via exosomes. This led us to perform exosome transfection 
study. We found that cancer exosomes containing oncogene FOXM1B mRNA were 
able to transfer its mRNA content into recipient cells (normal oral keratinocytes with 
very low level endogenous FOXM1B expression), although only transiently as the 
elevated levels of FOXM1B mRNA was lost after 72 hours (Fig 4.8, Page no. 116). 
This finding is not surprising as other studies have found the same phenomenon 
either by the presence of a cellular protective mechanism such as autophagy (Danzer 
et al., 2012, Baixauli et al., 2014) or the RNA interference through dicer complex as 
part of the RNA-induced silencing complex (RISC) (Jayachandran et al., 2012) which 
halters the undesired foreign invasion of exosomal contents. This protective 
mechanism against exosomes within recipient cells is yet to be explored. 
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In order to further understand the functional effects of normal and cancer exosomes 
on recipient cells, we performed microarray expression profiling in recipient cells 
transfected with either normal or cancer exosomes. We found that exosomes, 
irrespective of their origin (normal and cancer), altered gene expression patterns of 
certain genes in recipient cells. Upregulation of MMP9, TUBB6, FEZ1, OAS1 and 
PGAM1 were noted. These genes are found to be responsible for essential cellular 
functions such as breakdown of extracellular matrix, regulation of cytoskeleton, intra 
cellular transport, immune regulation and cellular metabolism (Peisker et al., 2017, 
Chao et al., 2012, Chua et al., 2013, van Vugt, 2017). While the expressions of 
TSC22D3, OTUD1 and BBOX1 involved in signal transduction cell survival pathway, 
regulation of P53 and cellular transport respectively were found to be downregulated 
(Espinasse et al., 2016, Piao et al., 2017, Dawany et al., 2011) (Fig 4.17A, Page no. 
137) (Table 4.1, Page no. 133) . Perturbation of these genes appears to suggest that 
exosomes may trigger matrix reorganisation and cellular motility in recipient cells.  
When comparing gene expression profiles of recipient cells transfected with normal 
and OSCC exosomes, we found that EFEMP1, EEF2K, DKK3, LMP2, SRPX, SPARC 
and ADAM9 were differentially upregulated in normal oral keratinocyte recipient cells. 
These genes are known to be involved in regulation of cellular morphology, protein 
synthesis, embryonic development, autophagy pathway, tissue remodelling, 
deposition of extracellular matrix and cellular adhesion (Han et al., 2017, Sugai et al., 
2017, Li et al., 2017, Lin and Chuang, 2012, Kim et al., 2017, Duffy et al., 2011). While 
genes including SPRR2E, IGFBP3, RRP12 and KLF6 involved in maintaining 
cornified cell envelop, regulating growth factors and nuclear proteins were 
downregulated (Zucchini et al., 2001, Yen et al., 2015, Choi et al., 2016, Masilamani 
et al., 2017) (Fig 4.17B ,Page no. 137) (Table 4.2, Page no. 136). Perturbation of 
these genes appears to indicate that cancer exosomes may trigger an oncogenic 
programme in recipient cells. Further studies are required to confirm the role of cancer 
exosomes on surrounding cells and tissues. 
Similar to other techniques liquid biopsy based on exosomes also have some 
limitations such as challenging and time consuming isolation, fluctuating yield as the 
final pellet can be easily missed while collection, simple techniques such as western 
blotting and RT-qPCR can be challenging due to lower protein and RNA yield. Due to 
gaps in our knowledge it is still unknown as to how long it will take to detect cancer 
exosomes in body fluids during the course of disease progression. More research is 
required to understand the dose and time needed by exosomes to exert an effect in 
the recipient cells. Through our dose and time experiment we know that some genes 
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are affected within 24 hours while others show a more drastic change at 48 hours 
(Fig  4.18, 4.19, Page no. 140, 141). 
7.1(A) Recent technological advancements for 
exosome detection 
The alluring idea of diagnosing cancer through a blood test has attracted much 
attention in recent research which has driven the technological advancements for 
easier detection of exosomes in body fluids. On-chip nano holographic imaging which 
is a handheld platform can detect nanoscale objects in a mobile format. It can be used 
in a practical clinical setting (McLeod et al., 2015). Similarly, nanopore ion occlusion 
based sensing measures single nanoparticles as they are driven through a nano-pore 
creating an ionic current flow. The change in the current is proportional  to the size of 
the particle, enabling quantitative particle sizing with appropriate calibration (Maas et 
al., 2014). 
Recently developed miniaturized nuclear magnetic resonance has been able to 
sensitively measure exosomes (Issadore et al., 2011). Surface Plasmon resonance 
(SPR) based nanosensors have gained much attention because of their ability to 
sensitively detect the binding of exceeding small numbers of molecules as few as 1 
molecule (Kravets et al., 2013). Weissleder/Lee group had developed an SPR based 
nano-plasmonic exosome (nPLEX) detector. It consists of a series of nanohole array 
coated with affinity ligands to capture a specific type of exosome. It can measure up 
to 105 independent nanopore arrays. The utility of nPLEX was demonstrated on 
samples from ovarian cancer patients which could be readily differentiated from 
normal controls. Each measurement required a small volume of 0.3μl of sample (Im 
et al., 2014). 
The use of micro and nano technology designed to overcome the technical challenges 
of exosome isolation and detection are ongoing. These techniques will allow rapid 
sample preparation and molecular analysis from small sample volumes in order to 
fully utilize the clinical potential of these circulating biomarkers. Such newly developed 
technological methods are yet to be tested on large cohort of OSCC patients. 
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7.2 Significance of genetic biomarkers for OSCC 
diagnosis 
Today we know that genetic changes precede the occurrence of OSCC lesions. 
Hence the importance to testing genetic bio-markers for early detection of the disease 
can not be underestimated. This would significantly improve the 5 year survival rate 
of OSCC patients. In addition lower the cost of treatment for healthcare systems.  
Such efforts have greatly benefitted patients suffering from cancers of other origins. 
In breast cancer patients, screening for BRCA1/2 gene mutation has led to early 
detection and optimized treatment leading to improved patient survival (Grindedal et 
al., 2017). Similarly in prostate cancer elevated levels of serum prostate-specific 
antigen is used for segregating high risk individuals from low risk (Helfand et al., 
2017). 
Ongoing efforts are being made to find an appropriate set of genetic biomarkers that 
would aid in early OSCC detection. Salivary IL-8, IL-6 and TNF-α have been proposed 
as potential diagnostic bio-marker (Sahibzada et al., 2017). Although testing their 
reliability on large cohort of patient samples is still pending. Through gene profiling 
array studies on OSCC samples aberrant expression of genes essential for normal 
cellular functions has been reported. These genes include TGF-β (Quan et al., 2013) 
, TP53 and EGFR (Bundela et al., 2014). 
In this study we validated a previously developed OSCC diagnostic system called 
qMIDS (quantitative malignancy index diagnostic system) on retrospectively collected 
FFPE samples from OSCC patients. qMIDS is based on the expression of oncogene 
FOXM1 isoform B and its downstream targets (Teh et al., 2013). FOXM1B is a 
transcription factor essential for cell cycle (Myatt and Lam, 2007). Increased 
expression of FOXM1B has been noted in cancers of many origins including oral, 
oesophageal, breast, lungs, kidney, bladder, prostate, colon, liver, pancreas, testis, 
ovary and uterus. This indicates that upregulation of FOXM1 may be an early 
molecular signal required for aberrant cell cycle and cancer initiation (Teh et al., 
2013).  
During the development of qMIDS, its efficiency was tested on a small set of FFPE 
samples. Fortunately for this study we were able to get archival FFPE samples 
collected from the same patient at different stages of the disease including dysplasia, 
tumour and lymph node metastasis. The samples were provided by our collaborators 
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from Norway. These samples gave us the opportunity to correlate qMIDS index to 
disease stages. 
Moderate to good yield of RNA could be isolated from FFPE samples for RT-qPCR. 
It was found that qMIDS index successfully correlated with disease stage with higher 
index values indicating advanced disease stage and vice versa. 
Validating qMIDS on FFPE samples has a greater impact on high risk communities 
of the impoverished world where limitations of infrastructure and storage facilities for 
fresh biopsy samples might not allow testing of genetic diagnostic adjuncts such as 
qMIDS.  
7.3 Non- bias OSCC bio-markers 
Multiple co-factors such as smoking, alcohol, betel quid chewing, HPV and genetic 
predisposition are involved in the development of OSCC. This gives rise to tumours 
that are molecularly different from each other depending on the exposure to the type 
of carcinogen (Yeh et al., 2016). Due to this heterogeneity among tumour types some 
patients responded better to treatment while others developed resistance resulting in 
poor prognosis, recurrence and a less than 5 year survival rate.  
Classifying tumours based on their genetic makeup will aid in providing targeted 
therapy. Hence it is essential to study large cohort of OSCC patient samples and 
determine genetic biomarkers that can differentiate one group of OSCC tumour sub-
type from another. 
In order to identify new OSCC biomarkers, we performed a non-bias meta-analysis 
of 8 OSCC microarray studies, where gene expression profiles were compared 
between OSCC and normal mucosa samples. Six bio-markers were selected for 
further validation on 100 OSCC biopsy tissues. These genes included PLAU, FN1, 
CDCA5 which are upregulated in OSCC while CRNN, CLEC3B and DUOX1 are found 
to be downregulated. We called this set of bio-markers q6. These genes are found to 
be involved in breakdown of extracellular matrix, cell adhesion and division, epidermal 
differentiation and mucosal defence (Zhang et al., 2015, Yen et al., 2013, Tokuzen et 
al., 2016, Salahshourifar et al., 2015, Arellano-Garcia et al., 2010, Ito et al., 2016) 
(Table 6.3 , Page no. 165). When we analysed the expression of q6 across the 100 
OSCC samples, a subgroup of OSCC samples were found to have inverse gene 
expression pattern (we called this group negative group) compared to the rest 
(positive group) (Fig 6.1 A, Page no. 167).  
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This led us to retrospectively correlate molecular findings with socio-clinical records 
of two extreme ends of the q6 expression spectrum. We compared twenty patients 
from each group and found that the group of patient showing positive q6 values were 
mostly men of older age group associated to heavy smoking and alcohol consumption 
while the group with negative q6 values were mostly younger female who chewed 
paan (Table 6.4, Page no. 168). Although our patient sample size was small, 
recurrence of OSCC lesions was mostly noted in q6 negative group (Paan chewers). 
The q6 panel of genes may potentially be exploited as prognostic biomarkers for 
segregating high and low risk of tumour recurrence due to radioresistance in OSCC 
patients. These finding needs to be further verified on a larger cohort of OSCC 
patients. Ideally the molecular findings should be correlated prospectively to patient’s 
socio-clinical records. Due to retrospective correlation in this study patient records 
were difficult to find due to death, relocation, and mismatch among patients.  
7.4 Final Conclusion 
In conclusion our work will assist in translating the use of genetic biomarkers for early 
detection of OSCC as an adjunct to histopathology resulting in development of 
personalized therapy for better prognosis and improved survival rate. We recommend 
the use of non-invasive screening methods such as exosome based liquid biopsy for 
segregating high risk individuals from low risk, enabling resources to be focused on 
high risk groups thereby lowering the burden on the health care system as funds can 
better be utilized to improve OSCC patient outcome by treating them earlier. 
We propose the presence of a biological mechanism through which cancer cells 
under stress conditions such as signalling dysregulation a hallmark of cancer alter 
the composition, content and number of exosomes released. These cancer 
exosomes further aid in passing on the oncogenic message to the neighbouring cells 
and distant cells by traveling through body fluids. Although to date the mechanism is 
not fully understood we believe that cancer exosomes play important roles in 
providing a fertile ground for local invasion and distant metastasis (Melo et al., 2015).  
Since exosomes reflect parental cells they offer a great advantage in diagnosing 
OSCC through non-invasive biopsy. They can also prove beneficial in cases where 
biopsies are very invasive and sometimes even life threatening such as brain and 
lungs cancers. In pancreatic cancer biopsies, the acquired diagnostic tissue is mostly 
so small that it fails to reflect the extend of the disease and the heterogeneity of the 
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tumour (Panagiotara et al., 2017). In such circumstances a non-invasive liquid biopsy 
based on exosomes might offer a solution.  
In addition to diagnostics, exosomes can be utilized to monitor patient progress 
throughout treatment. Failure and resistance to treatment can be identified earlier and 
can provide an opportunity to develop tailored therapeutics. It has also been shown 
that exosomes guide the metastatic process. In a study on pancreatic cancer 
metastasis to liver was found to be directed by tumour exosomes (Melo et al., 2015). 
Exosomes have also been proposed for use as therapeutic drug delivery vehicles. In 
comparison to other nano drug delivery vehicles they offer the advantage of being 
non-immunogenic as they can be isolated from the patient’s body fluids (Ha et al., 
2016). Clinical trials for melanoma and non-small cell lung cancer has shown that 
exosomes can be safely used to deliver immunotherapeutic regimens. They induced 
both innate and adaptive immune response, disease stabilisation and long term 
survival for patients (Delcayre and Le Pecq, 2006). 
In the field of cancer diagnostics, prognostics and therapeutics; exosomes offer a 
possible solution to current limitations. In order to tap their full potential for clinical 
translation a uniform and efficient method of isolation and verification needs to be 
adopted by researchers. A strong collaboration of engineers, biologist, clinicians and 
policy makers can further pave the way for future implementation of exosome 
technology for patient benefit. 
7.5 Future directions 
This study is the stepping stone to establish the use of non-invasive exosome based 
biopsy for OSCC patients. Validation of biomarker surface proteins, CEP55 through 
nano FACS analysis will facilitate its use as a fishing protein to segregate OSCC 
exosome from a mixed population of exosomes. We aim to uncover more robust 
protein-biomarkers through mass-spectrometry that can be identified in patient saliva 
or serum. 
In this study through microarray we reported unique genes altered by normal and 
cancer exosomes. Some of these genes such as BBOX1, FEZ1 and SRPX has not 
been studied with regards to OSCC development and little is known about their 
biological functions. We further need to understand the cellular functions of these 
genes and the pathways they are involved in, in order to understand the biology 
through which exosomes effect surrounding cells. 
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We have shown through RT-qPCR that mRNA of oncogenes can be transferred to 
recipient cells through exosomes. We further aim to perform gene sequencing of 
OSCC derived exosomes to determine the sequence of oncogenes packed within 
exosomes. 
In the capacity of this study we have only been able to study the diagnostic potential 
and functional significance of exosomes. In future we aim to study microvesicles 
which also classify as extracellular exosome and are released by cells through 
budding of cell membrane. They are bigger in size compared to exosomes measuring 
200 nm and hence will offer better workability.  
Future study aims to validate the 6 novel genes mentioned above for cancer 
prognosis to compliment the diagnostic test qMIDS. The expression of q6-biomarkers 
can be further validated by protein level quantification via western blotting in normal 
and cancer cell lines, along with immunostaining that would add information on 




Fig 8.1: (A) SVpgC2A exosomes with a Mean: 101nm, Mode: 40nm, size distribution 
(SD): 81nm. Total Concentration: 136.88 particles / frame, 21.65E8 particles / ml (B) 
SVFN10 exosomes with Mean: 151nm, Mode: 62nm, SD: 92nm. Total Concentration: 
162.46 particles / frame, 25.16E8 particles / ml. N=3. NanoSight LM20 was used. 
 
 




Fig 8.2: (A) Exosomes isolated from SVpgC2A with a Mean: 213nm, Mode: 157nm, 
Size Distribution (SD): 91nm. Total Concentration: 55.80 particles / frame, 8.58E8 
particles / ml (B) SVFN10 exosomes with Mean: 194nm, Mode: 145nm, SD: 113nm. 
Total Concentration: 81.76 particles / frame, 12.54E8 particles / ml. N=3. NanoSight 
LM20 was used. 
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Fig 8.3: Validation of exosomal GAPDH mRNA levels. Significantly low levels of 
RNA were found on treating the pellet with triton. The error bars represent the 
standard error of the mean of three independent experiments (n=3). Significant P 
values are denoted by (*P<0.05).*** 
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Fig 8.4: Exosomal RNA quantification and mRNA detection of genes including 
HOXA7, CCNB1, CENPA, DNMT3B, DNMT1, CEP55, NEK2, HELLS, BMI1, MAPK8 
AND AURKA by Rt-qPCR. Exosome pellets were treated with RNase A and Triton-X. 
Data was produced by MSc student Mohammad Arshad Aziz. 
 
This data showed selective packaging of genes within exosomes. mRNA levels of 
oncogene HOXA7 was three fold increased in SVFN10 derived exosomes compared 
to SVpgC2a exosomes.  
However, oncogenes MAPK8 and AURKA mRNA were not reisitant to RNAse A 
treatment suggesting that some mRNA could be co-precipated with the exosome 
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Fig 8.5: Beta galactosidase assay on NHOF-1 fibroblast cells treated with Etoposide 
(ETO) at the concentration of 1x10-7, SVpgC2a and SVFN10 exosomes. Untreated 
SVpgC2a cells were used as a control. 
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Fig 8.6: NK4 cells transfected with self exsomes (+NK4 EXO), exosomes isolated 
from tumour derived cell lines (+SqCC/Y1 EXO and +CaLH2 EXO), exosomes from 
premalignant cell line (+SVpgC2a EXO) and transformed malignant cell line 
(+SVFN10 EXO). Images at the magnification 10x taken after 48 hours of incubation. 
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